Download CURRICULUM VITAE ALEXANDER G.G. TURPIE MB, FRCP (Glasg

CURRICULUM VITAE
ALEXANDER G.G. TURPIE
MB, FRCP (Glasg., Lond.), FACP, FACC, FRCPC
Professor of Medicine
McMaster University
Hamilton, Ontario, Canada
and
Internist
Hamilton Health Sciences - General Hospital
Hamilton, Ontario, Canada
Business Address:
Hamilton Health Sciences, General Hospital
237 Barton Street East
Hamilton, Ontario, Canada
L8L 2X2
Telephone: (905) 528-9946
Fax:
(905) 521-1551
e-mail:
[email protected]
2
CURRICULUM VITAE
NAME:
Alexander Graham Grierson Turpie
HOME ADDRESS:
1127 Sulphur Springs Road, Dundas, ON, Canada L9H 5R3
TELEPHONE:
(905) 628-4534
BUSINESS ADDRESS:
McMaster Clinic, Hamilton Health Sciences
General Hospital, 237 Barton Street East, Hamilton,
Ontario, Canada L8L 2X2
BUSINESS TELEPHONE:
(905) 527-1710/(905) 528-9946
(905) 527-0271 extension 4484, 4486
(905) 521-1551 - Fax machine
[email protected] - email
DATE OF BIRTH:
February 23, l939.
NATIONALITY:
British, Canadian Citizen
CIVIL STATUS:
Married with three children
EDUCATION:
University of Glasgow; Glasgow, Scotland
1956-1962
UNDERGRADUATE
Glasgow, Scotland
Prize,
HONOURS:Ure
Systematic
Medicine,
1959
West of Scotland R.A.M.C. Memorial Prize, 1962
Macewan Medical, 1962
Herkless Prize for Clinical Surgery, 1962
Final Examination:
in Surgery, 1962
Distinctions in Medicine
William
UNDERGRADUATE BURSARIES:
Gardiner
Bursary,
1961
John McFarlane Bursary, 1962
QUALIFICATIONS: M.B., Ch.B. (with Honours)
University of Glasgow, 1962
E.C.F.M.G. Certificate, 1964
M.R.C.P. (Glasg.)
Royal
College
of
Physicians
Glasgow, 1967
M.R.C.P. (Lond.)
Royal College of Physicians
London, 1969
F.R.C.P. (C)
Royal College of Physicians and Surgeons
of Canada, 1972
and
Surgeons
3
F.A.C.P.
American College of Physicians, 1975
F.R.C.P. (Glasg.)
Royal College of Physicians and Surgeons
Glasgow, 1976
Licentiate
Medical Council of Canada, 1976
F.R.C.P. (Lond.)
Royal College of Physicians
London, 1981
F.A.C.C.
American College of Cardiology, 1990.
F.A.H.A.
Fellow of the American Heart Association
APPOINTMENTS:
RESIDENT HOUSE SURGEON
Royal
Infirmary,
Glasgow,
Scotland
August 1962 - January 1963
RESIDENT HOUSE PHYSICIAN
Stobhill
General
Hospital,
Glasgow, Scotland
February 1963 - July 1963
University Medical REGISTRAR
FAULDS CLINICAL RESEARCH
Department of Materia Medica
FELLOW AND MEDICAL
University
of
Glasgow
and
Unit, Stobhill General Hospital
Glasgow, Scotland
August 1963 - February 1965.
HONORARY CLINIC University of East Africa Medical School
LECTURER
Extension. Kenyatta National Hospital
SENIOR REGISTRAR IN
Nairobi, Kenya
MEDICINE
March 1965 - March 1966 (On secondment from
University of Glasgow)
LECTURER
Department
of
Materia
Medica
and
Therapeutics
University of Glasgow and University Medical
Unit, Stobhill General Hospital
May 1967 - June 1968
MEDICAL REGISTRAR
Department of Medicine, Royal Infirmary
Glasgow, Scotland
July 1968 - August 1969
SENIOR MEDICAL REGISTRAR
Department of Medicine, Royal Infirmary
Glasgow, Scotland
August 1969 - February 1972
3
4
(From October 1970 - on leave of absence)
POST DOCTORAL FELLOW Canadian Medical Research Council
Department of Pathology, McMaster University
Hamilton, Ontario
October 1970 - December 1972
ASSISTANT PROFESSOR
Department of Medicine, McMaster University
Hamilton, Ontario
January 1973 - June 1978
ASSOCIATE CLINICAL
Hamilton General Hospital
TEACHING UNIT January 1974 - June 198l
DIRECTOR
ASSOCIATE PROFESSOR
Department of Medicine
McMaster University, Hamilton, Ontario
July 1978 - June 1983
(Acting Chief of Medicine)
Hamilton General Hospital
January 1981 - September 1981
MCFARLANE VISITING
University of Glasgow
PROFESSOR
Royal Infirmary
Glasgow, Scotland
January 1988 - March 1988.
PRESENT APPOINTMENT
PROFESSOR
Department of Medicine
McMaster University
Hamilton, Ontario
July 1983 - present.
INTERNIST
Active Staff
Hamilton Civic Hospitals
Hamilton, Ontario
January 1973 - present.
CHIEF OF MEDICINE
Hamilton General Hospital
January 1985 - 1993.
EXTERNAL EXAMINER
MD Examination
MB, BS Examination
University of the West Indies
June 1990 - present
LEARNED SOCIETIES
U.K.
Medical Research Society, London,
Canadian Society for Clinical Investigation
International Society on Thrombosis and
4
5
Hemostasis
Central Society for Clinical Research
American Federation for Clinical Research
Canadian Cardiovascular Society
COMMITTEES
Member, Scientific Review Committee
Canadian Heart Foundation
1978 - 1983
Member, Examination Board in Internal Medicine
Royal College of Physicians and Surgeons
1982 - 1988
Chairman, Hamilton Civic Hospitals Research
and Ethics Committee
1982 - 1987
Member, Hamilton Civic Hospitals Institutional
Review Board
1973 - present
Member, Hamilton Civic Hospitals Education
Committee
1976 - 1982
Member, Department of Medicine Education
Committee
McMaster University
1975 - 1982
Member, Department of Medicine Resident
Appointments Committee
1975 - present
Member, Hamilton Civic Hospitals Redevelopment
Committee
1977 - present
Member, Committee for Scientific Development
McMaster University
1981 - 1986
Member, Presidents Ethics Committee
McMaster University
1976 - 1987
Elected Member, Board of Management
Regional Medical Associates
1977 - 1978
Elected Member, Department of Medicine
Executive Committee, McMaster University
1976 - 1978
5
6
Elected Member, Promotions and Tenure
Committee, Department of Medicine
McMaster University
1978 - 1980.
Member, Department of Medicine Executive
Committee
1981 - 1989
Elected Member, Faculty of Health Sciences
Appointments Committee
1984 - 1986
Elected Member, Faculty of Health Sciences
Promotions and Tenure Committee
1984 - 1988
Member, Hamilton General Hospital
Planning Subcommittee
l982 - present
Member, Medical Staff Advisory Committee
Hamilton General Hospital
1982-present
Member, Special Review Committee
NIH
1988 - present
Elected Member, Senate
McMaster University
1988 - present
Member, Editorial Advisory Committee
Touchstone - Journal of the
Hamilton Civic Hospitals
1986 - present
Elected Member
The Committee of Honorary Degrees
1991
Appointed Member
Senate Committee on Honorary Degrees
1992
Member
Thrombosis Interest Group (Canada)
1990 - present
Member
Thrombosis Forum
1990 - present
Member
Anticoagulation Forum
1990 - present
6
7
Member
Asociacion Colombiana de Angiologia y
Cirugia Vascular
2002
Honorary Member
Korean Society of Phlebology
2002
JOURNAL REVIEWER
Annals of Internal Medicine
Circulation
Thrombosis Research
Canadian Medical Association Journal
New England Journal of Medicine
Clinical and Investigative Medicine
Atherosclerosis
Thrombosis and Haemostasis
Drugs
EDITORIAL BOARD
Vascular Medicine Review
Blood Coagulation and Fibrinolysis
Acute Coronary Syndromes
HeartDrug (Co-editor)
7
8
PUBLICATIONS
1.
Turpie AGG, Thomson TJ: Carbenoxolone sodium in the treatment of gastric ulcer
with special reference to side effects. Gut 6:591-594, 1965.
2.
Forbes CD, Turpie AGG, McNicol GP: The anticoagulant action of puff adder (B.
Arietans) venom. East African Medical Journal 42:566-574, 1965.
3.
Forbes CD, Turpie AGG, McNicol GP: Enhancement of the activity of optimum
concentrations of urokinase by the venom of Echis Carinata. Nature 211:989-990, 1966.
4.
Forbes CD, Turpie AGG, McNicol GP, Douglas AS: Studies on East African Snakes:
mode of action of Echis Carinatus venom. Scottish Medical Journal 11:168-175, 1966.
5.
Forbes CD, Turpie AGG:
Journal 44:163-168, 1967.
A simple method of urea estimation.
6.
Turpie AGG, Forbes CD, McNicol GP:
British Medical Journal 3:646-648, 1967.
7.
Turpie AGG:
East Africa Medical
Idiopathic gangrene in African children.
Platelets and Thrombosis.
Scottish Medical Journal 13:430-433, 1968.
8.
Forbes CD, Turpie AGG, Ferguson JG, McNicol GP, Douglas AS: The effect of gaboon
viper (Bitis Gabonica) venom on blood coagulation, platelets and the fibrinolytic enzyme
system. Journal of Clinical Pathology 22:312-316, 1969.
9.
Prentice CRM, Turpie AGG, Hassanein AA, McNicol GP, Douglas AS:
platelet behaviour during Arvin therapy. Lancet i:644-647, 1969.
Changes in
10.
Turpie AGG, Runcie J, Thomson TJ: Clinical trial of deglycyrrhizinised liquorice
in gastric ulcer. Gut 10:299-302, 1969.
11.
Hassanein AA, Turpie AGG, McNicol GP, Douglas AS: Effect of RA 233 on platelet
function in vitro. British Medical Journal 2:83-86, 1970.
12.
McDougall AI, Addis GJ, Turpie AGG, MacArthur JG:
Clonidine. British Medical Journal 3:440-442, 1970.
Treatment of hypertension with
13.
Turpie AGG, Prentice CRM, McNicol GP, Douglas AS: In vitro studies with Ancrod
(Arvin). British Journal of Hematology 20:217-224, 1971.
14.
Hassanein AA, Turpie AGG, McNicol GP, Forbes CD, Douglas AS: Action of pyrimidopyrimidine compounds on platelet behaviour in vitro. Platelet adhesion and aggregation
in thrombosis. Countermeasures. FK Shattauer, Verlag-Stuttgart, New York, 1971.
15.
Turpie AGG, McNicol GP, Douglas AS: Platelet electrophoresis: effect of
defibrination by Ancrod (Arvin). Cardiovascular Research 6:101-108, 1972.
16.
Slater SD, Turpie AGG, Douglas AS, McNicol GP: Effect in vitro on platelet
function on two compounds developed from the pyrimido-pyrimidines. Journal of Clinical
Pathology 25:427-432, 1972.
17.
Prentice CRM, Turpie AGG, McNicol GP, Douglas AS: Urokinase therapy: dosage
schedules and coagulant side effects. British Journal of Hematology 22:567-577, 1972.
8
9
18.
Turpie AGG, Chernesky MA, Larke RPB, Packham MA, Mustard JF: Effect of Newcastle
disease virus on human or rabbit platelets. Aggregation and loss of constituents.
Laboratory Investigation 28:575-583, 1973.
19.
Chernesky MA, Larke RPB, Turpie AGG: Interaction between viruses and platelets.
Requirement of haemolytic activity for platelet aggregation induced by paramyxoviruses.
Journal of General Virology 21:205-213, 1973.
20.
Gallus AS, Hirsh J, Cade JF, Turpie AGG, Walker IR, Gent M: Thrombolysis with a
combination of small doses of streptokinase and small doses of heparin. Seminars in
Thrombosis and Haemostasis 2:14-32, 1975.
21.
Hull R, vanAken WG, Hirsh J, Gallus AS, Hoicka G, Turpie AGG, Walker IR, Gent M:
Impedance plethysmography using the occlusive cuff technique in the diagnosis of venous
thrombosis. Circulation 53:696-700, 1976.
22.
Turpie AGG, Gallus AS, Beattie WS, Hirsh J: Prevention of venous thrombosis in
patients with intracranial disease by intermittent pneumatic compression of the calf.
Neurology 5:435-438, 1977.
23.
Hull R, Hirsh J, Sackett DL, Powers P, Turpie AGG, Walker I: Combined use of leg
scanning and impedance plethysmography in suspected venous thrombosis. The New England
Journal of Medicine 296:1497-1500, 1977.
24.
Larke RPB, Turpie AGG, Scott S, Chernesky MA: Paramyxovirus-induced platelet
aggregation. Requirement for neuraminic acid receptors on platelets. Laboratory
Investigation 37:150-157, 1977.
25.
Turpie AGG, Hirsh J: Antiplatelet drugs:
atherosclerosis. Modern Medicine 50-57, 1977.
26.
Turpie AGG:
161, 1978.
La Pathogenie des Thromboses.
Their role in prevention of
L`Union Medicale du Canada, 107:151-
27.
Turpie AGG: Les Methodes Physiques de Prevention des Thrombo-Embolies Veineuses.
L`Union Medicale du Canada 107:227-231, 1978.
28.
Turpie AGG, Hirsh J:
34:183-190, 1978.
Platelet suppressant therapy.
British Medical Bulletin
29.
Hull R. Taylor DW, Hirsh J, Sackett DL, Powers P, Turpie AGG, Walker I:
plethysmography. The relationship between venous filling and sensitivity and
specificity for proximal vein thrombosis. Circulation 58:898-902, 1978.
Impedance
30.
Turpie AGG, Hirsh J: Prophylaxis and therapy of venous thromboembolism.
Reviews in Clinical Laboratory Science 10:247-274, 1979.
Critical
31.
Hull R, Hirsh J, Sackett DL, Powers P, Turpie AGG, Walker I, McBride J: The value
of adding impedance plethysmography to 125I-fibrinogen leg scanning for the detection of
deep vein thrombosis in high risk surgical patients: A comparative study between
patients undergoing general surgery and hip surgery. Thrombosis Research 15:227-234,
1979.
32.
Turpie AGG, Hirsh J:
Geriatrics 34:59-70, 1979.
When and how to use heparin prophylaxis and treatment.
33.
Heparin.
Turpie AGG, Hirsh J:
Nova Scotia Medical Bulletin, 58:25-29, 1979.
9
10
34.
Turpie AGG, Delmore T, Hirsh J, Hull R, Genton E, Hiscoe C, Gent M: Prevention of
venous thrombosis by intermittent sequential calf compression in patients with
intracranial disease. Thrombosis Research 15:611-616, 1979.
35.
Han P, Turpie AGG, Genton E: Plasma B-thromboglobulin: Differentiation between
intravascular and extravascular platelet destruction. Blood 54:1192-1196, 1979.
36.
Turpie AGG, Hirsh J: Venous thrombosis and pulmonary embolism:
detection and prevention. (Part I) Hospital Medicine 1:32-47, 1980.
Guide to
37.
Turpie AGG, Hirsh J: Venous thrombosis and pulmonary embolism: Guide to
detection and prevention. (Part II) Hospital Medicine 2:22-34, 1980.
38.
Han P, Butt RW, Turpie AGG, Walker WHC, Genton E: B-thromboglobulin
radioimmunoassay - A laboratory characterization and evaluation. The Journal of
Radioimmunoassay 1 (2):211-227, 1980.
39.
deBoer AC, Butt R, Turpie AGG, Genton E: The use of the evacuated blood
collection tube in the determination of plasma betathromboglobulin. Thrombosis Research
20:693-695, 1980.
40.
Hull R, Hirsh J. Sackett DL, Taylor DW, Carter C, Turpie AGG, Zielinsky A, Powers
P, Gent M: Replacement of venography in suspected venous thrombosis with impedance
plethysmography and 125I-fibrinogen leg scanning: A less invasive approach. Annals of
Internal Medicine 94:12-15, 1981.
41.
Turpie AGG: The effectiveness of drugs that modify platelet function in
peripheral venous thrombosis and pulmonary embolism. (Proceedings of the First World
Conference) Clinical Pharmacology and Therapeutics 224-233, 1981.
42. Hirsh J, Turpie AGG, Kelton J, Hull R, Carter C: Unresolved issue in the use of
heparin for management of venous thromboembolism. Chemistry and Biology of Heparin.
Lundblat RL, Brown WV, Mann KG, Roberts HR (eds) Elsevier North Holland Inc. New York
513-528, 1981.
43.
deBoer AC, Han P, Turpie AGG, Butt R, Zielinsky A, Genton E: Plasma and urine
betathromboglobulin concentration in patients with deep vein thrombosis. Blood 58:693698, 1981.
44.
Zielinsky A, Hirsh J, Straumanis A, Carter C, Gent M, Sackett DL, Hull R, Kelton
JG, Powers P, Turpie AGG: The diagnostic value of fibrinogen/fibrin Fragment E assay in
clinically suspected deep vein thrombosis. Blood 59:346-350, 1982.
45.
Turpie AGG:
Antiplatelet therapy.
Clinics in Haematology 10 (2):497-520, 1981.
46.
Hull R, Hirsh J, Sackett DL, Taylor DW, Carter C, Turpie AGG, Powers P, Gent M:
Clinical validity of a negative venogram in patients with clinically suspected venous
thrombosis. Circulation 64 (3):622-625, 1981.
47.
Hull R, Delmore T, Carter C, Hirsh J, Genton E, Gent M, Turpie AGG, McLaughlin D:
Adjusted subcutaneous heparin versus warfarin sodium in the long term treatment of
venous thrombosis. New England Journal of Medicine 306 (4):189-234, 1982.
48.
deBoer AC, Turpie AGG, Butt RW, Duke RJ, Bloch RF, Genton E: Plasma
betathromboglobulin and serum Fragment E in acute partial stroke. British Journal of
Haematology 50:327-334, 1982.
49.
deBoer AC, Genton E, Turpie AGG: Chemistry, measurement and clinical significance
of platelet specific proteins. C.R.C. Critical Reviews 18 (2):183-211, 1982.
10
11
50.
deBoer AC, Turpie AGG, Butt RW, Johnston RV, Genton E: Platelet release and
thromboxane synthesis in symptomatic coronary artery disease. Circulation 66:327-333,
1982.
51.
Turpie AGG, deBoer AC, Genton E: Platelet consumption in cardiovascular disease.
Seminars in Thrombosis and Hemostasis 8:157-181, 1982.
52.
Rosenfeld J, Devereaux D, Buchanan MR, Turpie AGG, High-performance liquid
chromatographic determination of dipyridamole. Journal of Chromatography 231:216-221,
1982.
53.
Hull R, Hirsh J, Jay R, Carter C, England C, Gent M, Turpie AGG, McLoughlin D,
Dodd P, Thomas M, Raskob G, Ockelford P: Different intensities of oral anticoagulant
therapy in the treatment of proximal vein thrombosis. New England Journal of Medicine
307:1676-1681, 1982.
54.
Buchanan MR, Rischke JA, Butt RW, Turpie AGG, Hirsh J, Rosenfeld J: The sex
related differences in platelet function and aspirin pharmacokinetics in rabbits and
man. Thrombosis Research 29:125-129, 1983.
55.
deBoer AC, Han P, Turpie AGG, Butt RW, Gent M, Genton E: Platelet tests and
antiplatelet drugs in coronary artery disease.
Circulation 67:500-504, 1983.
56.
Hull R, Carter C, Jay R, Ockelford P, Hirsh J, Turpie AGG, Zielinsky A, Gent M,
Powers P: The diagnosis of acute recurrent deep vein thrombosis. A diagnostic
challenge. Circulation 67:901-906, 1983.
57.
Duke RJ, Turpie AGG, Bloch RF, Trebilcock RG: Natural history of acute partial
stroke and stroke-in-evolution: A clinical trial of low-dose subcutaneous heparin for
the prevention of stroke progression. Cerebrovascular Diseases 399-405, 1983.
58.
Hull RD, Hirsh J, Carter CJ, Jay RM, Dodd PE, Ockelford PA, Coates G, Gill GJ,
Turpie AGG, Doyle DJ, Buller HR, Raskob GE: Pulmonary angiography, ventilation lung
scanning and venography for clinically suspected pulmonary embolism with abnormal
perfusion lung scan. Annals of Internal Medicine 98:891-899, 1983.
59.
Rosenfeld J, Buchanan MR, Reilly PA, Turpie AGG: Dipyridamole disposition after
chronic administration: Effect of aspirin. Thrombosis Research (Supp 14):137-143,
1983.
60.
Genton E, Turpie AGG: Anticoagulant therapy following acute myocardial infarction.
Modern Concepts of Cardiovascular Disease 52 (9):45-48, 1983 September (Part I).
61.
Genton E, Turpie AGG: Anticoagulant therapy following acute myocardial infarction.
Modern Concepts of Cardiovascular Disease 52 (10):49-51, 1983 October (Part II).
62.
Kelton JG, Brain H, Sheridan D, Powers PJ, Turpie AGG, Carter CJ: The clinical
usefulness of testing for a heparin-dependent platelet aggregating factor in patients
with suspected heparin-associated thrombocytopenia. Journal of Laboratory and Clinical
Medcine 103 (4):607-612, 1984.
63.
Turpie AGG, Gent M, deBoer AC, Giroux M, Kinch D, Butt R, Gunstensen J, Saerens
E, Genton E: Effect of suloctidil on platelet function in patients with shortened
platelet survival time. Thrombosis Research 35:397-406, 1984.
11
12
64.
Jay R, Hull R, Carter C, Ockelford P, Buller H, Turpie AGG, Hirsh J: Outcome of
abnormal impedance plethysmography results in patients with proximal vein thrombosis.
Frequency of return to normal. Thrombosis Research 36:259-263, 1984.
65.
Turpie AGG, Hirsh J: Venous thromboembolism:
Medicine 151-166, October 1984.
Current Concepts (Part I) Hospital
66.
Turpie AGG, Hirsh J: Venous thromboembolism:
Medicine 13-41, November 1984.
Current Concepts (Part II) Hospital
67.
Butt RW, deBoer AC, Turpie AGG, Evaluation of a commercial kit for the
radioimmunoassay of fibrinopeptide A. Journal of Immunoassay 5 (3 & 4):245-266, 1984.
68.
Turpie AGG, Gent M, Doyle DJ, Saerens E, deBoer AC, Talbot C, McNamee J, Hirsh J:
An evaluation of suloctidil in the prevention of deep vein thrombosis in neurosurgical
patients. Thrombosis Research 39:173-181, 1985.
69.
Gent M, Blakely JA, Hachinski V, Roberts RS, Barnett HJM, Bayer NH, Carruthers SG,
Collins SM, Gowel MG, Giroux-Klimek M, Hopkins MB, Jain P, Lamy M, Meloche JP, Saerens
E, Sicurella J, Turpie AGG: A secondary prevention, randomized trial of suloctidil in
patients with a recent history of thromboembolic stroke. Stroke 16 (3):4l6-424, 1985.
70.
Hull RD, Hirsh J, Carter CJ, Jay RM, Ockelford P, Buller H, Turpie AGG, Powers P,
Kinch D, Dodd P, Gill GJ, LeClerc JR, Gent M: Diagnostic efficacy of impedance
plethysmography for clinically suspected deep vein thrombosis. Annals of Internal
Medicine 102 (1):21-28, 1985.
71.
Turpie AGG: Platelet release proteins. Laboratory Management 23 (8):43-51, 1985.
72.
Turpie AGG: Thrombolytic therapy in myocardial infarction.
Cardiology 2 (2):46-51, 1986.
Perspectives in
73.
Turpie AGG, Levine MN, Hirsh J, Carter CJ, Jay R, Powers P, Andrew M, Hull R, Gent
M: A randomized controlled trial of PK 10169 low-molecular weight heparin (Enoxaparin)
for the prevention of deep vein thrombosis in patients undergoing elective hip surgery.
New England Journal of Medicine 315 (15):925-929, 1986.
74.
Turpie AGG, Levine MN, Hirsh J: Response to "Letter to the Editor" New England
Journal of Medicine 316 (15):pp 949, 1987.
75.
Duke RJ, Bloch RF, Turpie AGG, Trebilcock R, Bayer N: Intravenous heparin for the
prevention of stroke progression in acute partial stable stroke: A randomized controlled
trial. Annals of Internal Medicine 105:825-828, 1986.
76.
Duke RJ, Bloch RF, Turpie AGG:
Internal Medicine 106:781-782, 1987.
77.
Turpie AGG,
HN, Hull RD, Gent
heparinoid in the
Lancet i:523-526,
Response to "Letter to the Editor", Annals of
Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Magnani
M: A double-blind randomized trial of Org 10172 low molecular weight
prevention of deep vein thrombosis in patients with thrombotic stroke.
1987.
78.
Buchanan MR, Butt RW, Turpie AGG: Effect of Nafazatrom on platelet function and
release: Relationship to symptomatic episodes in patients with peripheral vascular
disease. American Heart Journal 113 (5):1033-1137, 1987.
79.
Doyle DJ, Turpie AGG, Hirsh J, Best C, Kinch D, Levine MN, Gent M: A randomized
trial of adjusted subcutaneous heparin versus continuous intravenous heparin in patients
with acute deep vein thrombosis. Annals of Internal Medicine 107 (4):441-445, 1987.
12
13
80.
Turpie AGG: Clinical Studies: Evidence for intervention with specific
antiplatelet drugs in arterial thromboembolism. Seminars in Thrombosis and Hemostasis
14 (1)41-49, 1988.
81.
Turpie AGG:
February 1988.
Recent advances in thrombolytic therapy.
Ontario Medicine, pp. 8,
82.
Turpie, AGG: Subcutaneous versus continuous intravenous heparin for deep vein
thrombosis. Cardiology Board Review, 5 (7) 103-114, 1988.
83.
Turpie AGG: The relationship between ex-vivo anti-Factor Xa levels and
efficacy/safety of low molecular weight heparin. Br J of Clin Practice 43 (1) Supp
65:18-25, 1988.
84.
Turpie AGG, Hirsh J, Gent M, Julian D, Johnson J: Prevention of deep vein
thrombosis in potential neurosurgical patients: A randomized trial comparing graduated
compression stockings alone or graduated compression stockings plus intermittent
pneumatic compression with control. Archives of Internal Medicine 149:679-681, 1989.
85.
Turpie AGG, Gunstensen J, Hirsh J, Nelson H, Gent M: A randomized trial comparing
two intensities of oral anticoagulant therapy following tissue heart valve replacement.
Lancet i:1242-1245, 1988
86.
ISIS-2 Collaborative Group: Randomised trial of intravenous streptokinase, oral
aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction:
ISIS-2. Journal of the American College of Cardiology 12 (6): 3A-12A, 1988.
87.
Turpie AGG: Low molecular weight heparins: Deep vein thrombosis prophylaxis in
elective hip surgery and thrombotic stroke. Acta Chir Scand Suppl 543:85-86, 1988.
88.
ISIS-2 Collaborative Group: Randomised trial of intravenous streptokinase, oral
aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction:
ISIS-2. Lancet ii:349-360, 1988.
89.
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group:
Randomized trial of intravenous streptokinase, oral aspirin, both or neither among
17,187 cases of suspected acute myocardial infarction: ISIS-2. Streptokinase for Acute
Myocardial Infarction: Results and Implications of the Major Clinical Studies.
Proceedings of a satellite symposium held in Vienna, Austria, P. Sleight (ed) August 31,
1988. pp 51-73.
90.
M. Gent, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E,
Roberts RS, J. Sicurella J, Turpie AGG: The Canadian American Ticlopidine Study (CATS)
in Thromboembolic Stroke. Stroke 19 (10):1203-1210, 1988
91.
Turpie AGG, Robinson JG, Doyle DJ, Mulji AS, Mishkel GJ, Sealey BJ, Cairns JA,
Hirsh J, Skingley L, Gent M: Prevention of left ventricular mural thrombosis in acute
transmural anterior myocardial infarction: A double blind trial comparing high dose
with low dose subcutaneous calcium heparin. N Engl J Med 320 (6):352-357, 1989.
92.
Turpie AGG, Gent M, Hirsh J: Letter to the Editor, N Engl J Med 321:259-260,
1989.
93.
Powers PJ, Gent M, Jay R, Julian D, Turpie AGG, Levine MN, Hirsh J: A randomized
trial of post-operative less-intense warfarin or acetylsalicylic acid in the prevention
of venous thromboembolism after surgery for fractured hip. Archives of Internal
Medicine, 149 (4):771-774, 1989.
13
14
94.
Turpie AGG, Bloch R, Duke R: Heparin in the treatment of thromboembolic stroke.
Annals of New York Academy of Sciences 556:406-415, 1989.
95.
Dormandy J, Mahir M, Ascady G, Balsano F, DeLeeuw P, Blombery P, Bousser MG,
Clement D, Coffman J, Deutshinoff A, Bletry O, Hampton J, Mahler F, Ohlin P, Rieger H,
Stranden E, Turpie AGG, Urai L, Verstraete M: Fate of the patient with chronic leg
ischaemia. A review article. J of Cardiovasc Surg 30 (2): 50-57, 1989.
96.
Prevention of Atherosclerotic Complications with Ketanserin Trial Group:
Prevention of atherosclerotic complications: controlled trial of ketanserin. Brit J
Med 298:424-430, 1989.
97.
Turpie AGG:
Thrombolytic therapy.
Medicine, North America 30: 5549-5554, 1989.
98.
Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E,
Roberts RS, Sicurella J, Turpie AGG and the CATS Group. The Canadian American
Ticlopidine Study (CATS) in Thromboembolic Stroke. Lancet i:1215-1220, 1989.
99.
Turpie AGG: Examining the role of anticoagulants in post-AMI.
Cardiology 5 (5):31-41, 1989.
100. Turpie AGG: Therapy of deep vein thrombosis.
14 (6) 341-347, 1989.
Perspectives in
Herz (Kardiovaskulare Erkankungen)
101. Ginsberg JS, Shin A, Turpie AGG, Hirsh J: Detection of previous proximal venous
thrombosis with doppler ultrasonography and photoplethysmography. Archives of Internal
Medicine 149:2255-2257, 1989.
102. Cruickshank MK, Levine MN, Hirsh J, Turpie AGG, Powers P, Jay R, Gent M: An
evaluation of impedance plethysmography and 125 I-fibrinogen leg scanning in patients
following hip surgery. Thrombosis and Haemostasis 62 (3) 830-834, 1989.
103. Turpie AGG, Robinson JG, Doyle DD, Mulji AS, Mishkel GJ, Sealey BJ, Cairns JA,
Skingley L, Hirsh J, Gent M: Comparison of high-dose with low-dose subcutaneous heparin
to prevent left ventricular mural thrombosis in patients with acute transmural anterior
myocardial infarction. N Engl J Med 320:352-357, 1989.
104. Turpie AGG, Hirsh J, Gent M, Julian D, Johnson J: Prevention of deep vein
thrombosis in potential neurosurgical patients. Arch of Int Med 149:679-681, 1989.
105. Turpie AGG:
64:41B-43B, 1989.
Prevention of left ventricular mural thrombosis.
Am J Cardiol
106. Turpie AGG: Anticoagulant therapy after acute myocardial infarction.
Cardiol 65:20C-23C, 1990.
Am J of
107. Turpie AGG, Levine MN, Hirsh J, Ginsberg JS, Cruickshank M, Jay R, Gent M: Tissue
plasminogen activator (rt-PA) versus heparin in deep vein thrombosis: results of a
randomized trial. Chest 97: 172S-175S, 1990.
108. Levine MN, Weitz J, Turpie AGG, Andrew M, Cruickshank M, Hirsh J: A new short
infusion dosage regimen of recombinant tissue plasminogen activator in patients with
venous thromboembolic disease. Chest 97: 168S-171S, 1990.
109. Turpie AGG: Thrombolytic agents in venous thrombosis. J of Vasc Surg August:
196-197, 1990.
14
15
110. Turpie AGG: Enoxaparin prophylaxis in elective hip surgery.
Scandinivica 156 (Supp 556) 1990.
Acta Chirurgica
111. Turpie AGG: Low-dose or high-dose heparin to prevent left ventricular mural
thrombosis. LeMonde Medical Magazine 25-29, 1990.
112. Levine M, Hirsh J, Weitz J, Cruickshank M, Neemeh J, Turpie AGG, Gent M: A
randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen
activator in patients with acute pulmonary embolism. Chest 98 (6) 1473-1479, 1990.
113. Hirsh J, Turpie AGG:
of Surg 14: 688-693, 1990.
114. Turpie AGG:
197, 1990.
Use of plasminogen activators in venous thrombosis.
Thrombolytic agents in venous thrombosis.
World J
J of Vasc Surg 12: 196-
115. Levine MN, Hirsh J, Gent M, Turpie AGG et al: Prevention of deep vein thrombosis
in patients undergoing elective hip surgery: A randomized trial comparing Enoxaparine
low molecular weight heparin with standard unfractionated heparin. Annals of Int Med
114 (7) 545-551, 1991.
116. Turpie AGG: Efficacy of a postoperative regimen of enoxaparin in deep vein
thrombosis prophylaxis. Am J of Surg 161:532-536, 1991.
117. Prins MH, Turpie AGG: Clinical and laboratory diagnosis of deep vein thrombosis:
current status. Current Medical Literature - Thrombosis (Scientific and Clinical
Perspectives) 1: (3) 67-74, 1991.
118. Turpie AGG: Atrial Fibrillation: Helping patients get into the rhythm of life.
Perspectives in Cardiology March: 41-48, 1991.
119. Connolly S, Laupacis A, Gent M (for the CAFA Study Coinvestigators): Canadian
Atrial Fibrillation Anticoagulation (CAFA Study). JACC 18 (2):349-355, 1991.
120. ISIS-4 Collaborative Group: Fourth International Study of Infarct Survival:
Protocol for a large simple study of the effects of oral mononitrate, of oral captopril
and of intravenous magnesium. Am J of Cardiol 68:87D-100D, 1991.
121. ISIS-3: Third International Study of Infarct Survival Collaborative Group.
3: A randomized comparison of streptokinase vs tissue plasminogen activator vs
anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of
suspected acute myocardial infarction. The Lancet 339:753-781, 1992.
ISIS-
122. Turpie AGG: Orgaran in the prevention of deep vein thrombosis in stroke patients.
Haemostasis 22:92-98, 1992.
123. Turpie AGG, Gent M, Cote R, Levine MN, Ginsberg JS, Powers PJ, Leclerc J, Geerts
W, Jay R, Neemeh J, Klimek M, Hirsh J. A low-molecular weight heparinoid compared with
unfractionated heparin in the prevention of deep vein thrombosis in patients with acute
ischemic stroke. Annals of Internal Medicine 117 (5):353-357, 1992.
124. European Consensus Group.
Angiology 11 (3)151:159, 1992.
Prevention of venous thromboembolism.
International
125. Stein PD, Alpert JS, Copeland J, Dalen JE, Goldman S, Turpie AGG: Antithrombotic
therapy in patients with mechanical and biological prosthetic heart valves. Chest
(Suppl) 102 (4):445S455S, 1992.
15
16
126. Stein PD, Dalen JE, Goldman S, Schwartz L, Turpie AGG, Theroux P: Antithrombotic
therapy in patients with saphenous vein and internal mammary artery bypass grafts
following percutaneous transluminal coronary angioplasty.
Chest (Suppl) 102 (4):508S515S, 1992.
127. Turpie A. Graham G, Rosenbloom David: Ticlopidine:
stroke prevention. Pharmacy Times 69-79, September 1992.
A new antiplatelet agent for
128. Turpie AGG: Heparin alternative called efficacious to stop thrombosis.
Anesthesiology News, pp 1 and 26, 1992.
129. Turpie AGG:
4719-4724, 1992.
Ischemic heart disease and anticoagulants. Medicine, North America
130. Turpie AGG: Thromboprophylaxis in orthopedic surgery.
Practice and Perspectives 5:1-16, 1992.
Thrombosis-Clinical
131. Turpie AGG: Long-term warfarin RX safe for elderly with atrial fibrillation.
Medical Post March 23, 1993.
132. Turpie AGG, Gent M, Laupacis A, Latour Y, Gunstensen J, Basile F, Klimek M, Hirsh
J. A comparison of aspirin with placebo in patients treated with warfarin after heartvalve replacement. N Engl J Med 329:524-529, 1993.
133. Turpie AGG:
661, 1993.
Acknowledgement of Scientific Reviewers.
Cdn Med Assoc J 149(5) pp
134. Heijboer H, Buller HR, Lensing AWA, Turpie AGG, Colly LP, ten Cate, JW: A
comparison of real-time compression ultrasonography with impedance plethysmography for
the diagnosis of deep-vein thrombosis in symptomatic outpatients. New Eng J Med 329
(19) 1365-1369, 1993.
135. Turpie AGG: Thromboprophylaxis in orthopaedic surgery.
International Edition 1 (5):396-401, 1993.
Orthopaedics
136. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised
trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and
stroke by prolonged antiplatelet therapy in
various categories of patients. Brit Med J 308:81-106, 1994.
137. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised
trials of antiplatelet therapy - II: Maintenance of vascular graft of arterial patency
by antiplatelet therapy. Brit Med J 308:159-168, 1994.
138. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised
trials of antiplatelet therapy - III: Reduction in venous thrombosis and pulmonary
embolism by antiplatelet prophylaxis among surgical and medical patients. Brit Med J
308:235-246, 1994.
139. Levine MN, Hirsh J, Gent M, Turpie AGG, Cruickshank M, Weitz J, Anderson D,
Johnson M. A randomized trial comparing activated thromboplastin time with heparin
assay in patients with acute venous thromboembolism requiring large daily doses of
heparin. Arch Int Med 154:49-56, 1994.
140. Turpie AGG, Gent M, Laupacis A, Latour Y, Gunstensen J, Basile F, Klimek M, Hirsh
J. Aspirin and warfarin after heart-valve replacement. ACP Journal Club, Jan/Feb,
1994.
16
17
141. Turpie AGG, Gent M, Laupacis A, Hirsh J: Warfarin and aspirin after heart-valve
replacement (Letter to the Editor) N Engl J Med 330 (7)507-509, 1994.
142. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for
fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview
of early mortality and major morbidity results from all randomised trials of more than
1000 patients. The Lancet 343:311-322, 1994.
143. Turpie AGG: Preventing thromboembolism in patients with prosthetic heart valves.
Cardiology Clinics 12 (3), 487-493, 1994.
144. Turpie AGG: Thrombolytic therapy in venous thrombosis and pulmonary embolism.
Fibrinolysis 8 (1):237-244, 1994.
145. The Stile Investigators: Results of a prospective randomized trial evaluating
surgery versus thrombolysis for ischemia of the lower extremity. Annals of Surgery 220
(3) 251-268, 1994.
146. Bolus Alteplase Pulmonary Group: Reduced dose bolus Alteplase vs conventional
Alteplase infusion for pulmonary embolism thrombolysis. Chest 106:718-724, 1994.
147. Ginsberg J, Nurmohamed MT, Gent M, MacKinnon B, Sicurella J, Brill-Edwards P,
Levine MN, Panju AA, Powers P, Stevens P, Turpie AGG et al: Use of hirulog in the
prevention of venous thrombosis after major hip or knee surgery. Circulation 90
(5):2385-2389, 1994.
148. Turpie AGG:
1995, pp 552.
Acknowledgement of Scientific Reviews.
Cdn Med Assoc J Februrary 15,
149. Turpie AGG: Ticlopidine in cardiovascular and peripheral vascular conditions.
Does it have a role in event prevention. A Special Report. Proceedings of a Symposium.
February 1995, 49:52.
150. Turpie AGG. Pathogenesis, diagnosis and treatment of deep vein thrombosis.
Current Concepts in Venous Thromboembolic Disorder 1:4-7, 1994.
151. Andrew M, Brigden M, Bormanis J, Cruickshank M, Geerts W, Giles A, Hirsh J, Hull
R, Johnson J, Johnston M, Leclerc J, Mant M, Pineo G, Robinson S, Robitaille D, Rutledge
Harding S, Scully MF, Turpie AG et al: INR reporting in Canadian Medical Laboratories.
Am J of Hematol 48:237-239, 1995.
152. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of
antithrombotic therapy in atrial fibrillation. Archives of Internal Medicine 154:14491457, 1994.
153. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group.
ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate,
and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial
infarction. Lancet 345 (8951):669-685, 1995.
154. Turpie AGG. The role of antiplatelet agents in cerebrovascular disease.
Consultation on Stroke 4:1, 1995.
155. Turpie AGG. Management of deep vein thrombosis: Prevention and treatment.
(Excerpta Medica) June Supplement, 1995.
156. Turpie AGG. Anticoagulation in cardiovascular disease.
European Heart Journal 16 (Supp D):38-39, 1995.
17
P & T
Concluding remarks.
18
157. Turpie AGG. DVT prophylaxis in the outpatient setting:
following hospital discharge. Orthopedics 18, July 1995.
Preventing complications
158. Turpie AGG. Antithrombotic therapy in acute coronary ischaemia.
Progress 8:49-51, 1995.
Biomedical
159. Levine MN, Hirsh J, Gent M, Turpie AGG, Weitz J, Ginsberg J, Geerts W, LeClerc J,
Neemen J, Powers P, Piovella F. Optimal duration of oral anticoagulant therapy: A
randomized trial comparing four weeks with three months of warfarin in patients with
proximal deep vein thrombosis. Thrombosis and Haemostasis 74 (2):606-611, 1995.
160. The STILE Investigators. Results of a prospective randomized trial evaluating
surgery versus thrombolysis for ischaemia of the lower extremity. Annals of Surgery 220
(3):251-268, 1995.
161. Parish S, Collins R, Peto R, Youngman L, Barton J, Jayne K, Clarke R, Appleby P,
Lyon V, Cederholm-Williams S, Marshall J, Sleight P for the International Studies of
Infarct Survival (ISIS) Collaborators. British Medical Journal 311:471-477, 1995.
162. Turpie AGG:
1995.
Danger of using antithrombotics postoperatively.
Vessels 1 (3)25-29,
163. Turpie AGG: Terapeutica antiplaquetaria en la prevencion primaria y secundaria
del accidente cerebrovascular. Revista Argentina de Cardiologia, Noviember-Diciembre 63
6):597, 1995.
164. Turpie AGG: Heparina en el accidente cerebrovascular isquemico.
Argentina de Cardiologia, Noviember-Diciembre 63 6):601, 1995.
Revista
165. Turpie AGG, Weitz JI, Hirsh J. Advances in antithrombotic therapy:
Thromb & Haemost 74 (1):565-571, 1995.
Novel agents.
166. Connolly SJ, Turpie AGG. Antithrombotic therapy in atrial fibrillation.
Canadian Journal of Cardiology 12 A:17A-20A, 1996.
The
167. Gent M, Hirsh J, Ginsberg JS, Powers PJ, Levine MN, Geerts WH, Jay RM, Leclerc J,
Neemeh JA, Turpie AGG. Low-molecular-weight heparinoid Orgaran is more effective than
aspirin in the prevention of venous thromboembolism after surgery for hip fracture.
Circulation 93 (1):80-84, 1996.
168. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AGG.
A comparison of low-molecular weight heparin administered primarily at home with
unfractionated heparin administered in the hospital for proximal deep vein thrombosis.
New England Journal of Medicine 334 (11):677-681, 1996.
169.
Turpie AGG.
Hirudin and thrombosis prophylaxis.
The Lancet 347:632-633, 1996.
170. Nurmohamed MT, van Riel AM, Henkens CMA, Koopman MMW, Que GTH, d'Azemar P, Buller
HR, ten Cate JW, Hoek JA, van der Meer J, van der Heul C, Turpie AGG, Haley S, Sicurella
J, Gent M. Low molecular-weight heparin and compression stockings in the prevention of
venous thromboembolism in neurosurgery. Thromb & Haemost 75 (2):233-238, 1996.
171. Levine MN, Gent M, Hirsh J, Weitz J, Turpie AG et al. Ardeparin (Low molecular
weight heparin) vs graduated compression stockings for the prevention of venous
thromboembolism. Arch Intern Med 156:851-856, 1996.
18
19
172. Turpie AGG. New therapeutic opportunities for heparins: What does low molecular
weight heparin offer? Journal of Thrombosis and Thrombolysis 3:145-149, 1996.
173. Turpie AGG, Connolly SJ. Antithrombotic therapy in atrial fibrillation.
Family Physician 42:1341-1345, 1996.
Canadian
175. Altman R, Rouvier J, Gurfinkel E, Scazziota A, Turpie AGG. Comparison of highdose with low-dose aspirin in patients with mechanical heart valve replacement treated
with oral anticoagulants. Circulation 94 (9) 2113-2116, 1996.
176. Kearon C, Turpie AGG. Diagnosis of deep venous thrombosis. Thrombosis Scientific and Clinical Perspectives. Current Medical Literature, 6 (4):95-98 1996.
177. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus
aspirin in patients at risk of ischaemic events (CAPRIE). The Lancet 348:1329-1339,
1996.
178. Turpie AGG. Prevention and treatment of venous thromboembolism.
(Special Edition) 2 (2):22-25, 1996.
Orthopedic
178a. Tirone ED, Gott VL, Harker LA, Miler GE, Naftel DC, Turpie AGG. Letter to the
Editor. Mechanical Valves. Annals of Thoracic Surgery 62:1565-1570, 1996.
179. Turpie AGG. Diagnosis and treatment of deep vein thrombosis.
International V, pg 377-381, 1997.
Surgical Technology
180. Turpie AGG. Low molecular weight heparin: From the bench to the orthopaedic
patient. Orthopedics (February supplement) 10-13, 1997.
181. Turpie AGG. Safer anticoagulant therapy heart valve replacement.
for less intense regimens. Postgraduate Medicine 101 (3):85-94, 1997.
Recommendations
182. Lensing AWA, Doris CI, MNcGrath FP, Cogo A, Sabine MJ, Ginsberg J, Prandoni P,
Turpie AGG, Hirsh J. A comparison of compression ultrasound with color Doppler
ultrasound for the diagnosis of symptomless postoperative deep vein thrombosis.
Archives of Internal Medicine 157 (7):765-768, 1997.
183. Turpie AGG. Prophylaxis of venous thromboembolism in stroke patients.
in Thrombosis and Hemostasis 23:155-157, 1997.
Seminars
184. Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AGG, van der Meer J,
Olaisson E, Undeland S, Ludwig K for the FRIC Investigators. Comparison of lowmolecular-weight heparin with unfractionated heparin acutely and with placebo for 6
weeks in the management of unstable coronary artery disease. Circulation 96 (1):61-68,
1997.
185. Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S, Langer A,
Califf RM, Fox KAA, Premmereur J, Bigonzi F. A comparison of low molecular weight
heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med
337 (7):447-452, 1997.
186. Turpie AGG. New frontiers in the management of unstable coronary artery disease.
Am J of Cardiol 89 (5A):21E-24E, 1997.
187. Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AGG, van der Meer J,
Olaisson E, Undeland S, Ludwig K for the FRIC Investigators. Comparison of lowmolecular-weight heparin with unfractionated heparin acutely and with placebo for 6
19
20
weeks in the management of unstable coronary artery disease.
(5A):21E-24E, 1997.
Am J of Cardiol 89
188. Ginsberg JS, Kearon C, Douketis J, Turpie AGG et al. The use of D-dimer and
impedance plethysmographic examinations in patients with clinical indications for deep
vein thrombosis. Arch of Intern Med 157:1077-1081, 1997.
189. The COLUMBUS Investigators. Low molecular weight heparin in the treatment of
patients with venous thromboembolism. N Engl J Med 337 (10):657-662, 1997.
190. Lengyel M, Fuster V, Keltai M, Roudaut R, Schulte HD, Seward JB, Chesebro JH,
Turpie AGG. Guidelines for management of left-sided prosthetic valve thrombosis: A
role for thrombolytic therapy. JACC 30 (6):1521-1526, 1997.
191. Ray JG, Turpie AGG. Survey of cardiac surgeons' perceptions of the addition of
ASA to warfarin for patients with mechanical heart valves. Canadian Journal of
Cardiology 13 (12):1162-1165, 1997.
192. Turpie AGG. Antithrombotic therapy: The expanding role of low molecular weight
heparin. Indian Heart J 49:489-492, 1997.
193. Cogo A, Lensing AWA, Koopman MMW, Piovella F, Siragusa S, Wells PS, Villalta S,
Buller HR, Turpie AGG, Prandoni P. Compression ultrasonography for diagnostic
management of patients with clinically suspected deep vein thrombosis: prospective
cohort study. BMJ 316:17-20, 1998.
194. Turpie AGG. Thrombolysis in prosthetic valve thrombosis: When - and for which
patients? Clinical Update. J of Critical Illness 13 (2):132-133, 1998.
195. Turpie AGG. Antithrombotic therapy in acute non-ST segment elevation coronary
ischaemia. Cardiology Today II (1):46-48, Jan-Feb 1998.
196. Kearon C, Julian JA, Math M et al. Noninvasive diagnosis of deep
thrombosis. Annals of Internal Medicine 128 (8) 663-677, 1998.
197. Turpie AGG, Weart CW, White R.
Care April 106-125, 1998
venous
Anticoagulation; Promises and Pitfalls, Patient
198. Caprini JA, Barie PS, Comerota AJ, Turpie AGG. Symposium: DVT pro- phylaxis in
high risk general surgery patients. Contemporary Surgery 52 (4):279-298, 1998
199. ISIS-3 Collaborative Group. Comparisons of early mortality and major morbidity
among 26,480 men and 9,600 women with suspected acute myocardial infarction treated with
fibrinolytic therapy in the ISIS-3 study. N Engl J Med (accepted for publication) 1997.
200.
Mark DB, Cowper PA, Berkowitz SD, Davidson-Ray L, DeLong ER, Turpie AGG et al.
Economic assessment of low-molecular-weight heparin (Enoxaparin) versus unfractionated
heparin in acute coronary syndrome patients. Results from the ESSENCE Randomized trial.
Circulation 1998; 97:1702-1707.
201.
Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg JS for the Canadian
Collaborative Group. The incidence of symptomatic venous thromboembolism during and
after prophylaxis with enoxaparin. Arch of Intern Med 158:873, 1998.
202.
Brigden M, Johnston MJ (for the Thrombosis Interest Group). INR reporting in
Canadian Medical Laboratories. Am J of Clin Path 109 (5):589-594, 1998.
20
21
203.
Campbell RWF, Walletin L, Verheugt FWA, Turpie AGG, Maseri A, Klein W, Cleland
JGF, Bode C, Becker R, Anderson J, Bertrand ME, Conti CR. Management strategies for a
better outcome in unstable coronary artery disease. Clin Cardiol 21:314-322, 1998.
204. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R.on behalf of the
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. ISIS-2: 10
year survival among patients with suspected acute myocardial infarction in randomised
comparison of intravenous streptokinase, oral aspirin, both or neither. Br Med J
316:1337-1343, 1998.
205. Ageno W, Turpie AGG.
Paulo 7 (3):406-417, 1997.
Aspirin and ticlopidine.
Rev Soc Cardiol Estado de Sao
206. Ageno W, Turpie AGG. Anticoagulation in surgical patients.
Estado de Sao Paulo 7 (3):372-382, 1997.
Rev Soc Cardiol
207. Turpie AGG. Clinical potential of antithrombotic drugs in coronary syndromes.
J Cardiol 1998; 82:11L-14L.
Am
208. Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S, Langer A,
Califf RM, Fox KAA, Premmereur J, Bigonzi F for the ESSENCE Study Group. Low-molecularweight heparins in non-ST-segment elevation ischaemia: The ESSENCE Trial. Am J Cardiol
1998; 82:19S-24L.
209.
Kearon C, Julian JA, Math M et al (for the McMaster Diagnostic
imaging Practice Guidelines Initiative). Noninvasive diagnosis of deep venous
thrombosis. Annals of Intern Med 128:663-677, 1998.
210.
Wells PS, Ginsberg JS, Anderson DR, Kearon C, Gent M, Turpie
Alexander G, Bormanis J, Weitz J, Chamberlain M, Bowie D, Barnes D, Hirsh J. Use of a
clinical model for safe management of patients with suspected pulmonary embolism.
Annals of Intern Med 129:997-1005, 1998.
211.
Johnston M, Brigden M (for the Thrombosis Interest Group of Canada). A crossCanada survey of prothrombin time testing. Am J Clin Path 110:683-690, 1998.
212. Ginsberg JS, Wells P, Kearon C, Anderson D, Crowther M, Weitz JI,
Bormanis J, Brill-Edwards P, Turpie AG, MacKinnon B, Gent M, Hirsh J. Sensitivity and
specificity of a rapid whole-blood assay for D-Dimer in the diagnosis of pulmonary
embolism. Ann Intern Med 129:1006-1011, 1998.
213. Turpie AGG. Antithrombotic therapy in coronary ischaemia: The
expanding role of low molecular weight heparin. Haemostasis 1998; 28 (Suppl 3):35-42.
214. Ageno W, Turpie AGG. A randomized comparison of a computer-based dosing program
with a manual system to monitor oral anticoagulant therapy. Thrombosis Research 91:237240, 1998.
215. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AGG, Green D,
Ginsberg JS, Wells P, MacKinnon B, Julian JA. A comparison of three months of
anticoagulation with extended anticoagulation for a first episode of idiopathic venous
thromboembolism. N Engl J Med 340 (12)901-907, 1999.
216. Turpie AGG, Kher A. Prevention of venous thrombosis after elective hip surgery.
Orthopaedics Review pp 1275-1281, 1999
217.
Turpie AGG.
Orthopaedics (Letter to the Editor):477-478, 1999
21
22
218. Lowe GDO, Haverkate F, Thompson SG, Turner RM, Bertina RM, Turpie
AGG, Mannucci PM. Prediction of deep vein thrombosis fter elective hip
replacement surgery by preoperative clinical and haemostatic variables:
The ECAT DVT Study. Thromb Haemost 81:879-886, 1999.
219. Turpie AGG. The ten most commonly asked questions about chronic
anticoagulant use in cardiology. Cardiology in Review 7 (3):125-126, 1999.
220. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C,
Leizorovicz A, Nguyen H, Olsson CG, Turpie AGG, Weisslinger N for the
prophlaxis in medical patients with enoxaparin study group. A comparison
of enoxaparin with placebo for the prevention of venous thromboembolism in
acutely ill medical patients. N Engl J Med 341:793-800, 1999.
221. Haas S, Turpie AGG. Introduction.
Fibrinolysis 10 (suppl 2):S1-S3, 1999.
Blood Coagulation and
222. Turpie AGG. Customizing our approach in deep vein thrombosis and
pulmonary embolism treatment: overview of our clinical experience.
Blood Coagulation and Fibrinolysis 10 (suppl 2):S107-S115, 1999.
223. Turpie AGG. Antithrombotic therapy in the new millennium - the role
of low molecular weight heparin. South African Medical Journal 89:
(Cardiovascular suppl 3):C151-C155.
224. Turpie AGG. Anticoagulants in acute coronary syndromes.
Cardiol 84:2M-6M, 1999.
Am J Card
225. Antman EM, McCabe CH, Gurfinkle EP, Turpie AGG, Bernink PJLM, Salein D, Bayes de
luna A, Fox K, Lablanche J-M, Radley D, Premmereur J, Braunwald for the TIMI 11B
Investigators. Enoxaparin prevents death and cardiac ischemic events in unstable
angina/non-Q-wave myocardial infarction (TIMI) 11B trial. Circulation 100:1593-1601,
1999.
226. Antman EM, Cohen M, Radley D, McCabe C, Rush J, Premmereur J, Braunwald E for the
TIMI 11B (Thrombolysis in myocardial infarction) and ESSENCE (Efficacy and safety of
subcutaneous enoxaparin in non-Q-wave coronary events) Investigators Assessment o the
treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction.
TIMI 11B-ESSENCE Meta-analysis. Circulation 199: 1602-1608, 1999.
227. Verheugt FW, Becker RC, Bertrand ME, Bode C, Chesebro JH, Cleland JG, Conti R,
Hillis WS, Klein W, Maqseri A, Turpie AGG, Wallentin L, Waters DD. Management
strategies in unstable coronary artery disease – current problems and future directions.
The UCAD Council. Clin Cardiol Sept 22 (9): 551-553, 1999.
228. Haas S, Turpie AG. Building a new era in DVT management.
Coagul Fi8brinolysisl Aug: 10 Suppl 2:S1-S3, 1999.
Introduction.
Blood
229. Toal CB, Motr M, Baird MG, Klinke P, Sclarowski S, Zilberman A, Marmor A, Kostuk
WJ, Lotan C, Weiss A, Erne P, Palant A, Stolero, Belanger L, Turpie AGG. Effectiveness
of nifedipine GITS I combination with atenolol in chronic stable angina. Can J Cardiol
15 (10):1103-1109, 1999.
230. Ageno W, Turpie AGG. Exaggerated initial response to warfarin following heart
valve replacement. Am J Cardiol 84: 905-908, 1999.
231. Turpie AGG. Clinical trials of low molecular weight heparins.
(Suppl R); 418-427, 1999.
22
Europ Heart J 1
23
232. Ageno W, Turpie AGG. Prevention and treatment of venous thromboembolism.
Surgery News June 13-16, 1999.
General
233. Ageno W, Turpie AGG. Prevention and treatment of venous thromboembolism.
Pharmacy Practice News June 11-14, 1999.
234. Ageno W, Turpie AGG. The use of antiplatelet agents in the secondary prevention
of stroke. Leading Article. Stroke, 1999.
235. Sosis MB. Enoxaparin for the prevention of venous thromboembolism.
N Engl J Med 342: 136, 2000 (Correspondence).
236. Turpie, AGG. Low molecular weight heparins in acute unstable coronary artery
disease. An update. Haemostasis 29 (Suppl 1):72-75, 1999.
237. Ageno W, Turpie AGG. The use of glycoprotein IIb/IIIa receptor inhibitors in
unstable angina. G Ital Cardiol 29:1357-1365, 1999.
238. Turpie AGG. Is lung scanning necessary in all patients with confirmed DVT?
Critical Illness 15: (2): 2000
239. Turpie AGG. Can we differentiate the low-molecular weight heparins?
(Suppl I):I-4-I-7, 2000.
J of
Clin Card 23
240. Antman EM, Fox KM for the International Cardiology Forum. Guidelines for the
diagnosis and management of unstable angina and non-Q-wave myocardial infarction:
Proposed revisions. Am Heart J 2000; 139:461-475.
241. Huber K, Gaul G, Glogar D, Kaliman J und Miczoch J for the International Cardiology
Forum. Richtlinien zur Diagnostik und Therapie der instabilen Angina pectoris und des
Non-Q-Wave-Myokardinfarktes: vorgeschlagene Revisionen. J Kardiol 2000; 7:60-72.
242. Turpie AGG.
2000; 45:40-42.
Management of deep vein thrombosis and pulmonary embolism.
Scot Med J
243. Turpie AGG. Prophylaxis for venous thromboembolism in medical patients.
Critical Illness (Supplement) July 2000:S24-S30.
J
244. Turpie AGG, Elliot G, Fernandez B. Suspicions and subtleties in venous
thromboembolism. Are clinical models and strategies effective? Medical Crossfire
2(8):35-46, 2000.
245. Wells PS, Anderson DR, Rodger M, Ginsbert JS, Kearon C, Gent M, Turpie AG, Bormanis
J, Weitz J, Chamberlain M, Bowie D, Barnes D, Hirsh J. Derivation of a simple clinical
model to categorize patients probability of pulmonary embolism: increasing the models
utility with the SimpliRED D-Dimer. Thromb Haemost Mar 83 (3):416-420m 2000.
246. Ageno W, Turpie AGG. Low molecular weight heparin in the treatment of pulmonary
embolism. Seminars in Vasc Surg 13 (3):189-193, 2000.
247. Turpie AGG. Deep vein thrombosis (DVT) and pulmonary embolism (PE) post
significant diagnostic and management challenges to clinicians. “DVT often arises in
primary-care settings and crosses many subspecialty borders” noted Victor Tapson MD,
Associate Professor of Medicine in the Division of Pulmonary and Critical Care Medicine,
Duke University Medical Center, in Durham, North Carolina. “We need to emphasize that,
whatever the setting, there is much to consider in treating venous thrombosis and
pulmonary embolism. Medical Crossfire 2 (8):35-45, 2000.
23
24
248. Cohen M, Elliot EM, Gurfinkel E, Turpie AGG, Furst J, Bigonzi F, Radley D.
of enoxaparin low molecular weight heparin in patients with Q-wave myocardial
infarction. Am J Cardiol 86: 553-556, 2000.
249. Turpie AGG. Prevention of venous thromboembolism is medical patients.
Journal of Haematology (Suppl) 17 (3):96-101, 2000.
Impact
Turkish
250. Cohen M, Turpie AGG. Management of unstable angina and myocardial infarction.
(letter). Lancet 356: 119, 2000.
251. Cohen M, Antman EM, Gurfinkel E, Turpie AGG, Furst J, Bigonzi F and Radley D.
of enoxaparin low molecular weight heparin in patients with Q-wave myocardial
infarction. Am J Cardiol 86; Sept 1; p553-556, 2000.
Impact
252. Samama MM, Cohen AT, Darmon J-Y, Desjardins L, Eldor A, Janbon C, Leizorovicz A,
Nguyen H, Olsson C-G, Turpie AG, Weisslinger N. Hastalarda Enoksaparin Ile profilaksi
Calisma Grubu. Akut Meeical Hastalarda Venoiz Tromboemboli Profilaksisinde Enoksaparin
Ile Plasebonun Karsilastirilmasi. N Engl J med 341:793-800, 1999.
253. Ageno W, Johnson J, Nowacki B, Turpie AGG. A computer generated induction system
for hospitalised patients starting on oral anticoagulant therapy. Thromb Haemost 83:
849-852, 2000.
254. Turpie AGG. Antithrombotics and anticoagulants in coronary syndromes and stroke.
Seminars in Thromb and Hemost 26 (Suppl 1) 79-83, 2000.
256. Cohen M, Turpie AGG. Management of unstable angina and myocardial infarction.
Lancet (Correspondence) 356:1193-1194, 2000.
The
257. Goodman SG, Cohen M. Bigonzi F, Gurfinkel EP, Radley DR, LeIouer V, Fromell GJ,
Demers C, Turpie AGG, Califf RM, Fox KAA, Langer A for the Efficacy and Safety of
Subcutaneous Enoxaparin in Non-Q Wave Coronary Events (ESSENCE) Study Group. Randomized
trial of low molecular weight heparin (Enoxaparin) versus unfractionated heparin for
unstable coronary artery disease. JACC 36 (3):693-698, 2000.
258. Buchanan MR, Schwartz L, Bourassa MG, Brister SJ, Peniston CM on behalf of the BRAT
Investigators. Results of the BRAT Study – A pilot study investigating the possible
significance of ASA nonresponsiveness on the benefits and risks of ASA on thrombosis in
patients undergoing coronary artery bypass surgery. Can J Cardiol 16 (11):1385-1390,
2000.
259. Turpie AGG. Pentasaccharide Org31540/SR90107A clinical trials update: Lessons for
practice. Am Heart J 142S9-S15, 2001.
260. Turpie AGG. Thrombosis prophylaxis in the acutely ill medical patient: Insights
from the prophylaxis in MEDical patients with ENOXaparin (Medenox) Trial. Am J Cardiol
86 (Suppl) 48M-52M, 2000.
261. Ageno W, Turpie AGG. Therapy of unstable angina with the low molecular weight
heparins. Vascular Medicine 5:217-223, 2000
262. Ageno Walter, Turpie Alexander GG. Glycoprotein IIb/IIIa receptor antagonists in
the treatment of unstable angina. JICC 1 (1): 26-31, 2000.
24
25
263. Turpie AGG, Gallus AS, Hoek JA for the Pentasaccharide Investigators. A synthetic
pentasaccharide for the prevention of deep vein thrombosis after total hip replacement.
N Engl J Med 334 (9):619-625, 2001.
264. Ageno W, Turpie AGG. Outpatient treatment of deep vein thrombosis.
Medicine April 74-81, 2001.
Emergency
265. Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AGG. Antithrombotic therapy in
patients with mechanical and biological prosthetic heart valves. Chest 119:220S-227S,
2001.
266. Turpie AGG. Looking forward in the treatment of deep vein thrombosis.
Hematol 38 2 (5): 49-57, 2001.
Sem in
267. Turpie AGG, Antman EM. Low-molecular-weight heparins in the treatment of acute
coronary syndromes. Arch Intern Med 161:1484-1490, 2001.
268. Ageno W, Turpie AGG, Steidl L, Ambrosini F, Cattaneo R, Codari RL, Nardo B, Venco
A. Comparison of a daily fixed 2.5 mg warfarin dose with a 5 mg, International
Normalized Ratio adjusted, warfarin dose initially following heart valve replacement.
Am J of Cardiol 88:40-44, 2001.
269. Bath PMW, Lindenstrom E, Goysen G, De Deyn Peter, Friis P, Leys D, Marttila R,
Olsson J-E, O’Neill D, Orgogozo J-M, Ringelstein B, van der Sande J-J, Turpie AGG for
the TAIST Investigators. Tinzaparin in acute ischaemic stroke (TAIST): a randomixed
aspirin-controlled trial. The Lancet 358:702-710, 2001.
270. Holper EM, Antman EM, McCabe CH, Premmereur J, Gurfinkel E, Bernink PJ, Turpie AG
Bayes de Luna A, Lablanche JM, Fox KM, Salein D, Radley DR, Braunwald E. A simple
readily available method for risk stratification of patients with unstable angina and
non-ST elevation myocardial infarction. Am J Cardiol April 15; 87 (8): 1008-1010, 2001,
271. Becker RC, Eisenberg P, Turie AG. Pathobiologic features and prevention of
thrombotic complications associated with prosthetic heart valves: fundamental principles
and the contribution of platelets and thrombin. Am Heart J 14 (6):1025-1037, 2001.
272. Ginsberg JS, Turpie AG.
2001.
Thromboembolism and pregnancy.
Int Angiol 20 (2):103-109,
273. Turpie AG. Setting a standard for venous thromboembolism prophylaxis.
Syst Pharm 58 (Suppl 2)S18-S23m 2991,
274. Turpie AGG. Pentasaccharide Org31540/SR90107A clinical trials update
practice. American Heart Journal (Supplement) 142 (2):S9-S15, 2001
Am j Health
Lessons for
275. Bauer KA, Eriksson BI, Lassen MR, Turpie AG. A new antithrombotic strategy, the
selective inhibition of coagulation factors, and its importance to the orthopedic
specialist. J South Orthop Assoc 11 (4):197-202, 2002.
276. Eriksson BI, Bauer KA, Lassen MR, Turpie AGG for the Steering Committee of the
Pentasaccharide in hip fracture surgery study. Fondaparinux compared with enoxaparin
for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med
345: 1298-1304, 2002.
277. Bauer KA, Eriksson BI, Lassen MR. Turpie AGG for the Steering Committee of the
Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for
25
26
the prevention of venous thromboembolism after elective major knee surgery.
Med 345: 1305-1310, 2002.
N Engl J
278. Turpie AG. Overview of the clinical results of pentasaccharide in major orthopedic
surgery. Haematologica 86 (Supp 2):59-62, 2001.
279. Ageno W, Turpie AG. New advances in the management of acute coronary syndromes:
Low-molecular weight heparins. CMAJ 166 (7):919-924, 2002.
280. Turpie AGG.
2001.
New data on long-term antiplatelet therapy.
Hematologia 5 (2):47-48,
281. Turpie AGG. New strategies in the prevention and treatment of venous
thromboemblism. Hematologia 5 (2): 45-46, 2001.
282. Bath PMW, Linderstrom E,
J-E, O’Neill D, Orgogozo J-M,
investigators. Tinzaparin in
controlled trial. Lancet 358
Boysen G, De Deyn P, Friis P, Leys D, Marttila R, Olsson
Ringelstein B, van der Sande J-J, Turpie AGG for the TAIST
acute ischaemic stroke (TAIST): A randomised aspirin(983):703-710, 2001.
283. Mohr JP, Thompson JLP, Lazar RM, Levin B, Sacco RL, Furie KL et al.
of warfarin and aspirin for the prevention of recurrent ischemic stroke.
345: 1444-1451, 2001.
284. Turpie AGG.
pp59.
Is new antithrombotic agent superior?
A comparison
N Engl J Med
The Medical Post January 2002,
285. Antman EM, Cohen M, McCabe C, Goodman SG, Murphy SA and Braunwald E for the TIMI11B
and ESSENCE Investigators. Enoxaparin is superior to unfractionated heparin for
preventing clinical events at 1 year follow-up of TIMI 11B and ESSENCE. European Heart
Journal 23:308-314, 2002.
286. Turpie AGG, Mason JA. Review of enoxaparin and its clinical applications in venous
and arterial thromboembolism. Expert Opin Pharmacother 3 (5):575-598, 2002.
287. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR for the PENTATHLON 2000 Study Steering
Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of
venouis thromboembolism after elective hip replacement surgery: a randomised doubleblind trial. The Lancet 359:1721-1726, 2002.
288. Lassen MR, Bauer KA, Eriksson BI, Turpie AGG for the European Pentasaccaride Hip
Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus
preoperative enoxaparin for prevention of venous thromboembolism in elective hipreplacement surgery: a randomised double-blind comparison. The Lancet 359:1715-1720,
2002.
289. Turpie AGG, Bauer KA, Eriksson BI, Lassen. Major Ortopedik Cerrahide Venoz
Tromboembolinin Onlenmesinde Fondaparinuks ile Enoksaparinin Karsilastirilmasi:
Randomize, Cift-kor 4 Calismanin Metaanalizi. Arch Intern Med 162: 1833-1840, 2002.
290. Turpie AGG, Buller HR.
evidence, and applications.
New standards in antithrombotic therapy: concepts, clinical
Semin in Thromb and Hemost 28 (Supp 2):1 2002.
26
27
291. Turpie AGG: Optimizing prophylaxis of venous thromboembolism.
Hemost 28 (Supp 2):25-32, 2002.
292. Turpie AGG, Buller HR. Benefit of selective factor inhibition.
and Hemost 28 (Supp 2):49-50, 2002.
Semin in Thromb and
Semin in Thromb
293.Turpie AGG. Introduction: unstable angina- its pathogenesis and management.
in Thromb and Hemost 28 (Suppl 2) 1-3, 2002.
Semin
294.Antithrombotic Trialis’ Collaboration.
Collaborative meta-analysis of randomised
trials of antiplatelet therapy for prevention of death, myocardial infarction, and
stroke in high risk patients. Brit Med J 324;71-86, 2002.
295. Turpie AGG.
171.
Pentasaccharides.
Seminars in Hematology 39 (3):July, 2002 pp 158-
296. Turpie AG, Eriksson BI, Lassen MR, Bauer KA.
A meta-analysis of fondaparinux
versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic
surgery. J South Orthop Assoc 11 (4):182-188, 2006.
297. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the
prevention of venous thromboembolism in major orthopaedic surgery.
Arch Intern Med
162:1833-1840,2002.
298. Lassen MR, Bauer KA, Eriksson BI, Turpie AGG for the Euopean Pentasaccharide Hip
Elective Surgery Study (EPHESUS) Committee.
Postoperative fondaparinux versus
preoperative enoxaparin for prevention of venous thromboembolism in elective hip
replacement surgery: a randomised double-blind comparison. The Lancet 359 (9319):17151720,2002.
299. Simoons ML, Krzeminska-Pakula M, Alonso A, Goodman SG, Kali A, Loos U, Gosset F,
Louer V, Bigonzi F for the AMI-SK Investigators.
Improved reperfusion and clinical
outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial
infarction.Eur HeartJ 23:1282-1290,2002
.
300. Turpie AGG, Buller HR.
New standards in antithrombotic therapy:
clinical evidence and applications. Introduction. Seminars in Thromb and
(Suppl2), 2002
concepts,
Hemost 28
301. Turpie AGG.
State of the Art – A Journey through the world of antithrombotic
therapy. Thromb and Hemost 28 (Suppl 2):3-11, 2002.
302. Turpie AGG, Lassen MR, Eriksson BI, Bauer KA.
Factor Xa inhibitors in the
prevention and treatment of venous thromboembolism – The role of fondaparinux, first of
a new class of antithrombotic agents. Today’s Therapeutic Trends. 253-267. 2002.
303. Turpie AGG, Chin BSP, Lip GYH.
ABC of antithrombotic therapy.
Venous
thromboembolism: pathophysiology, clinical features, and prevention.
Brit Med J 325:
887-890, 2002.
304. Turpie AG, Chin BS, Lip GY.
Venous thromboembolism: pathophysiology, clinical
features and prevention. BMJ 325: 887-890, 2002
305. Ageno W, Turpie AG.
low molecular weight heparins in the treatment of unstable
angina. Minerva Cardioangiol 50 (6):643-651, 2002.
27
28
306. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR for the Steering Committee of the
Pentasaccharide Orthopedic Prophylaxis Studies
Fondaparinux vs enoxaparin for the
prevention of venous thromoembolism in major orthopedic surgery.
Arch Intern Med
162:1833-1840, 2002.
307. Turpie AGG.
Use of selective factor Xa inhibitors in special
Supplement to American Journal of Orthopedics. XXXI (11S) November 2002.
308. Goldsmith I, Turpie AGG, Lip GYH. ABC of antithrombotic therapy.
disease and prosthetic heart valves. Brit Med J 325:1228-1231, 2002.
populations.
Valvular heart
309. Turpie AGG, Eriksson BI, Lassen MR, Bauer KA.
A meta-analysis of fondaparinux
versus enoxaparin in the prevention of venous thromboembolilsm after major orthopaedic
surgery. JSOA 11 (4):182-188, 2002.
310. Ageno W, Turpie AGG.
Deep venous thrombosis in the medically ill.
Hematology Reports 1:73-78, 2002.
Current
311. Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA,
Haley S, Kovacs MJ, Gent M. for the Randomized comparison of low-molecular-weight
heparin versus oral anticoagulant therapy for the prevention of recurrent venous
thromboembolism in patients with cancer (CLOT) investigators.
Low-molecular-weight
heparin versus a coumarin for the prevention of recurrent venous thromboembolism in
patients with cancer. N Engl J Med 349 (2):146-153, July 2003.
312. Turpie AG, Eriksson BI, Lassen MR, Bauer KA.
Fondaparinux, the first selective
factor Xa inhibitor. Curr Opin Hematol 10 (5):327-332, 2003.
313. Cannon CP, Turpie AGG. Unstable angina and non-ST-elevation myocardial infarction.
Circulation 107:2640-2645, 2003.
314. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, MacKinnon B,
Weitz JI, Crowther MA, Dolan S, Turpie AGG et al. Comparison of low-intensity warfarin
therapy with conventional-intensity warfarin therapy for long-term prevention of
recurrent venous thromboembolism. N Engl J Med 349:631-639, 2003.
315. Turpie AGG, Bauer K, Eriksson B, Lassen M on behalf of the Steering Committees of
the Pentasaccharide Orthopedic Prophylaxis Studies. Thromb Haemost 90:364-366, 2003.
316. Eriksson BI, Lassen MR for the PENTasaccharide in Hip-FRActure Surgery Plus
(PENTHIFRA Plus) Investigators. Duration of prophylaxis against venous thromboembolism
with fondaparinux after hip fracture surgery. Arch Intern Med 163337-1342, 2003.
317. Ageno W, Turpie AGG.
Breathing life into pulmonary embolism.
Cardiology 19 (10):36-39, 2003.
Perspectives in
318. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR Wells P, Julian JA, MacKinnon B,
Weitz JI, Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, van Nguyen P, Demers C,
Kahn SR, Kassis J, Rodger M, Hambleton J, Gent M.
Extended low-intensity
anticoagulation for Thrombo-Embolism Investigators.
Comparison of low intensity
warfarin therapy with conventional-intensity warfarin therapy for long-term prevention
of recurrent venous thromboembolism. N Engl JMed 349 (7):631-639, 2003.
319. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, Janbon C,
Leizorovicz A, Olsson CG, Turpie AG.
Prevention of venous thromboembolism in medical
28
29
patients with enoxaparin: a subgroup analysis of the MEDENOX Study.
Fibrinolysis 14 (4):341-346, 2003.
Blood Coagul
320. The MATISSE Investigators.
Subcutaneous fondaparinux versus intravenous
unfractionated heparin in the initial treatment of pulmonary embolism.
N Engl J Med
349:1695-1702, 2003.
321.
Topol EJ for the APPCR panel.
Arch Intern Med 163:3251-3252, 2003.
Amtocpagi;atopm wotj [rpstjetoc cardiac va;ves/
322. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR.
362: 1582-1583. 2003.
Letter to the Editor, The Lancet
323. Turpie AGG.
Future therapeutic directions for factor Xa inhibiton in the
prophylaxis and treatment of thrombotic disorders. Am J Health-Syst Pharm, 60 (Suppl)
S20-S24, 2003.
324.
Data Safety Monitoring Board – Member – Colwell CW, Berkowitz D, Davidson BL,
Lotke PA, Ginsberg G, Lieberman JR, Naubauer J, mcElhattan JL, Peters GR and Francis CW.
Comparison of Ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the
prevention of venous thromboembolism following total hip replacement.
A randomised,
double-blind study. Journal of Thrombosis and Haemostasis 1:2119-2130, 2003.
325. Turpie A, Bauer K, Eriksson B, Lassen M on behalf of the Steering Committee of the
Pentasaccharide Orthopedic Prophylaxis Studies. Efficacy and safety of fondaparinux in
major orthopedic surgery according to the timing of its first administration.
Thromb
Haemost 90:364-366, 2003.
326. Turpie AG.
2003.
Choice of low molecular weight heparins.
J Thromb Haemost 2 (3):598,
327. Dunn AS, Turpie AG.
Perioperative management of patients receiving
anticoagulants: a systemic review. Arch Interjn Med 163 (8):901-908, 2003
oral
328. Turpie AG, Bauer kA, Eriksson BI, Lassen MR. Fondaparinux and prevention of venous
thromboembolism after orthopaedic surgery. Lancet 362:1582-1583, 2003.
329. Turpie Alexander G.G.:
Fondaparinux (Arixtra) in the future:
horizons. Thromb & Haemost (Suppl) Sept 13-14, 2004, Prague.
exploring new
330. Turpie AGG.
Proven strategies for preventing thromboembolism in heart failure.
Cardiology Special Edition (based on the American Heart Association Scientific sessions,
2003), March 2004.
331. Kearon C, Ginsberg JS, Anderson DR, Kovacs MJ, Wells P, Julian JA, MacKinnon B,
Demers C, Douketis J, Turpie AG, Van Nguyen P, Green D, Kassis J, Kahn R, Solymoss S,
Desjardins L, Geerts W, Johnston M, Weitz JI, Hirsh J, Gent M and the SOFAST
Investigators.
Comparison of 1 month with 3 months of anticoagulation for a firwt
episode of venous thromboembolism associated with a transient risk factor. J Thromb and
Haemo 2:743-749, 2004.
332. Turpie AG.
Venous thromboembolism prophylaxis: role of factor Xa inhibition by
fondaparinux. Surg Technol Int 13:261-267, 2004
29
30
333.
Turpie AGG.
The design of venous thromboembolism prophylaxis trials:
Fondaparinux is definitely more effective than enoxaparin in orthopaedic surgery. Int J
Clin Pract 58:483-493, May 2004.
334.
Turpie AGG.
Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy.
Expert Opin Pharmacother 5 (6): 1373-1384, 2004.
335.Douketis JD, Johnson JA, Turpie AG.
Low molecular weight heparin as briding
anticoagulation during interruption of warfarin: assessment of a standardized
periprocedural anticoagulation regimen. Arch Intern Med 164:1319-1326, 2004.
336. Ageno W, Crotti S, Turpie AG.
The safety of
pregnancy. Expert Opin Drug Saf 3 (2):113-118, 2004.
antithrombotic
therapy
during
337. Turpie AGG, Norris TM.
Thromboprophylaxis in medical patients: the role of lowmolecular weight heparin. Thromb Haemost 92:3-12, 2004.
338. Leizorovicz A, Cohen AT, Turpie AGG, Olsson C-G, Vitkus PT, Goldhaber SZ for the
PREVENT Medical Thromboprophylaxis Study Group. Randomised, placebo-controlled trial of
dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Circulation 110:874-879, 2004.
339.
Lee, AYY, Gent M, Julian J, Bauer KA, Eriksson BI, Lassen MR, Turpie AGG.
Bilateral vs ipsilateral venography as the primary efficacy outcome measure in
thromboprophylaxis clinical trials: a systematic review.
J Thromb and Haemost 2:1-8,
2004.
340. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR.
Superiority of fondaparinux over
enoxaparin in preventing venous thromboembolism in major orthopedic surgery using
different efficacy endpoints. Chest 126:501-508, 2004.
341. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor , Janbon C,
Leizorovicz A, Olsson CG, Turpie AG: MEDENOX Study.
Arch intern Med 164 (9):963-968,
2004
342. Kearon C, Ginsberg JS, Anderson DR, Kovacs MJ, Wells P, Julian JA Mackinnon B,
Demers C, Douketis J, Turpie AG, Van Nguyen P, Green D, Kassis J, Kayhn SR, Solymoss S,
Desjardins L, Geerts W, Johnston M, Weitz JI, Hirsh J, Gent M; SOFAST Investigators.
Comparison of 1 month with 3 months of anticoagulation for a first episode of venous
thromboembolism associated with a transient risk factor.
J Thromb Haemost 2 (5):743749, 2004.
343. Desjardins L, Bara I, Boutitie F, Samama MM, Cohen AT, Combe S, Janbon C,
Leizorovicz A, Olsson CG, Turpie AG. Correlation of plasma coagulation parameters with
thromboprophylaxis, ptient characteristics and outcome in the MEDENOX Study.
Arch
Pathol lb Med 128 (5):519-526, 2004.
344. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C. Csiba L, Kaste M, Leys D,
matias-Guiu J, Rupprecht HJ on behalf of the MATCH Investigators.
Aspirin and
clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient
ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebocontrolled trial. The Lancet 394 (9431):331-337, 2004.
345. Leizorovicz A, Turpie AGG, Cohen AT, Wong W, Yoos MC, Dans A for the SMART Study
Group.
Epidemiology of venous thromboembolism in Asian patients undergoing major
30
31
orthopedic surgery without thromboprophylaxis.
7, 2004.
The SMART Study.
J Thromb Haemost 2:1-
346.
Vaitkus PT, Leizorovicz A, Cohen AT, Turpie AGG, Olsson C-G, Goldhaber for the
PREVENT Medical Thromboprophylaxis Study Group.
Mortality rates and risk factors for
asymptomatic deep vein thrombosis in medical patients. Thromb Haemost 93: 76-79, 2005.
347. Turpie AGG, Eriksson BI, Bauer KA, Lassen MR.
12:371-375, 2004.
Fondaparinux.
J Am Acad Orthop Surg
348. Kovacs MJ, Kearon C, Rodger m, Anderson DR, Turpie AG, Bates SM, Desjardins L,
Douketis J, Kahn SR, Solymoss S, Wells PS.
Single-arm study of bridging therapy with
low molecular weight heparin for patients at risk of arterial embolism who require
temporary interruption of warfarin. Circulation 10 (12):1658-1663, 2004.
349. O’Donnell M, Turpie AGG.
Heart/Drug 4:111-118, 2004.
Low-molecular-weight heparin in acute coronary syndromes.
350. Leizorovicz A, Turpie AGG, cohen AT, Dhillon KS, Angchaisuksiri P, Wang C-J for the
SMART Study Group.
Epidemiology of post-operative venous thromboembolism in Asian
Countries. Int’l J of Angiology 13:101-108, 2004.
351. Turpie AGG, Norris TM.
Thromboprophylaxis in medical patients:
molecular weight heparin. Thromb Haemost 92: 3-12, 2004,
the role of low
352. Leizorovicz A, Turpie AGG, Cohen AT, Wong L, Yoo MC, Dans A for the SMART Study
Group.
Epidemiology of venous thromboembolism in Asian patients undergoing major
orthopedic surgery without thromboprophylaxis. J Thromb Haemost 3:28-34, 2005.
353. Turpie AGG.
Venous thromboembolism prophylaxis: Role of Factor Xa inhibition by
fondaparinux. Surg Tech Int’l XIII:261-267, 2005.
354. Kearon C, Ginsbert JS, Douketis J, Crowther MA, Turpie AG, Bates SM, Lee A, BrillEdwards P, Finch T, Gent M.
A randomised trial of diagnostic strategies after normal
proximal vein ultrasonography for suspected deep venous thrombosis: D-dimer testing
compared with repeated ultrasonography. Ann Intern med 142:490-496, 2005.
355. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR.
Major Ortopedik Cerrahie Venoz
Tromboembolinin Onlenmesinde Fonaparinuks ile Enoksaparinin Karsilastirilmasi. Archives
of Internal Medicine (Turkce tipkibasim) 162:1883-1840, 2005.
356. Abramson BL, Huckell V, Anand S, Forbes T, Gupta A, Harris K, Junaid A, Lindsay T,
McAlister F, Roussin A, Sar J, Teo KK, Turpie AG, Verma S.
Canadian Cardiovascular
Society Consensus Conference: peripheral arterial disease – executive summary.
Can J
Cardiol 21 (12):997-1006, 2005.
357. Spyropoulos AC, Turpie AG.
Perioperative bridging interruption with heparin for
the patient receiving long-term anticoagulation.
Curr Opin Pulm Med 11 (5)373-379,
2005.
358. Turpie AG.
thromboembolism.
The safety of fondaparinux for the prevention and treatment of venous
Expert Opin Drug Saf 4 (4)707-721, 2005
359. Douketis JD, Julian JA, Kearon C, Anderson DR, Crowther MA, Bates SM, Barone M,
Piovella F, Turpie AG, Middeldorp S, van Nguyen P, Prandoni P, Wells PS, Kovacs MJ,
MacGillavry MR, Constantini L, Ginsberg. Does the type of hormone replacement therapy
31
32
influence the risk of deep vein thrombosis?
Haemost 3 (5):943-948, 2005.
A prospective case-control study.
J Thromb
360. Kovacs MJ, Kearon C, Julian JA, Douketis jD, Demers C, Wells PS, turpie AG,
Anderson DR, Kahn SR, Nguyen PV, Green D, Kassis J, Geerts W, Mackinnon B, Ginsberg JS.
Influence of warfarin on symptoms of fatigue: findings of a randomised trial.
Ann
Pharmacother 39 (5):840-842, 2005.
361. Antman EM, Morrow DA, McCabe CH, Jiang F, White HD, Fox KAA, Sharma , Chew P,
Braunwald E for the EXTRACT-TIMI 25 Investigators.
Enoxaparin versus unfractionated
heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation
myocardial infarction: Design and rationale for the Enoxaparin and Thrombolysis
Reperfusion for Acute Myocardial Infarction treatment-thrombolysis in Myocardial
Infarction study 25 (ExTRACT-TIMI 25). American Heart Journal 149:217-226, 2005.
362. Turpie AGG.
Fondaparinux: a Factor
Expert Opinion Pharmacother 5:1-12, 2004.
Xa
inhibitor
for
antithrombotic
therapy.
363. Ageno W, Turpie AGG.
What’s new for DVT prophylaxis for the medically ill.
Disease of the Month 51:194-199, 2005.
364.Turpie AGG. The safety of fondaparinux for the prevention and treatment of venous
thromboembolism. Expert Opinion. Drug Safety. 4 (4):707-721, 2005.
365. Turpie AG. Multidetector-row computed tomography in suspected pulmonary embolism.
N Engl j Med 353 (6):630-631. 2005.
366. Kucher N, Leizorovicz A, Vaitkus PT Cohen AT, Turpie AG et al. Efficacy and safety
of fixed low-dose dalteparin in preventing venous thromboembolism among obese or eoderly
hospitalised patients: a subgroup analysis of the PREVENT trial.
Arch Intern Med 165
(3):341-345, 2005.
367. Goldhaber SZ, Turpie AGG. Prevention of venous Thromboembolism among hospitalised
medical patients. Circulation 111:e1-e3, 2005.
368. Leizorovicz A, Turpie AG, Cohen AT Wong L, Yoo MC, Dans A.
Haemost 3 (1) 28-34, 2005.
SMART study.
J Thromb
369. Vaitkus PT, Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Goldhaber SZ. PREVENT
Medical Thromboprophylaxis Study Group.
Mortality rates and risk factors for
asymptomatic deep vein thrombosis in medical patients. Thromb Haemostst 93 (1):76-79,
2005.
370. Cohen, AT, Alikhan R, Arcelus I, bergmann J-F, Haas S, Merli GJ, Spyropolous AC,
Tapson VP, Turpie AGG.
Assessment of venous thromboembolism risk and the benefits of
thromboprophylaxis in medicalpatients. Thromb Haemost 94:750-759, 2005.
371. Turpie AGG, Fisher WD, Bauer KA, kwong M, Irwin MW, Kalebo P, Misselwitz F, Gent M
for the ODIXa-Knee Study Group. BAY 59-7939: an oral, direct Factor Xa inhibitor for
the prevention of venous thromboembolism in patients after total knee replacement.
A
phase II dose-ranging study. J Thromb & Haemost 3: 2479-2486, 2005.
372. Turpie AGG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kalebo P, Misselwitz F, Gent M
for the ODIXa-Knee Study Group.
Bay 59-7939: an oral, direct Factor Xa inhibitor for
the prevention of venous thromboembolism in patients after total knee replacement.
A
phase II dose-ranging study. J Thromb & Haemost 3:2479-2486, 2005.
32
33
373. Anand SS, Turpie AGG.
Medical Treatment.
Can J Cardiol 21 (12)1002-1003, 2005.
374. Piovella F, Wang CJ, Lu H, Lee K, Lee LH, Lee WC, Turpie AGG, Gallus AS, Planes A,
Passera R. Rouillon A for the AIDA investigators.
Deep-vein thrombosis rates after
major orthopedic surgery in Asia.
An epidemiological study based on postoperative
screening with centrally adjudicated bilateral venography.
J Thromb Haemost 3:26642670, 2005.
375. Eikelboom JW, Quinlan DJ, Mehta SR, Turpie AG, Menown IB, Yusuf S. Unfractionated
and low molecular weight heparin as adjuncts to thrombolysis in aspirin-treated patients
with ST-elevation acute myocardial infarction.
A meta-analysis of the randomised
trials. Circulation 112:3855-3867, 2005.
376. Seshadri N, Goldhaber SZ, Elkayam U, Grimm RA, Groce JB, Heit JA, Spinler
SA, Turpie AG, Bosker G, Klein AL. The clinical challenge of bridging anticoagulation
with low molecular weight heparin in patients with mechanical prosthetic heart valves:
an evidence-based comparative review focusing on anticoagulation options in pregnant and
nonpregnant patients. Am Heart J 50 (s):27-34, 2005.
377. Ageno W, Turpie AG. Clinical trials of deep vein thrombosis prophylaxis in medical
patients. Clin Cornerstone 7 (4):16-22, 2005.
378. Kahn SR, Panju A, Geerts W, Pineo GF, Desjardins l, Turpie AGG, Glezer S, Thabane
L, Sebaldt for the CURVE Study Investigators.
Multicenter evaluation of the use of
venous thromboembolism prophylaxis in acutely ill medical patients in Canada.
Thromb
Res March 1; 2006.
379. Natarajan MK, Velianou JL, Turpie AG, Mehta SR, Raco D, Goodhart DM, Afzal R,
Ginsberg JS.
A randomised pilot study of dalteparin versus unfractionated heparin
during percutaneous coronary interventions. Am Heart J 151 (1)175, 2006
380. Gray LJ, Sprigg N, Bath PMW, Sorensen P, Lindenstrom E, Boysen G, De Deyn PP, Frils
P, Leys D, Marttila R, Olsson J-E, O’Neill D, Ringelstein B, van der Sande J-J, Turpie
AGG for the TAIST Investigators. J Neurol Neurosurg Psychiatry 77:327-333, 2006.
381. Colwell CW, Kwong LM, Turpie AGG, Davidson B.
Flexibility in administration of
fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic
surgery. J of Arthroplasty 21 (1) 36-45, 2006.
382. Cohen AT, Davidson BI, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AGG,
Egberts JFM, Lensing AWA for the ARTEMIS Investigators.
Efficacy and safety of
fondaparinux for the prevention of venous thromboembolism in older acute medical
patients: randomised placebo controlled trial. BMJ 10:1-5, 2006.
383. Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, Budaj A, LopezSendon JL, Guneri S, Jiang F, White HD, Fox KAA, Braunwald E for the ExTRACT-TIMI 25
Investigators.
Enoxaparin versus unfractionated heparin with fibrinolysis for STelevation myocardial infarction. N Eng J Med 354:1477-1488, 2006
384. Spyropoulos AC, Turpie AGG, Dunn AS, Spandorfer j, Douketis J, Jacobson A, Frost Fj
for the REGIMEN Investigators.
Clinical outcomes with unfractionated heparin or low
molecular weight heparin as bridging therapy in patients on long-term oral
anticoagulants: the REGIMEN Registry. J Thromb Haemost; 2006; 4:1246-1252.
385. Kearon C, Ginsberg Js, Douketis J, Turpie AG, Bates SM, Lee AY, Crowther MA, Weitz
JI, Brill-Edwards P, Wells P, Anderson D, Kovacs MJ, Linkins L-A. Julian JA, Bonilla LR,
33
34
386. Gent M for the Canadian Pulmonary Embolism Diagnosis Study (CANPEDS) Group.
evaluation of D-Dimer in the Diagnosis of Pulmonary Embolism. A Randomized Trial.
Intern Med 144:812-821, 2006.
An
Ann
387. Turpie AGG. Clinical efficacy and safety of fondaparinux: an emphasis on results
in the elderly. Aging Health 2 (5) 1-13, 2006.
388. Kearon C Ginsberg JS Julian JA, Douketis J, Solymoss S, Ockelford P, Jackson S,
Turpie AG MacKinnon B, Hirsh J, Gent M.
Comparison of fixed-dose weight-adjusted
unfractionated heparin and low molecular weight heparin for acute treatment of venous
thromboembolism. JAMA 296:935-942, 2006.
389. Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Turpie AG, Wildgoose P,
Yusen RD.
Extended-duration thromboprophylaxis in acutely ill medical patients with
recent reduced mobility: Methodology for the EXCLAIM study. J Thromb Thrombolysis 22
(1):31-38, 2006.
390. Shellong SM, Beyer J, Kakkar AK, Schmidt B, Halbritter K, Eriksson B, Turpie AGG,
Misselwitz F, Kalebo P.
Validierung von zentral befundetem venosen Ultraschall bei
Patienten eine Woche nach orthopadischem Gelenkersatz: Die VENUS-Studie. VASA 35 (Suppl
69: 18, 2006.
391. Turpie AGG, Leizorovicz A. Prevention of venous thromboembolism in medically ill
patients: a clinical update. Postgraduate Medical Journal (Accepted for publication).
34
35
ABSTRACTS AND COMMUNICATIONS
1.
The anticoagulant action of puff adder (B. arientans) venom. (Jointly)
Association of Physicians of East Africa, Nairobi, July 1965.
2.
Mode of action of Echis Carinatus venom. (Jointly)
Physicians of East Africa, Kampala, April 1966.
3.
The role of the fibrinolytic enzyme in spontaneous gangrene in African children.
(Jointly) Royal Medico-Chirurgical Society, Glasgow, November 1966.
4.
Snake venom - friend of foe?
Glasgow, November 1966.
5.
Spontaneous gangrene in African children.
February 1967.
6.
Effect of gaboon viper (Bitis Gabonica) venom on blood coagulation, platelet
aggregation and the fibrinolytic enzyme. (Jointly) Scotish Society for
Experimental Medicine, Glasgow, June 1967.
7.
Trial of deglycyrrhizinised liquorice in gastric ulcer.
Society of Gastroenterology, Prague, July 1968.
8.
Changes in platelet behaviour associated with Arvin therapy.
Research Society, March, 1969.
9.
Action of pyrimido-pyrimidine compounds on platelet behaviour in vitro.
(Jointly) Vth Congress of Asian and Pacific Society of Haematology, Istanbul,
September, 1969.
(Jointly)
Association of the
Royal Medico-Chirurgical Society,
Medical Research Society, London,
(Jointly)
European
(Jointly)
Medical
10.
Platelets. Vascular Surgical Society of Great Britain and Ireland.
November, 1969.
11.
Action of pyrimido-pyrimidine compounds on platelet behaviour in vitro.
(Jointly) 18th Annual Symposium on Blood. Wayne State University School of
Medicine, Detroit, 1970.
12.
Platelets. Association of Surgeons of Great Britain and Ireland.
April, 1970.
13.
Platelet electrophoresis: Effect of defibrination by ancrod.
International Congress of Haematology, Munich, August, 1970.
14.
The effect of cigarette smoking on blood coagulation, platelet aggregation and
fibrinolysis. (Jointly) Scottish Society for Experimental Medicine, Dundee,
January, 1971.
15.
Interaction of Newcastle Disease Virus (NDV) with blood platelets. (Jointly)
American Society of Microbiology, Minneapolis, May, 1971.
Interaction of Newcastle Disease Virus (NDV) with platelets. (Jointly)
Federation of American Societies of Experimental Biology, Atlantic City, April,
1972.
16.
17.
Glasgow,
Glasgow,
Thirteenth
Contrasting effects of human and rabbit platelets in Chikungunya Virus (CV)
infectivity. (Jointly) American Society for Microbiology, Philadelphia, April,
1972.
35
36
18.
Requirement for hemolytic activity in virus-induced platelet aggregation.
(Jointly) Canadian Federation of Biological Societies, Quebec City, June, 1972.
19.
Thrombocytopenia and vasculitis induced in rabbits by Newcastle Disease Virus.
(Jointly) III Congress, International Society on Thrombosis and Hemostasis,
Washington, D.C., August, 1972.
20.
Effect of bacteria on platelet aggregation and the platelet release reaction.
(Jointly) Federation of American Societies of Experimental Biology, Atlantic
City, April, 1973.
21.
Haematological and vascular changes in rabbits inoculated with Newcastle Disease
Virus. (Jointly) American Society for Microbiology, May, 1973.
22.
Thrombolysis with a combination of small doses of subcutaneous heparin.
(Jointly) IV Congress, International Society on Thrombosis and Hemostasis,
Vienna, June, 1973.
23.
Prevention of venous thrombosis with small doses of subcutaneous heparin.
(Jointly) IV Congress, International Society on Thrombosis and Hemostasis,
Vienna, June, 1973.
24.
Virus-induced platelet aggregation: Requirement for sialic acid receptors.
(Jointly) Canadian Society of Microbiologists, Edmonton, June 1973.
25.
125
26.
Prevention of venous thrombosis in neurosurgical patients by intermittent calf
compression. (Jointly) Vth Congress, International Society on Thrombosis and
Hemostasis, Paris, July 1975.
27.
Failure of aspirin and dipyridamole to influence the incidence of leg scandetected venous thrombosis after elective hip surgery. (Jointly) Vth Congress,
International Society on Thrombosis and Hemostasis, Paris, July 1975.
28.
The role of the platelet in thrombosis. Symposium on the Detection and Treatment
of Thromboembolism. Royal College of Physicians and Surgeons of Glasgow, April,
1976.
Impedance Plethysmography. Symposium on the Detection and Treatment of
Thromboembolism. Royal College of Physicians and Surgeons of Glasgow, April,
1976.
29.
I-fibrinogen leg scanning after cardiac revascularization surgery.
Meeting, Toronto, June, 1974.
OMA Tri-City
30.
Diagnosis of venous thrombosis. Invited participant.
Physicians, Atlanta, October, 1976.
31.
Physical methods of venbous thrombosis prophylaxis.
Heart Association, Miami Beach, November, 1976.
32.
Pathogenesis of Thrombosis. Symposium on the Prevention and Treatment of Human
Thromboembolism. Laval University School of Medicine, Quebec City, March, 1976.
33.
Venous Thromboembolism. Prevention by physical methods. Symposium on the
Prevention and Treatment. Symposium on the Prevention and Treatment of Human
Thromboembolism. Laval University School of Medicine, Quebec City, March, 1977.
36
American College of Chest
Plenary session.
American
37
34.
Prevention of venous thrombosis by intermittent sequential calf compression in
neurological and neurosurgical patients. International Society of Haematology,
Paris, July, 1978.
35.
Platelet Suppressant Therapy. Interstate Postgraduate Medical Association,
Washington, D.C., October, 1978.
36.
Turpie AGG, Hirsh J, Genton E, Han P, Gent M: Comparative effects of sodium and
calcium heparin on plasma heparin concentration, partial thromboplastin time,
platelet count and bleeding. Circulation II 58, #801, l978.
37.
Han P, Turpie AGG, Genton E, Hirsh J, Gent M: Negative correlation between
platelet survival, B-thromboglobulin and platelet aggregate ratio in patients
with coronary artery disease. Circulation II 58, #451, 1978.
38.
Zielinsky A, Hirsh J, Hull R, Powers P, Turpie AGG, Han P: Evaluation of
radioimmunoassay for Fragment E (FgE) in the diagnosis of venous thrombosis.
Thrombosis and Hemostasis 42, #0054, 1979.
39.
Kelton J, Neame PB, Walker I, Turpie AGG, McBride J, Han P, Nicholson W, Hirsh J:
Thrombotic thrombocytopenic purpura: Mechanism for effectiveness of
plasmapheresis. Thrombosis and Hemostasis 42, #0264, 1979.
40.
Han P, Turpie AGG, Genton E, Gent M: The effect of antiplatelet drugs on plasma
B-thromboglobulin in coronary artery disease. Thrombosis and Hemostasis 42,
#0131, 1979.
41.
Han P, Turpie AGG, Genton E: Plasma B-thromboglobulin measurement to
differentiate types of thrombocytopenia. Thrombosis and Hemostasis 42, #6010,
1979.
42.
Turpie AGG, Han P, Genton E, Butt RW, Zielinsky A: The effect of contrast media,
125-Iodine labelled fibrinogen, heparin and aspirin on plasma BTG concentration.
Thrombosis and Hemostasis 42, #0721, 1979.
43.
Turpie AGG: Intermittent pneumatic compression prophylaxis in neurosurgery.
Third Annual Symposium on Vascular Surgery, New York, New York, November, 1979.
44.
Turpie AGG: Diagnosis of venous thromboembolism. Third Annual Symposium on
Vascular Surgery, New York, New York, November, 1979.
45.
Turpie AGG: Treatment of venous thromboembolism. Third Annual Symposium on
Vascular Surgery, New York, New York, November, 1979.
46.
Han P, Turpie AGG, Butt RW, LeBlanc P: The use of B-thromboglobulin release to
assess platelet damage during cardiopulmonary bypass. Hematology Society of
Australia, Hobart, Tasmania, February, 1980.
47.
Turpie AGG: Clinical effectiveness of drugs in venous occlusion and pulmonary
embolism. Haematologist's point of view. Conference on Clinical Pharmacology
and Therapeutics, London, England, August, 1980.
48.
deBoer AC, Stewart A, Butt R, Turpie AGG, Genton E: 125I-fibrinogen dilute whole
blood clot lysis time: the effect of intermittent pneumatic compression of the
calves. Joint Meeting of the 18th Congress of the International Society of Blood
Transfusion, Montreal, Canada, August, 1980.
37
38
49.
Turpie AGG, Neame PB, Kelton JG, deBoer AC: Plasma betathromboglobulin
concentration in thrombocytopenia and thrombocytosis. Joint Meeting of the 18th
Congress of the International Society of Haematology and the 16th Congress of the
International Society of Blood Transfusion, Montreal, Canada, August, 1980.
50.
Duke RJ, Turpie AGG, Bloch RF, Devine EE, Derby IR, Kronby MH, Bayer NH:
Clinical trial of low-dose heparin for the prevention of stroke progression.
Circulation II 62: #56, November, 1980.
51.
Turpie AGG, Genton E, Han P, deBoer AC, Gent M: Evaluation of gamma function
calculation of platelet survival time (PST). Circulation II 62: #1060, November,
1980.
52.
Turpie AGG, Genton E, Hull R, Hirsh J, deBoer AC, Hiscoe C. Johnston M, Gent M:
Calf and thigh compression to prevent venous thrombosis (VT) in intracranial
disease (ICD). Circulation II 62: #1300, November, 1980.
53.
Turpie AGG, deBoer AC, Genton E, Duke RJ, Bloch RF, Devine EE, Zielinsky A:
Plasma betathromboglobulin (BTG) and serum fragment E (FgE) in acute partial
stroke. Circulation II 62: #447, November, 1980.
54.
Zielinsky A, Hirsh J, Carter C, Hull R, Powers P, Turpie AGG, Straumanis G: An
evaluation of the radioimmunoassay for Fragment E in the diagnosis of venous
thrombosis in clinically symptomatic patients. Circulation II 62: #634,
November, 1980.
55.
Hull R, Hirsh J, Sackett DL, Taylor W, Carter C, Turpie AGG, Zielinsky A, Powers
P, Gent M: Replacement of venography in suspected venous thrombosis by impedance
plethysmography and 125I-fibrinogen leg scanning. Circulation II 62: #1298,
November, 1980.
56.
Turpie AGG, deBoer AC, Genton E, Butt R, Han P, Gunstensen J: Platelet survival
time and betathromboglobulin in cardiac valve replacement. Am J of Cardiology
47, #498, 1981.
57.
deBoer AC, Han P, Turpie AGG, Butt R, Gent M: The effect of antiplatelet drugs
on platelet survival time and betathromboglobulin in coronary artery disease.
Thrombosis and Hemostasis 46, #60l, July, 1981.
58.
Turpie AGG, deBoer AC, Sealey BJ, Butt R, Genton E: Betathromboglobulin and
fibrinopeptide A in exercise-induced myocardial ischemia. Thrombosis and
Hemostasis 46, #618, July, 1981.
59.
deBoer AC, Turpie AGG, Butt RW, Genton E: The contribution of increased
fibrinolysis induced by intermittent pneumatic compression of the legs in the
prevention of deep vein thrombosis. Thrombosis and Hemostasis 46 #596, July,
1981.
60.
Turpie AGG, deBoer AC, Han P, Butt R, Genton E: Plasma and urine
betathromboglobulin concentration in deep vein thrombosis. Thrombosis and
Hemostasis 46, #515, July, 1981.
61.
deBoer AC, Turpie AGG, Butt R, Genton E: Thromboxane B2 and betathromboglobulin
in symptomatic coronary artery disease. Thrombosis and Hemostasis 46, #844,
July, 1981.
38
39
62.
Kelton JG, Powers PJ, Turpie AGG, Carter CJ: Heparin associated thrombocytopenia
is not a typical drug induced thrombocytopenia. Thrombosis and Hemostasis 46,
#678, July, 1981.
63.
Hull R, Carter CJ, Ockelford P, Hirsh J, Zielinsky A, Turpie AGG, Powers P: The
use of non-invasive testing and venography for the diagnosis of acute recurrent
deep vein thrombosis. International Vascular Symposium, London, October, 1981.
64.
Turpie AGG, deBoer AC, Johnston RV, Butt R, Sealey BJ, Genton E: Plasma
thromboxane B2 and urine betathromboglobulin in exercise-induced myocardial
ischemia. Canadian Cardiovascular Society, Montreal, 1981.
65.
Turpie AGG, Treatment of cerebrovascular disorders. Microsymposium Nieuwe
ontwikkelinger in de diagnostiek en behandeling van arteriele en veneuze
thrombose. Bergwegziekenhuis Rotterdam, Holland, March, 1982.
66.
Hull R, Carter C, Ockelford P, Hirsh J, Turpie AGG, Powers P: Objective
diagnosis of acute recurrent deep vein thrombosis by combined non-invasive
testing and venography. Annals of the Royal College of Physicians and Surgeons
of Canada 15, #132, 1982.
67.
Turpie AGG, deBoer AC, Butt R, Genton E: Activation of platelets and blood
coagulation in exercise-induced myocardial ischemia. Annals of the Royal College
of Physicians and Surgeons of Canada 15, #134, 1982.
68.
Turpie AGG, deBoer AC, Giroux M, Kinch D, Butt R, Gunstensen J, Gent M, E.
Genton: Platelet survival and betathromboglobulin after heterograft mitral valve
replacement. thrombosis and Hemostasis 50 (1), #63, 1983.
69.
Doyle DJ, Turpie AGG, deBoer AC, Talbot C, McNamee J, Hirsh J, Gent M: Failure
of suloctidil to prevent deep venous thrombosis in neurosurgical patients.
Thrombosis and Hemostasis 50 (1), #248, 1983.
70.
Turpie AGG, Butt R, Evaluation of a radioimmunoassay kit for fibrinopeptide A.
Blood 62 (5) Suppl. 1, #1018, 1982.
71.
Doyle DJ, Belbeck LW, McDonald S, Turpie AGG, Gunstensen J; Comparison of lowmolecular weight heparin (Choay 222) with standard heparin for cardiopulmonary
bypass in dogs. Blood 62 (5) Suppl 1, #1102, 1983.
72.
Buchanan MR, Butt RW, Nazir D, Turpie AGG, Hirsh J: The regulation of
platelet/endothelial cell adhesion by two arachidonic acid metabolites.
Thrombosis and Hemostasis 50 (1), #190, 1983.
73.
Hull R, Carter C, Turpie AGG, Jay R, Hirsh J, Kinch D, Raskob G: A randomized
trial of sequential pneumatic limb compression in the prevention of venous
thromboembolism following elective hip surgery. Thrombosis and Hemostasis 50
(1), #66, 1983.
74.
Hull R, Carter C, Turpie AGG, Hirsh J, Jay R, Powers P, Raskob G, Dodd P: A
randomized trial of diagnostic strategies for symptomatic deep vein thrombosis.
Blood 62 (5) Suppl. 1, #1114, 1983.
75.
Hull RD, Carter C, Turpie AGG, Hirsh J, Jay R, Powers P, Kinch D, Raskob G, Dodd
P: A randomized trial of diagnostic strategies for symptomatic deep vein
thrombosis. Clinical and Investigative Medicine 6 (Suppl 1), #117, 1983.
39
40
76.
Jay R, Hull R, Carter C, Ockelford P, Buller H, Turpie AGG, Hirsh J: Outcome of
abnormal impedance plethysmography results in patients with proximal vein
thrombosis: frequency of return to normal. Thrombosis and Hemostasis 50 (1),
#152, 1983.
77.
Hull R, Carter C, Turpie AGG, Hirsh J, Jay R, Kinch D, Raskob G: A randomized
trial of diagnostic strategies for symptomatic deep vein thrombosis. Thrombosis
and Hemostasis 50 (1), #160, 1983.
78.
Hull RD, Hirsh J, Carter C, Jay R, Coates G, Gill J, Turpie AGG: Pulmonary
angiography, ventilation scanning and venography in patients with clinically
suspected pulmonary embolism and abnormal perfusion scans. Thrombosis and
Hemostasis 50 (1), #328, 1983.
79.
Hull R, Carter C, Turpie AGG, Hirsh J, Jay R, Powers P, Dodd P, Gent M: A
randomized trial of diagnostic strategies for symptomatic deep vein thrombosis.
Annals of the Royal College of PHysicians and Surgeons 16, #353, 1983.
80.
Gent M (on behalf of the Study Group): An evaluation of suloctidil in the
secondary prevention of cardiovascular events in patients surviving a
thromboembolic stroke. Ninth International Joint Conference on Stroke and
Cerebral Circulation, Tampa, February, 1984.
81.
Doyle DJ, Cairns JA, Turpie AGG, McEwan P, Holder D, Steele M: Systemic
urokinase in acute myocardial infarction: Dose schedules, lytic effect and
correlation with peak creatine kinase. Clinical and Investigative Medicine 6
(Suppl 1), #71, 1983.
82.
Doyle DJ, Cairns JA, Turpie AGG, Holder DA, McEwan MP: Intravenous urokinase
(UK) and streptokinase (SK) in acute myocardial infarction (AMI). Evaluation by
CK evolution and angiography. Hemostasis 14, #8, 1984.
83.
Turpie AGG: The diagnosis and prevention of venous thromboembolism. Education
Programme, XX Congress of the INternational Society of Hematology, Buenos Aires,
Argentina, September, 1984.
84.
Turpie AGG: Antiplatelet drugs in the prevention of postoperative deep vein
thrombosis. Symposium - Drugs, Present and Future. XX Congress of the
International Society of Hematology, Buenos Aires, Argentina, September, 1984.
85.
Turpie AGG: Non-invasive diagnostic methods in thrombotic occlusive diseases.
XX Congress of the International Society of Hematology, Buenos Aires, Argentina,
September, 1984.
86.
Turpie AGG: EnFermedad Thromboembolica. XXXII Anniversario Del Hospital, Buenos
Aires, Interzonal de Agudos Buenos Aires, Argentina, September, 1984.
87.
Raskob G, Hull R, Leclerc J, Jay R, Hirsh J, Rosenbloom D, Johnston M, David M,
Turpie AG, Gent M: Sustained therapeutic heparinization by subcutaneous
administration for the primary treatment of acute venous thrombosis. Circulation
70 (Suppl II) #36l, 1984.
88.
Raskob G, Hull R, Leclerc J, Jay R, Hirsh J, Rosenbloom D, Johnston M, David M,
Turpie AG, Gent M: Sustained therapeutic heparinization by subcutaneous
administration for the primary treatment of venous thrombosis. Clinical and
Investigative Medicine (Suppl 10) #40, 1984.
40
41
89.
Raskob G, Hull R, Rosenbloom D, Leclerc J, Jay R, David M, Thomas M, Johnston M,
Turpie AG, Gent M, Hirsh J: Lostistics of double-blinding a randomized trial of
intravenous venous subcutaneous heparin for the treatment of venous thrombosis.
Controlled Clinical Trials, 5:300, 1984.
90.
Raskob G, Doyle D, Hull R, Turpie AGG, Hirsh J, David M, Jay R, Leclerc J, Gent
M, Rosenbloom D. Sustained therapeutic anticoagulation with subcutaneous heparin
for the primary treatment of venous thrombosis. Clinical Pharmacology and
Therapeutics 35:268, 1984.
91.
Turpie AGG: Antiplatelet drugs in ischemic heart disease, coronary artery bypass
or peripheral arterial surgery. XVIIth International Congress of Internal
Medicine, Kyoto, Japan, October, 1984.
92.
Jay RM, Turpie AGG, Carter CJ, Hirsh J: Systemic fibrinolysis in venous
thrombosis patients treated with recombinant tisue-type plasminogen activator.
Thrombosis and Hemostasis 54, #01031, 1985.
93.
Turpie AGG, Butt RW, Buchanan MR: The role of the lipoxygenase pathway in the
mechanism of action of Nafazatrom. Thrombosis and Hemostasis 43, #1436, 1985.
94.
Turpie AGG: Venous anatomy: Deep vein thrombosis and misconception about the
disease. Third Annual Seminar on Peripheral Vascular Disease and Hypertension.
Toronto, August, 1985.
95.
Turpie AGG, Jay RM, Carter CJ, Hirsh J: Systemic fibrinolysis in venous
thrombosis patients treated with recombinant tissue-type plasminogen activator.
Clinical and Investigative Medicine 8 (4), #166, 1985.
96.
Turpie AGG, Jay RM, Carter CJ, Hirsh J: A randomized trial of recombinant tissue
plasminogen activator for the treatment of proximal deep vein thrombosis.
Circulation II: 72 (4), #770, 1985.
97.
Turpie AGG, Duke RJ, Bloch RF, Trebilcock RG, Bayer N: A randomized controlled
trial of intravenous heparin for the prevention of stroke progression in acute
thrombotic stroke. Circulation ii: 72 (4) #536, 1985.
98.
Turpie AGG: Thrombolytic therapy in venous and arterial diseases. Clinic Day in
Internal Medicine, Essex Medical Society, Windsor, Ontario, November 20, 1985.
99.
Duke RJ, Turpie AGG, Bloch RF, Trebilcock RG, Bayer NH: A randomized controlled
trial of heparin in acute partial thrombotic stroke. 11th International Joint
Conference on Stroke and Cerebral Circulation. San Francisco, February, 1986.
100.
Turpie AGG: Current trends in treating thromboembolic disorders.
County Medical Socity, February 19, 1986.
Wellington
101.
Turpie AGG: Treatment of deep venous thrombosis. Medical College of Ohio,
Department of Surgery, Toledo, Ohio, April 19, 1986.
102.
Turpie AGG:
thrombosis.
103.
Turpie AGG, Levine MN, Hirsh J, CArter CJ, Jay RM, Powers PJ, Andrew M, Hull RD,
Gent M: Randomized controlled trial of PK 10169 low molecular weight heparin
(LMWH) for venous thrombosis prophylaxis after elective hip surgery. Circulation
74 (Supp II) #941, October, 1986.
Clinical trials with low-molecular weight heparin in venous
Thrombosis Research (Suppl VI) #132, 1986.
41
42
104.
Turpie AGG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Magnani
HN, Hull RD, Gent M: A double blind randomized trial of Org 10172 low molecular
weight heparinoid in the prevention of deep vein thrombosis in patients with
thrombotic stroke. Blood 68 (Supp 1) #342, November, 1986.
105.
Turpie AGG: Current uses of thrombolytic therapy. Presented at the
American College of Physicians/Royal College of Physicians of Canada at the
Ontario Annual Meeting, Toronto, March 7, 1987.
106.
Turpie AGG: Current status of prophylactic anticoagulation: valve replacement,
hip and knee surgery. 59th Annual Scientific Session, The New York Cardiological
Society, April 25, 1987.
107.
Turpie AGG: Anticoagulation in venous and arterial thromboembolism.
for Dupont, Kitchener, Ontario, May 12, 1987.
108.
Turpie AGG: Thrombolytic therapy. Canadian Society of Laboratory Technologists.
Hamilton, Ontario, June 21-26, 1987.
109.
Turpie AGG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Magnani
HN, Hull RD, Gent M: A double blind randomized trial of Org 10172 low molecular
weight heparinoid in the prevention of deep vein thrombosis in patients with
thrombotic stroke. XIth International Congress on Thrombosis and Haemostasis,
Brussels, Belgium, July 6-10, 1987.
110.
Powers PJ, Gent M, Jay R, Hirsh J, Levine M, Turpie G: Deep vein thrombosis
prophylaxis in surgically treated fractured hip patients. XIth International
Congress on Thrombosis and Haemostasis, Brussels, Belgium, July 6-10, 1987.
111.
Turpie AGG, Gunstensen J, Hirsh J, Gent M: Optimal level of anticoagulation
following tissue valve replacement: A randomized trial. Circulation 76 (Supp
IV) #2061, October, 1987.
112.
Turpie AGG, Bloch R, Duke R: Heparin in the treatment of thromboembolic stroke.
New York Academy of Sciences, November 3-5, 1987.
113.
Tratamiento Antitrombotico. Curso Educacional de Avances en Hemostasia Y
Trombosis. Barcelona, Spain, March 3-5, 1988.
114.
Turpie AGG: Current trends in antithrombotic therapy. 33rd Annual Scientific
Assemby of the College of Family Physicians of Canada, Alberta Chapter, Banff,
Alberta, March 6-11, 1988.
115.
Turpie AGG, Robinson J, Mulji AS, Mishkel GJ, Sealey BJ, Doyle DJ, Cairns JA,
Hirsh J, Gent M: Prevention of left ventricular mural thrombosis in acute
myocardial infarction: A double-blind trial comparing high dose with low dose
subcutaneous heparin. Journal of the American College of Cardiology 11 (2) Suppl
A, 26A, 1988.
116.
ISIS Collaborative Group: Results of a large randomised trial of intravenous
streptokinase and oral aspirin in acute myocardial infarction. Journal of the
American College of Cardiology 11 (2) Suppl A, 232A, 1988.
117.
Turpie AGG: Antithrombotic effects of aspirin. Annual Towsley Lecture, Midland
Hospital Centre, Midland, Michigan, April 11, l988.
118.
Turpie AGG: Current trends in thromboembolic disorders: prophylaxis and
treatment. Halton Medical Society Presentation, Oakville, May 18, 1988.
42
Presented
43
119.
Turpie AGG, Levine MN: The relationship between ex-vivo anti-factor Xa levels
and efficacy and safety of low molecular weight heparin. Satellite Symposium Xth International Congress on Thrombosis, Athens, Greece, May 22-27, 1988.
120.
Turpie AGG, Hirsh J, Gent M, Julian D, Johnson J: A randomized trial comparing
graduated compression stockings alone or graduated compression stockings plus
intermittent pneumatic compression with control in the prevention of deep vein
thrombosis in neurosurgical patients. Xth International Congress on Thrombosis,
Athens, Greece, #269, 1988.
121.
Turpie AGG: A randomized study of two intensities of warfarin for prosthetic
heart valve surgery. Xth International Congress on Thrombosis, Athens, Greece,
#77, 1988.
122.
Turpie AGG: Current trends in anticoagulation. "One Day in Hematology 88", The
College of Family Physicians of Canada, Saskatchewan Chapter, May 28, 1988.
123.
Turpie AGG, Robinson JG, Doyle DJ, Mulji AS, Mishkel GJ, Sealey BJ, Cairns JA,
Hirsh J, Gent M: Prevention of left ventricular mural thrombosis in acute
transmural anterior myocardial infarction: A double blind trial comparing high
dose with low dose subcutaneous calcium heparin. XXII Congress of the
International Society of Hematology, Milan, Italy, August 28-September 2, 1988.
124.
Turpie AGG: Platelet involvement in the pathogenesis of atherothrombotic
disease. XXII Congress of the International Society of Hematology, La
Ticlopidina Nella Prevenzione Degli Eventi Trombotici Maggiori Nella Malattia
Vascolare Ischemica Symposium, Milan, Italy, August 28-September 2, 1988.
125.
Turpie AGG: Recombinant tissue plasminogen activator (rt-PA) in pulmonary
embolism and deep venous thrombosis. Special Symposium on Thrombolytic Therapy,
Cardiology Symposium, Section of Cardiology and
Department of Continuing Medical Education, University of Manitoba, September 9,
1988.
126.
Turpie AGG: Premier Symposium Suisse sur l'heparine a bas poids moleculaire.
Etude comparative contre Placebo de l'efficacite de l'Enoxaparine dans a
prevention des thromboses veineuses profondes dans la chirurgie de la hanche.
Berne, Switzerland, December 1, 1988.
127.
Turpie AGG: What is thrombolytic therapy and why do we use it? Contemporary
Management of Cardiovascular Disease - Heart and Stroke Foundation of Ontario,
Toronto, December 15-16, 1988.
128.
Turpie AGG: Thrombolytic therapy in venous thromboembolism. Joint Meeting of
the Forum on Angiology of the Royal Society of Medicine and the British Society
for Haemostasis and Thrombosis. London, England, March 21, 1989.
129.
Turpie AGG: Profilaxis de la thrombosis venosa profunda con heparinas bajo peso
molecular, en pacientes traumatologicos. Academia Nacional de Medicina, Buenos
Aires, Argentina, April 4, 1989.
130.
Turpie AGG: Prevencion de la thrombosis mural ventricular en pacientes con IAM
anterior trasmural: un estudio doble ciego comparando heparina calcica en dosis
altas o bajas. Academia Nacional de Medicina, Buenos Aires, Argentina, April 4,
1989.
43
44
131.
Turpie AGG: Comparacion randomizada de dos intensidades de anticoagulacion oral
luego del reemplazo valvular con protesis biologicas. Academia Nacional de
Medicina, Buenos Aires, Argentina, April 4, 1989.
132.
Turpie AGG: El uso en terapeutica de TVP de las heparinas de bajo peso
molecular. Academia Nacional de Medicina, Buenos Aires, Argentina, April 5,
1989.
133.
Turpie AGG: Nuevas drogas fibrinoliticas en el tratamiento de la embolia
pulmonar. Academia Nacional de Medicina, Buenos Aires, Argentina, April 5, 1989.
134.
Turpie AGG: CATS: Estudio Americano Canadiense sobre Ticlopidina. TASS:
Estudio Ticlopidina-Aspirina en accidente cerebro vascular isquemico. 2o Simposio
Educacional Reunion Satelite Grupo CAHT, Buenos Aires, Argentina, April 6, 1989.
135.
Turpie AGG: Comparacion randomizada de dos intensidades de
anticoagulacion oral luego del reemplazo valvular con protesis biologicas. 2o
Simposio Educacional en Profilaxis Y Terapeutica Antitrombotica Reunion
Cientifica Del Grupo Caht. Chateau Carreras, Cordoba, Argentina, April 7, 1989.
136.
Turpie AGG: The Anti-Clotters in Heart Disease and Stroke.
Education - Telemedicine, April 19, 1989.
137.
Turpie AGG: Anticoagulant therapy after acute myocardial infarction. Thrombosis
and Antithrombotic Therapy: Direction for the '90s" symposium, Fort Lauderdale,
Florida, April 13, 1989.
138.
Turpie AGG: Prevention of post-operative venous thrombosis with low molecular
weight heparin. V Congreso Nacional de la Sociedad Espanola de Trombosis y
Hemostasia. Bilbao, Spain, May 4, 1989.
139.
Turpie AGG: When time is muscle. Critically Speaking, Current Issues.
Henderson General Hospital, Hamilton, June 1, 1989.
140.
Turpie AGG: The Canadian American Stroke Study (CATS). Simposio Internacional
Sobre Terapeutica Antiagregante Plaquetaria Nas Isquemias Cerebrovasculares.
Academia Brasileira de Neurologia, Rio de Janeiro, Brazil, July 25, 1989.
141.
Turpie AGG: The Ticlopidine Aspirin Stroke Study (TASS). Simposio Internacional
Sobre Terapeutica Antiagregante Plaquetaria Nas Isquemias Cerebrovasculares.
Academia Brasileira de Neurologia, Rio de Janeiro, Brazil, July 25, 1989.
142.
Turpie AGG: The Canadian American Stroke Study (CATS). XII Congreso
Interamericano de Cardiologia, Rio de Janeiro, Brazil, July 26, 1989.
143.
Turpie AGG: Prevencion del Accidente Cerebrovascular Isquemico. Resultado de
los Estudios CATS (The Canadian American Ticlodipine Aspirin Study). Symposium
Internacional Sobre Terapeutica Antiplaquetaria, Socieded Argentina Para el
Estudio de la Trombosis. Buenos Aires, Argentina, July 28, 1989.
144.
Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M, Turpie AGG:
Relationship between anti-factor Xa level and clinical outcome in patients
receiving enoxaparine to prevent deep vein thrombosis after hip replacement.
XIIth Congress of the International Society on Thrombosis and Haemostasis.
Tokyo, Japan, August 1989.
44
Continuing Medical
45
145.
Turpie AGG: Clinical evaluation of International Normalized Ratio (INR) for
control of oral anticoagulants. XIIth Congress of the International Society on
Thrombosis and Haemostasis, Tokyo, Japan, August 1989.
146.
Turpie AGG: Significance of CATS and TASS studies from USA and Canada in
prevention of secondary cardiac and cerebral infarction. Academy of Medicine of
Manila, Manila, Philippines, August 1989.
147.
Turpie AGG: Significance of CATS and TASS studies from USA and Canada in
prevention of secondary cardiac and cerebral infarction. Neurological Society of
Thailand, Bangkok, Thailand, September 1, 1989.
148.
Turpie AGG: Enoxaparin prophylaxis in elective hip surgery. Venous
Thromboembolism: Managing the Risk. Rhone-Poulenc Symposium, Berlin, West
Germany, October 5, 1989.
Turpie AGG: The Canadian American Ticloipdine Study (CATS) in thromboembolic
stroke. Prevention and treatment of arterial thromboembolism: New aspects of
Ticlopidine. Lancet (German Supplement) October 6, 1989.
149.
150.
Turpie AGG: TPA vs Heparin in deep venous thrombosis: results of a randomized
controlled trial. American College of Chest Physicians, 55th Annual Scientific
Assembly and XVI World Congress on Diseases of the Chest, Boston, Massachusetts,
October 29, 1989.
151.
Massel D, Turpie AGG, Gill JB, Cairns JA, Russett J: Development of neutralizing
antibodies after 1.5 million units of streptokinase in the treatment of acute
myocardial infarction. Clin and Invest Medicine 12 (5) #120, 1989.
152.
Turpie AGG: Anticoagulant therapy in cardiac disease. Continuing Medical
Education - Day in Medicine, Hamilton Convention Centre, November 1, 1989.
153.
Massel D, Turpie AGG, Gill JB, Cairns JA, Russett J: Development of neutralizing
antibodies after 1.5 million units of streptokinase in the treatment of acute
myocardial infarction. Circulation 80 (4) Suppl, #1398 Abst 1989.
154.
Turpie AGG: Side effects of antithrombotic therapy - optimal dosage. Stroke
Prevention; A symposium. Montreal, Toronto, Halifax, Nov 27-30, 1989.
155.
Turpie AGG: Deep vein thrombosis. Contemporary Management of Cardiovascular
Disease. Heart and Stroke Foundation of Ontario. Toronto, Ontario, December 1415, 1989.
156.
Turpie AGG: The efficacy and tolerance of high-dose or low-dose heparin in the
prevention of mural thrombosis. Prospects and Strategies in Cardiovascular
Research II - Heparins in Cardiology Workshop, Second International Symposium,
Antwerp, Belgium, February 19, 1990.
157.
Turpie AGG: Prevention of cerebral emboli.
Telemedicine Canada, March 2, 1990.
158.
Turpie AGG: Ticlopidine in Recent Thromboembolic Stroke: The Canadian American
Ticlopidine Study (CATS). J of Neurol 237:(2): 161, 1990.
159.
Turpie AGG. Thrombolytic therapy in acute myocardial infarction.
County Medical Society, Guelph, Ontario May 16, 1990.
160.
Turpie AGG. New concepts in antithrombotic therapy. Residents Evening in
Anticoagulant Therapy. DuPont Pharmaceuticals, Hamilton May 24, 1990.
45
Continuing Medical Education -
Wellington
46
161.
Turpie AGG. Update in Thromboembolic Diseases.
Barcelona June 18-19, 1990.
162.
Turpie AGG. Dilemma of the 90's - Stroke Prevention - When to Anticoagulate.
Chinese Canadian Medical Society, Toronto, August 22, 1990.
163.
Connolly SJ. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study.
Clinical and Investigative Medicine 13 (5): #251 Abst 1990.
164.
Massel D, Turpie AGG, Cairns JA, et al. Persistence of neutralizing antibodies
at one year following IV streptokinase for acute myocardial infarction. Clinical
and Investigative Medicine 13 (5). #224 Abst 1990.
165.
Massel D, Gill JB, Turpie AGG, Cairns JA. Thrombolysis does not increase the
rate of cardiac catheterization in the first year post-MI. Clinical and
Investigative Medicine 13 (5) #119 Abst 1990.
166.
Turpie AGG: A symposium on modern anticoagulant therapy.
Foundation of Ontario. Hamilton October 24, 1990.
167.
Connolly SJ (CAFA Study Group) Canadian Atrial Fibrillation Anticoagulation
Study. Circulation 82 Suppl III, #0426, 1990.
168.
Massel D, Turpie AGG, Cairns JA, Gill JB, O'Dell C, Russett, J: Persistence of
neutralizing antibodies at 1 year following IV streptokinase for acute myocardial
infarction. Circulation 82 (4) Suppl, #1007 Abst 1990.
169.
Turpie AGG: Atrial fibrillation revisited.
Hamilton, October 31, 1990.
170.
Turpie AGG: Continuing Medical Education. Valvular Heart Disease -Its
thromboembolic complications and their prevention. "Issues in Thromboembolism in
the 1990's". Tampa, Florida, November 3, 1990.
171.
Levine M, Hirsh J, Gent M, Turpie A et al: A randomized trial comparing
Enoxaparine low molecular weight heparin with standard unfractionated heparin in
patients undergoing elective hip surgery. Blood 76 (10):Suppl 1:513a #2043, Nov
15, 1990.
172.
Turpie AGG: Continuing Medical Education. Prevention of thromboembolic stroke
in non-valvular atrial fibrillation. Lambton County Medical Society, Sarnia,
November 21, 1990.
173.
Turpie AGG: Continuing Medical Education. Indications for Anticoagulation.
Dept. of General Practice Rounds, November 27, 1990
174.
Turpie AGG: Visiting Professor, Medical Grand Rounds, University of California,
San Diego, November 30, 1990.
175.
Turpie AGG: Review of Canadian Atrial Fibrillation Anticoagulation Study.
University of California, San Diego, December 1, 1990.
176.
Turpie AGG: Anticoagulation in prosthetic and natural valve disease.
Contemporary management of Cardiovascular Disease 1990. Heart and Stroke
Foundation of Ontario, Toronto, December 6, 1990.
46
Kabi Pfrimmer S.A. Laboratories.
The Heart and Stroke
17th Annual Day in Medicine,
47
177.
Turpie AGG: The prevention of stroke in non-valvular atrial fibrillation.
Lincoln County Academy of Medicine, St. Catharines, January 12, 1991.
178.
Turpie AGG: The use of heparin in cardiology.
Cardiology, Brussels, Feb 1-2, 1991.
179.
Turpie AGG: Current issues in Anticoagulation.
Society, Brockville, February 13, 1991.
180.
Turpie AGG: Anticoagulant Therapy for Valve Disease. All Heart Symposium '91,
UBC-Continuing Medical Education, Vancouver, February 22, 1991.
181.
Turpie AGG: Fragmin in Australia.
Australia, March 24, 1991.
182.
Turpie AGG: Resultados del estudio ISIS 3. 4 Simposium Internacional, Nuevas
Perspectivas Terapeuticas en Trombosis. Academia Nacional de Medicina, Buenos
Aires, Argentina, April 9, 1991.
183.
Turpie AGG: Terapeutica anticoagulante en la enfermedad coronaria isquemica. 4
Simposium Internacional, Nuevas Perspectivas Terapeuticas en Trombosis. Academia
Nacional de Medicina, Buenos Aires, Argentina, April 10, 1991.
184.
Turpie AGG: Trombosis mural ventricular en el IAM. 4 Simposium Internacional,
Nuevas Perspectivas Terapeuticas en Trombosis. Academia Nacional de Medicina,
Buenos Aires, Argentina, April 11, 1991.
185.
Turpie AGG: Fibrilacion auricular: reduccion de riesgo de stroke. 4 Simposium
Internacional, Nuevas Perspectivas Terapeuticas en Trombosis. Academia Nacional
de Medicina, Buenos Aires, Argentina, April 11, 1991.
186.
Turpie AGG: Estudios en prevencion de TVP y EP
traumatologica con heparina y heparinas de bajo
Internacional, Nuevas Perspectivas Terapeuticas
de Medicina, Buenos Aires, Argentina, April 11,
187.
Turpie AGG: Anticoagulant therapy for valvular heart disease. Directions for
the "90's. Heart and Stroke Foundation of Ontario, May 1, 1991.
188.
Turpie AGG: Atrial fibrillation - Strategies to reduce the rate of stroke. The
Hong Kong Neurological Society and Australian Association of Neurologists Joint
Scientific Meeting, Hong Kong, May 6-8, 1991.
189.
Turpie AGG: Thrombolysis for acute non-myocardial conditions. 7th World
Congress on Emergency and Disaster Medicine. Montreal, May 15, 1991.
190.
Turpie AGG: Heparin and thrombolysis - ISIS-3 and other trials.
Thrombolysis Symposium. Toronto May 24-25, 1991.
191.
Turpie AGG: How to use anticoagulant and fibrinolytic therapy in stroke.
Toronto Neurology Update 1991, Toronto, May 31, 1991.
192.
Turpie AGG: Prevention of stroke in atrial fibrillation. Continuing Medical
Education - Health Care for the Elderly. Hamilton, June 5, 1991.
193.
Turpie AGG: Results and implications of ISIS-3. Issues in reperfusion for the
1990's. The University of Calgary, Banff, June 9, 1991.
Belgian Association for
The Leeds and Grenville Medical
Fragmin Symposium, Hayman Island, Queensland,
47
en el postoperatorio de cirugia
peso molecular. 4 Simposium
en Trombosis. Academia Nacional
1991.
Canadian ISIS-3
48
194.
Turpie AGG:
An evening in Thrombolytics.
195.
Turpie AGG, Levine MN, Powers P, Ginsberg JS, Jay R, Klimek M: A double blind
randomized trial of ORG 10172 low molecular weight heparinoid versus
unfractionated heparin in the prevention of deep vein thrombosis. Thrombosis and
Haemostasis 65 (6) #303, 1991.
196.
Turpie AGG: Lomoparan in the prevention of deep vein thrombosis in stroke
patients. Satellite Symposium, ISTH, Amsterdam, Netherlands, July 6, 1991.
197.
Turpie AGG: Risk factors and prophylaxis of DVT with a LMWH, Fraxiparine.
Satellite Symposium, ISTH, Amsterdam, Netherlands, July 6, 1991.
198.
Turpie AGG: Non-valvular atrial fibrillation: Risks and benefits of
anticoagulant therapy. Essex County Medical Society, Windsor Ontario, July 10,
1991.
199.
Turpie AGG: ISIS III: Resultados de SK vs APSAC vs TPA. XLVII Congresso da
Sociedade Brasileira de Cardiologia. Sao Paulo, Brazil, September 15-19, 1991.
200.
Turpie AGG: Update in Heparin Therapy.
Bangkok, Thailand, September 27, 1991.
201.
Turpie AGG: Advancement in heparin therapy - Singapore Haematological Society,
Singapore, September 29, 1991.
202.
Turpie AGG: Strategies in risk reduction for stroke in patients with ischaemic
heart disease. Singapore Haematological Society, Singapore, September 29, 1991.
203.
Turpie AGG: Role of low molecular weight heparin (Fraxiparine) in cardiology.
An International Symposium. Hypertension and Coronary Heart Disease Beijing,
China, October 1, 1991.
204.
Turpie AGG: Ticlopidine in prevention of major ischemic vascular event. An
International Symposium. Hypertension and Coronary Heart Disease, Beijing,
China, October 1, 1991.
205.
Turpie AGG: Strategies for the prevention of cardioembolic stroke.
Society of Cardiology. Beijing, China, October 2, 1991
206.
Turpie AGG: Advances in heparin therapy.
Kong, October 4, 1991.
207.
Turpie AGG, Gent M, Laupacis A, Latour Y, Wright D, Hoffman J, Gunstensen J,
Basile F, Klimek M, Hirsh J: Reduction in mortality by adding acetylsalicylic
acid (100 mg) to oral anticoagulants in patients with heart valve replacement.
Can J Cardiol 7:95A (Suppl A): August 1991.
208.
Turpie AG: La ticlopidina en la prevencion de accidentes vasculares isquemicos
graves. XXIV Congreso Nacional Sociedad Venezolana de Cardiologia. Caracas,
Venezuela, October 21, 1991.
209.
Turpie AGG: Antithrombotic therapy in rheumatic heart disease.
Foundation of Ontario Symposium, Hamilton, November 6, 1991.
210.
Turpie AGG: Prevention of stroke in atrial fibrillation. Clinical Geriatric
Traineeship. Continuing Medical Education. Hamilton, November 7, 1991.
48
Port Colborne, June 12, 1991.
Haematological Association of Thailand,
Chinese
Hong Kong Haematological Society, Hong
Heart and Stroke
49
211.
Massel D, Turpie AGG, Cairns JA, Ofosu F, Buchanan M: Previous streptokinase
(SK) therapy inhibits subsequent SK thrombolysis. Circulation 84 (4) Abstract
#1858, 1991.
212.
Turpie AGG: Ticlopidine in recent thromboembolic stroke (CATS) and after stroke
precursors (TASS). XII International Congress on Haemostasis and Thrombosis,
Buenos Aires, Argentina, November 19, 1991.
213.
Turpie AGG: Risk factors of DVT. Clinical experience with Fraxiparine in the
prophylaxis and treatment of DVT. XII International Congress on Haemostasis and
Thrombosis, Buenos Aires, Argentina, November 21, 1991.
214.
Turpie AGG: Anticoagulation update - What's new in the 90's. Cambridge Memorial
Hospital Conjoint Clinical Meeting, Cambridge, November 28, 1991.
215.
Turpie AGG: Thrombolysis in acute myocardial infarction: Preliminary Results of
ISIS-3. X Biennial Cardiology Conference, Pakistan Cardiac Society, December 57, 1991.
216.
Turpie AGG: Thrombolytic therapy in acute venous thrombosis. Department of
Surgery, Northwestern University Medical School, Chicago, December 14, 1991.
217.
Turpie AGG: Should I anticoagulate my patient with atrial fibrillation?
Peterborough County Medical Society, Peterborough, Ontario, January 31, 1992.
218.
Turpie AGG:
Cardiology.
219.
Turpie AGG: The role of heparin. Newfoundland Society of Cardiology.
Cornerbrook, Newfoundland, February 1, 1992.
220.
Turpie AGG: Different indications for heparins in cardiology. Third
International Congress in Cardiovascular Research. Antwerp, Belgium, February
17, 1992.
221.
Turpie AGG: Modern anticoagulant therapy.
Brantford, February 26, 1992.
222.
Turpie AGG: Recent advances in antithrombotic therapy.
Toronto, March 3, 1992.
223.
Turpie AGG: Coumadin: Use in patients undergoing hip surgery.
Rounds, Scarborough General Hospital, March 4, 1992.
224.
Turpie AGG: Non-valvular atrial fibrillation. Who to anticoagulate?
anticoagulate? Scarborough Grace General, March 4, 1992.
225.
Turpie AGG:
5, 1992.
Post-MI Anticoagulation.
Jewish General Hospital, Montreal, March
226.
Turpie AGG:
5, 1992.
Post-MI Anticoagulation.
Institute of Cardiology, Montreal, March
227.
Turpie AGG:
1992.
Post-MI Anticoagulation.
Sacre Coeur Hospital, Montreal, March 6,
Expanded Criteria for Thrombolysis. Newfoundland Society of
Cornerbrook, Newfoundland, February 1, 1992.
49
Brantford General Hospital,
St. Michael's Hospital,
Medical/Surgical
How to
50
228.
Turpie AGG: The risk of stroke and the role of antithrombotic therapy. "A Closeup on the Evidence". York County Hospital, Medical Education Committee,
Bradford, Ontario, March 11, 1992.
229.
Turpie AGG: Antithrombotic therapy - Direction for the 90's. Medical Grand
Rounds, Sunnybrook Health Science Centre, Toronto, March 24, 1992.
230.
Turpie AGG: Antithrombotic therapy following heart valve replacement.
Valve Surgery Programme, Lake Louise, Alberta, March 27-29, 1992.
231.
Turpie AGG, Gent M, Laupacis A, Latour Y, Gunstensen J, Basile F, Klimek M, Hirsh
J. Reduction in mortality by adding aspirin (100 mg) to oral anticoagulants in
patients with heart valve replacement. JACC 19 (3):103A, 1992.
232.
Turpie AGG. Antiplatelet therapy in Cardiovascular disease. Joint Board for
Postgraduate Medical Education, Riyadh, Saudi Arabia, April 26, 1992.
233.
Turpie AGG. Antithrombotic therapy in ischaemic heart disease. Joint Board for
Postgraduate Medical Education, Riyadh, Saudi Arabia, April 27, 1992.
234.
Turpie AGG. Low molecular weight heparin, mode of action and clinical
evaluation. Joint Board for Postgraduate Medical Education, Riyadh, Saudi
Arabia, April 27, 1992.
235.
Turpie AGG. Antithrombotic therapy in stroke. Joint Board for Postgraduate
Medical Education, Riyadh, Saudi Arabia, April 27, 1992.
236.
Turpie AGG. The prevention of systemic embolism in mechanical heart valve
replacement. Thrombosis and Its Management. Leon Poller Retirement Symposium,
Manchester, England, May 7-8, 1992.
237.
Turpie AGG: New approach in the management of stroke. Asian/Pacific Congress on
Bleeding Disorders and Transfusion Medicine, Bangkok Thailand, May 10-15, 1992.
238.
239.
Turpie AGG. Thrombosis update. Asian Pacific Congress on Bleeding Disorders and
Transfusion Medicine. Bangkok Thailand, May 10-15, 1992.
Turpie AGG: Risk factors and management of deep vein thrombosis in surgery - New
approach with low molecular weight heparin. Kuala Lumpur Medical Society, Kuala
Lumpur, Malaysia, May 16, 1992.
240.
Turpie AGG: Recent advances in antithrombotic therapy.
Medicine, Manila Philippines, May 18, 1992.
Manila Academy of
241.
Turpie AGG: Recent advances in antithrombotic therapy.
Society, Cebu City Philippines, May 18, 1992.
Cebu City Medical
242.
Turpie AGG: Recent advances in antithrombotic therapy.
Society, Davao City Philippines, May 19, 1992.
Davao City Medical
243.
Turpie AGG. Antiplatelets/Antithrombins/Antibodies. Reperfusion 1992:
Emergency. Univ. of British Columbia, May 23-24, 1992.
244.
Turpie AGG. Final results of the ISIS-3 Study.
Aires, Argentina, June 19, 1992.
245.
Turpie AGG. New advances in ischemic cardiopathy with antiplatelet drugs and
LMWH. Instituto de Cardiologia, Buenos Aires, Argentina, June 19, 1992.
50
Heart
Instituto de Cardiologia, Buenos
51
246.
Turpie AGG. Aspirin, the ageless remedy: Comparison with oral anticoagulants.
Rounds in Emostasi E Trombosi, Instituto di Clinica Medica 2, Pavia Italy,
September 7, 1992.
247.
Turpie AGG. Anticoagulant Therapy - Directions for the 90's.
di Bergamo, Bergamo Italy, September 8, 1992.
248.
Samama MM, Forbes C, Turpie AGG, Lowe G: Treatment of venous thromboembolism.
16th World Congress of the International Union of Angiology, Paris September 16,
1992.
249.
Turpie AGG: Antithrombotic therapy following heart valve replacement.
Tenon, Service de Cardiologie, September 17, 1992.
250.
Turpie AGG: Anticoagulant Therapy. Update on Drugs - Coumadin. Geriatric
Medicine for the Practising Physician. Ontario Association of Medical Directors
of Homes for Senior Citizens. Toronto, September 21, 1992.
251.
Turpie AGG: Anticoagulation: How I would do it. 3rd Annual Cardiovascular
therapeutics related to anticoagulant therapy. The Heart and Stroke Foundation.
Hamilton, October 14, 1992.
Turpie AGG: Thromboembolism - Diagnosis and Treatment. Grey-Bruce Medical
Society, October 15, 1992.
252.
Ospedali Riuniti
Hopital
253.
Gill JB, Fondevila CG, Brister SJ, Turpie AGG et al: Contrast media induces
thrombin generation during PTCA. Canadian Cardiovascular Society, Ottawa,
October 22, 1992.
254.
Turpie AGG: Antithrombotic therapy following heart valve replacement.
Cardiovascular Society, Ottawa, October 23, 1992.
255.
Turpie AGG: Antithrombotic therapy following heart valve replacement.
Controversies in Antithrombotic Therapy. The Thrombosis Interest Group, Ottawa,
October 23, 1992.
256.
Turpie AGG:
Physicians.
257.
Turpie AGG: Anticoagulation.
November 4, 1992.
258.
Turpie AGG:
Physicians.
259.
Turpie AGG: Interchange Forum: Developments in prophylactic therapy for venous
thromboembolic disease. Dallas, November 13, 1992.
260.
Turpie AGG: Clinical update on antithrombotic therapy. The University of
Arizona College of Medicine, New Orleans, November 14, 1992.
261.
Ginsberg JS, Hirsh J, Gent M, McKinnon B, Turpie AGG et al. A phase II study of
Hirulog in the prevention of venous thrombosis after major hip or knee surgery.
Circulation 86 (4) ppI-409, 1992.
262.
Turpie AGG: Combined antiplatelet therapy and full dose anticoagulation in
patients with artificial heart valves. American Heart Association, New Orleans,
November 1992.
Canadian
Thrombophlebitis - Long term treatment. American College of Chest
58th Scientific Assembly, Chicago, October 26, 1992.
19th Annual Day in Medicine, CME, Hamilton,
Therapeutic anticoagulation.
Toronto, November 12, 1992.
51
The Ontario College of Family
52
263.
Turpie AGG: V.T.E.D. Diagnosis: Which investigations?
Congress, San Diego, November 23, 1992.
264.
Turpie AGG: V.T.E.D. Treatment: Treatment in the 90's?
Congress, San Diego, November 24, 1992.
265.
Turpie AGG: Pulmonary thromboembolism. Contemporary Management of
cardiovascular disease. Toronto, December 11, 1992.
266.
Turpie AGG: Low molecular weight heparin and heparinoids and anticoagulation.
American College of Physicians, Indiana Chapter, Indianapolis, Indiana Feb. 20,
1993.
267.
Turpie AGG: DVT and PE in trauma patients.
Hamilton, Feb. 23, 1993.
268.
Turpie AGG: Should I anticoagulate my patient with atrial fibrillation. Special
Education Seminar, Huronia Medical Association, Midland, February 24, 1993.
269.
Turpie AGG: Antithrombotic Update: Direction for the 90's. Continuing Medical
Education, North York Branson Hospital, Toronto, March 4, 1993.
270.
Turpie AGG: Thrombin Inhibitors. ISIS Collaborators Meeting; American College
of Cardiology, Anaheim, California, March 16, 1993.
271.
Turpie AGG: Anticoagulation in the 90's.
Rounds, March 25, 1993.
272.
Turpie AGG, Stanton E: The use of heparin in ischemic heart disease "Unanswered
Questions", Medical Grand Rounds, St. Joseph's Hospital, Hamilton, April 14,
1993.
273.
Turpie AGG: The use of low molecular weight heparins in orthopaedic surgery.
University of Manitoba, Faculty of Medicine, April 19, 1993.
274.
Turpie AGG: The use of low molecular weight heparins in Cardiology. Visiting
Professor, Department of Cardiology, University of Manitoba, April 20, 1993.
275.
Turpie AGG: Short and long-term management of lower extremity venous thrombosis.
The Anticoagulation Forum. Monterey, California, April 23, 1993.
275.
Turpie AGG: Prevention of recurrent Stroke.
York, April 24, 1993.
276.
Turpie AGG: Clinical experience with Orgaran in deep vein thrombosis prophylaxis
in high risk patients. "Clinical use of the new antithrombotic Orgaran in high
risk situations" Symposium, Oss, The Netherlands, April 29, 1993.
277.
Turpie AGG: Prevention of stroke in atrial fibrillation. Continuing Medical
Education, McMaster University, Burlington, Ontario, May 5, 1993.
278.
Turpie AGG: Update on thrombolytic therapy in acute myocardial infarction.
Ontario College of Pharmacists, Toronto, Ontario, May 6, 1993.
279.
Turpie AGG: Oral anticoagulation: New indications and old indications
revisited. Anticoagulation for the 90's Symposium. Springfield, Illinois May 8,
1993.
52
I.S.E.R.V.D. 1st
I.S.E.R.V.D. 1st
Multi-disciplinary Trauma Series,
Belleville General Hospital, Grand
Columbia University, New York, New
53
280.
281.
282.
Turpie AGG: Chairman - New Concepts in Stroke, Pathophysiology anhd Prevention.
2nd International Conference on Stroke, Geneva, Switzerland, May 12-15, 1993.
Turpie AGG: Venous Thromboembolism. Clinical Advances in Venous Thrombo-Embolic
Disease Symposium, McMaster University Faculty of Health Sciences Symposium,
Queen's Landing Inn, Niagara on the Lake, May 15, 1993.
Turpie AGG: Trials with Heparin. European Atherosclerosis Society Meeting,
Capri, Italy, May 16-19, 1993.
283.
Turpie AGG: DVT - Diagnosis, Prevention and Treatment.
General Hospital, Kitchener, Ontario, May 27, 1993.
284.
Turpie AGG: Thromboembolic disease in joint replacement. 48th Annual Meeting of
the Canadian Orthopaedic Association, 27th Annual Meeting of the Canadian
Orthopaedic Research Society, Montreal, Quebec, June 1, 1993.
285.
Turpie AGG: Prevention of deep vein thrombosis after orthopedic surgery.
Orthopedic Rounds, Buffalo General Hospital, June 2, 1993.
286.
Turpie AGG: Platelet dysfunction during cardiopulmonary bypass. Blood
Conservation '93. Department of Anaesthesia of the University of Ottawa.
Halifax, Nova Scotia, June 8, 1993.
287.
Turpie AGG: Diagnosis of venous thromboembolism and pulmonary embolism.
Thrombosis Forum, XVII World Congress on Diseases of the Chest, Amsterdam, June
15, 1993.
288.
Turpie AGG: Controversies in the diagnosis and treatment of venous
thromboembolism.
Thrombosis Forum, XVII World Congress on Diseases of the
Chest, Amsterdam, June 17, 1993.
289.
Turpie AGG: Prophylaxis and treatment of DVT and pulmonary embolism with
heparin/Coumadin, and update on usage of low molecular weight heparin. The
Credit Valley Hospital, Medicine Rounds, Mississauga, June 29, 1993.
290.
Turpie AGG (on behalf of the Thrombosis Interest Group). Control of
anticoagulant therapy: A cross Canada survey. Thromb Haemost 69 (6):667, 1993.
291.
Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsburg J, Geerts W, Neemeh J,
Leclerc J, Powers P, Piovella F, Skingley P. Optimal duration of oral
anticoagulant therapy: A randomized trial comparing four weeks with three months
of warfarin in patients with proximal deep vein thrombosis (DVT). Thromb Haemost
69 (6):982, 1993.
292.
Fondevila CG, Gill JB, Brister SJ, Turpie AGG, Holder DA, Ofosu FA, Buchanan MR.
Contrast media induces thrombin generation during PTCA. Thromb Haemost 69
(6):1014, 1993.
293.
Powers P, Gent M, Klimek M, Levine M, Geerts W, Neemeh J, Turpie AGG, Jay R,
Leclerc J, Ginsberg J, Hirsh J. A randomized double-blind trial comparing a lowmolecular weight heparinoid, Orgaran, with aspirin in the prevention of venous
thromboembolism following surgery for hip fracture. Thromb Haemost 69 (6):1116,
1993.
294.
Levine MN, Hirsh J, Gent M, Turpie AGG, Cruickshank M, Weitz J, Anderson D,
Johnson M. A randomized trial comparing the activated thromboplastin time with
the heparin assay to monitor heparin therapy in patients with acute venous
53
Grand Rounds, St. Mary's
54
thromboembolism requiring large daily doses of heparin.
(6):1122, 1993.
Thromb Haemost 69
295.
Lensing AWA, Doris I, McGrath F, Prandoni P, Ginsberg J, Turpie A, Hirsh J.
Color doppler vs real-time ultrasonography in the diagnosis of postoperataive
asymptomatic DVT. Thrombosis and Haemostasis 69 (6):1361, 1993.
296.
Oberhardt BJ, Gresalfi J, Fearrington T, Goslen G, Turpie AG, Massel D. Rapid
determination of resistance to SK in thrombolytic therapy patients using a simple
in vitro dry chemistry test. Thromb Haemost 69 (6):1654, 1993.
297.
Turpie AGG: Hirulog: A new direct thrombin inhibitor. Potential role in the
prevention of deep vein thrombosis. ISTH Satellite Symposium, New York City,
N.Y. July 10, 1993.
298.
Turpie AGG: Stroke and Cardiac Patients: Preventing vascular events and MI's.
Consultation on Stroke. Kommunicom Publications, 1993.
299.
Turpie AGG: Anticoagulation in the 90's.
Pittsburg PA, July 27, 1993.
Grand Rounds, Jefferson Hospital,
300.
Turpie AGG: Anticoagulation in the 90's.
Pittsburg, PA, July 28, 1993.
Grand Rounds, St. Frances Hospital,
301.
Turpie AGG: The clinical use of low molecular weight heparin.
Rounds, McMaster University, August 5, 1993.
302.
Turpie AGG: Preventing thromboembolic complications from prosthetic heart
valves. 4th Annual Thrombosis, Thromboembolism and Thrombolysis Symposium, Yale
University, August 20, 1993.
303.
Turpie AGG: Prophylaxis and treatment of deep vein thrombosis (Low molecular
weight heparin: Enoxaparin). Detroit Medical Society, Detroit Michigan, August
25, 1993.
304.
Turpie AGG: Venous thromboembolism prophylaxis in orthopaedic surgery.
'93, Seoul Korea, August 30, 1993.
305.
Turpie AGG: Prophylaxis and treatment of DVT and Pulmonary Embolism: Update on
low molecular weight heparin. Grand Rounds, Peel Memorial Hospital, September
17, 1993.
306.
Massel D, Turpie AGG, Oberhardt BJ, Gresalfi NJ, Fearrington T, Goslen G:
Estimation of resistance of streptokinase: A preliminary report of a rapid
bedside test. The Canadian Journal of Cardiology 9 (Suppl E) Abstract #279,
1993.
307.
Turpie AGG: Deep vein thrombosis: Diagnosis and Treatment. Thrombosis: New
Perspectives in Diagnosis and Treatment Symposium, Robert Wood Johnson Medical
School, New Brunswick, New Jersey, October 1, 1993.
308.
Turpie AGG: Diagnosis and treatment of deep vein thrombosis. Current Concepts
in Venous Thromboembolic Disorders Symposium, Episcopal Hospital, Philadelphia,
PA, October 2, 1993.
309.
Turpie AGG: Valvular Heart Disease. "Thrombosis and its Management" Triennial
Symposium, McMaster University, Hamilton, Ontario, October 6, 1993.
54
Medical Grand
SICOT
55
310.
Turpie AGG: Heparin in acute coronary ischaemia. Medical Grand Rounds, Hamilton
Civic Hospitals, Hamilton, Ontario, October 8, 1993.
311.
Turpie AGG: Prophylaxis and treatment of deep vein thrombosis (Low molecular
weight heparin: Enoxaparin). Pulmonology Conference, Kansas University Medical
Centre, Kansas City, MO, October 12, 1993.
312.
Turpie AGG: Prophylaxis and treatment of deep vein thrombosis (Low molecular
weight heparin: Enoxaparin). Noon Conference, Kansas University Medical Centre,
Kansas City, MO, October 12, 1993.
313.
Turpie AGG: Prophylaxis and treatment of deep vein thrombosis (Low molecular
weight heparin: Enoxaparin). Orthopaedic Conference, Research Hospital, Kansas
City, MO, October 12, 1993.
314.
Turpie AGG: Low molecular weight heparin; advancement in antithrombotic therapy.
Medical Rounds, Lincoln General Hospital, Lincoln NE, October 12, 1993.
315.
Turpie AGG: Prophylaxis and treatment of deep vein thrombosis (Low molecular
weight heparin: Enoxaparin). Grand Rounds, Research Hospital, Kansas City, MO,
October 13, 1993.
316.
Turpie AGG: Prophylaxis and treatment of deep vein thrombosis (Low molecular
weight heparin: Enoxaparin). Orthopedic Surgery Grand Rounds, Research Hospital,
Kansas City, MO, October 13, 1993.
317.
Turpie AGG: Prophylaxis and treatment of deep vein thrombosis (Low molecular
weight heparin: Enoxaparin). Orthopedic Surgery Grand Rounds, Truman Medical
Center, Kansas City, MO, October 14, 1993.
318.
Turpie AGG: Prophylaxis and treatment of deep vein thrombosis (Low molecular
weight heparin: Enoxaparin). Thursday Conference, St. Joseph Hospital, Kansas
City, MO, October 14, 1993.
Turpie AGG: Deep venous thrombosis. Medical Grand Rounds, Grant Medical Center,
Columbus, Ohio, November 2, 1993.
319.
320.
Turpie AGG: Prevention of deep vein thrombosis and pulmonary embolism following
total joint replacement: New advances with low molecular weight heparin. The
Southern Tier Orthopedic Society, Binghamton, New York, November 15, 1993.
321.
Turpie AGG: New advances in the prophylaxis of deep vein thrombosis and
pulmonary embolism. The Medical Symposia, Atlanta Georgia, November 16, 1993.
322.
Turpie AGG: Prophylaxis and treatment of DVT and pulmonary embolism: Update on
low molecular weight heparin. Grand Rounds, The Wellesley Hospital, November 17,
1993.
323.
Turpie AGG: Anticoagulants in Haemodialysis. Nephrology Association of
Thailand. Chiang Mai, Thailand, November 23, 1993.
323.
Turpie AGG: Low molecular weight heparin. Its benefits in clinical practice.
Heart Association of Thailand, Bangkok, Thailand, November 25, 1993.
324.
Turpie AGG: New progress in antiplatelet therapy. International Scientific
Meeting of Haematologists from South-East Asian Countries. Medan, Indonesia,
December 2, 1993.
55
56
325.
Turpie AGG: State-of-the-art Lecture. Low molecular weight heparin. Its
benefits in clinical practice. International Scientific Meeting of
Haematologists from South-East Asian Countries. Medan, Indonesia, December 2,
1993.
327.
Turpie AGG: An Overview of antiplatelet in cardiology and neurology.
Heart Association, Jakarta, Indonesia, December 4, 1993.
328.
Turpie AGG: Recent experience with the use of Ticlopidine in cardiology and
neurology. Indonesian Heart Institute, Jakarta, Indonesia, December 4, 1993.
329.
Turpie AGG: Deep vein thrombosis and pulmonary embolism in surgery. Philippines
College of Surgeons, Plenary Lecture. Manila, Philippines, December 8, 1993.
330.
Turpie AGG: New progress in antiplatelet therapy. International Scientific
Meeting of Haematologists from South-East Asian Countries. Medan, Indonesia,
December 2, 1993.
331.
Turpie AGG: State-of-the-art Lecture. Low molecular weight heparin. Its
benefits in clinical practice. International Scientific Meeting of
Haematologists from South-East Asian Countries. Medan, Indonesia, December 2,
1993.
332.
Turpie AGG: Thrombolytics - Prevention of deep vein thrombosis. Medical Grand
Rounds, St. Alphonsus Regional Medical Center, Boise Idaho, December 10, 1993.
333.
Turpie AGG: Thrombolytics - Prevention of deep vein thrombosis.
Orthopedic Association, Boise Idaho, December 10, 1993.
334.
Turpie AGG: The role of low molecular weight heparin in the management of
thromboembolic disease. Medical Grand Rounds. St. Vincent Hospital,
Indianapolis, Indiana, December 13, 1993.
335.
Turpie AGGT: The role of low molecular weight heparin in the management of
thromboembolic disease. Medical Grand Rounds. Lutheran Hospital of Indiana,
Fort Wayne, Indiana, December 14, 1993.
336.
Turpie AGG: New insights on aortic disease, valvular heart disease and
anticoagulation therapy. New Perspectives on the Marfan Syndrome: An Anniversary
Celebration. Stanford University Medical Centre, January 8, 1994.
337.
Turpie AGG: Advances in antithrombotic therapy: role of low molecular weight
heparins. Sutter Community Hospital Noon Conference, San Francisco, CA, February
11, 1994.
338.
Turpie AGG, Gent M: Comparison of warfarin and ASA in patients with
bioprosthetic heart valves. 19th Int'l Joint Conference on Stroke and Cerebral
Circulation. American Heart Association, February 18, 1994.
339.
Turpie AGG: Venous thromboembolism. Advances in prophylaxis and treatment.
Medical Grand Rounds, Baylor University Medical Centre, Dallas, Texas, February
22, 1994.
340.
Turpie AGG: Venous thromboembolism. Advances in prophylaxis and treatment.
Medical Grand Rounds, Presbyterian Hospital, Dallas, Texas, February 23, 1994.
56
Indonesian
Idaho
57
341.
Turpie AGG: Venous thromboembolism. Advances in prophylaxis and treatment.
Medical Grand Rounds, South Western Medical School, Dallas, Texas, February 23,
1994.
342.
Turpie AGG: Antithrombotic Therapy; A major contributor to stroke prevention in
patients with NVAF. The Ukrainian Medical Association of Toronto, Toronto, March
9, 1994.
343.
Turpie AGG: Advances in antithrombotic therapy: role of low molecular weight
heparin. Medical-Surgical Grand Rounds, New Britain General Hospital, New
Britain, CT. March 24, 1994.
344.
Turpie AGG: Advances in antithrombotic therapy: role of low molecular weight
heparin. Surgical Grand Rounds, Hartford General Hospital, Hartford, CT. March
25, 1994.
345.
Turpie AGG: Antithrombotic therapy following heart valve replacement.
Surgery Fellows Symposium, Minneapolis, Minnesota, April 9, 1994.
346.
Turpie AGG: Anticoagulants: Current usage and future prospects.
Conference on Thrombolysis: Montreal, April 15, 1994.
347.
Turpie AGG: Atrial Fibrillation. Practical approach to antithrombotic therapy
in the 1990's. Sunnybrook Health Science Centre, Toronto, June 1, 1994.
348.
Turpie AGG: Advances in antithrombotic therapy: role of low molecular weight
heparin. Medical Grand Rounds, Cedar Sinai Hospital, Los Angeles, California,
June 9, 1994.
349.
Turpie AGG: The role of low molecular weight heparin. Kaiser Foundation
Hospital, Medicine Grand Rounds, Honolulu, Hawaii, July 6, 1994.
350.
Turpie AGG: Current advances in therapy: The role of low molecular weight
heparin. Straub Clinic & Hospital, Honolulu, Hawaii, July 7, 1994.
351.
Turpie AGG: Optimizing Oral Anticoagulant Rx.
Niagara-on-the-Lake, July 17, 1994.
352.
Turpie AGG: Hirudin, Low MW Heparin.
the-Lake, July 17, 1994.
353.
Turpie AGG: Coagulation tests in the diagnosis and management of arterial and
venous thrombosis. American College of Clinical Chemists, New Orleans,
Louisiana, July 19, 1994.
354.
Turpie AGG: Pathophysiology of thromboembolic diseases. American College of
Clinical Chemists, New Orleans, Louisiana, July 19, 1994.
355.
Gawad YA, Skea D, Takahashi M, Tanser PH, Stanton EB, Sayles MJ, Turpie AG et al.
Development and evaluation of an assay specific for human anti-streptokinase
antibodies (IgG). Clin Chem 40 (6): 991, 1994.
356.
Turpie AGG: Coagulation tests in the diagnosis and management of arterial and
venous thrombosis. American Association for Clinical Chemistry, New Orleans,
Louisiana, July 19, 1994.
357.
ISIS-3 Collaborative Group. Mortality in relation to female sex in ISIS-3.
Circulation 88 (4) II: #1178, 1994.
57
Cardiac
First McGill
Canadian Therapeutics Update,
Canadian Therapeutics Update, Niagara-on-
58
358.
ISIS Collaborative Group: ISIS-4: Randomised study of oral captopril in over
50,000 patients with suspected acute myocardial infarction. Circulation 88 (4)
II: #2113, 1994.
359.
ISIS Collaborative Group: ISIS-4: Randomised study of oral isosorbide
mononitrate in over 50,000 patients with suspected acute myocardial infarction.
Circulation 88 (4) II: #2115, 1994.
360.
Turpie AGG: Anticoagulation in cardiovascular diseases. XVI Congress of the
European Society of Cardiology, Berlin, Germany, September 10, 1994.
361.
Turpie AGG: Thrombolysis in venous thrombosis and pulmonary embolism.
Int'l Congress on Fibrinolysis, Leuven, Belgium, September 19, 1994.
362.
Turpie AGG: Thrombogenesis and Atherosclerosis. 39th Annual Scientific Meetings
of the Royal College of Pathologists of Australia, October 4, 1994.
363.
Turpie AGG: Hyper-coagulability. Pathology Professional Activities Committee,
39th Annual Scientific Meetings of the Royal College of Pathologists of
Australia, October 6, 1994.
364.
Turpie AGG: Haemostatic risk factors in thrombosis. Plenary Lecture, 39th
Annual Scientific Meetings of the Royal College of Pathologists of Australia,
October 6, 1994.
365.
Turpie AGG: The effectiveness of thromboembolic prophylaxis in the general
surgical patient. New insights into the Etiology and Prevention of Postsurgical
DVT. Temple University School of Medicine, Chicago, October 8, 1994.
366.
Turpie AGG: Prevention of deep vein thrombosis and pulmonary embolism.
Continuing Medical Education, St. James Hospital, Chicago, Il, October 10, 1994.
XIIth
367. Turpie AGG: Prevention of deep vein thrombosis and pulmonary embolism - The role
of low molecular weight heparin. Continuing Medical Education, St. Anthony
Hospital, Chicago Il, October 12, 1994.
368.
Turpie AGG: Cardiomyopathy and mitral prosthesis malfunction. 5th Annual
Cardiovascular Therapeutics Related to Anticoagulant Therapy, Hamilton, October
19, 1994.
369.
Turpie AGG: Curso de actualizacion en tromboembolismo pulmonar: Hospital
Britanico de Buenos Aires, Buenos Aires, Argentina, October 22, 1994.
370.
Turpie AGG: Antiagregantes en la prevencion primaria y secundaria del Stroke.
III Congreso Interdisciplinaro de Enfermedades Encefalovasculares (Stroke),
Buenos Aires, Argentina, October 24, 1994
371.
Turpie AGG: Queda algo por decir acerca de la fibrilacion auricular. Jornadas
Rioplanteneses de Cardiologia, Buenos Aires, Argentina, October 25, 1994.
372.
Turpie AGG: Advances in antithrombotic therapy: The role of low molecular weight
heparin. Illinois Scientific Meeting, American College of Physicians, October
28, 1994.
373.
Turpie AGG: New anticoagulant agents. Contemporary Management of Cardiovascular
Diseases. Heart and Stroke Foundation of Ontario. December 9, 1994.
58
59
374.
Turpie AGG: Low dose ASA therapy with coumadin. Coagulation Dilemmas in the
Treatment of Cardiovascular Disease, Mercy Heart Institute, February 26, 1995.
375.
Turpie AGG: Oral anticoagulants and aspirin in the prevention of thromboembolism
in patients bearing prosthetic heart valves. Simposio Sulla Terapia
Anticoagulante. Rome, Italy, March 11, 1995.
376.
Turpie AGG: Low molecular weight heparin and prevention of thromboembolic
disease. Brotman Medical Staff Foundation, 33rd Annual Scientific Seminar.
Century City, CA, March 25, 1995
377.
Turpie AGG: Chairman, International Symposium on Thrombosis and LMWH.
College of Physicians of Thailand, Pattaya, Thailand, April 21, 1995.
378.
Turpie AGG: Venous thromboembolism: Consensus statements and management
strategies. The Royal College of Physicians of Thailand, Pattaya, Thailand,
April 21, 1995.
379.
Turpie AGG: Overview of antithrombotic therapy in Cardiology.
The Royal College of Physicians of Thailand, Pattaya, Thailand, April 21, 1995.
380.
Turpie AGG. Venous thromboembolism:
CONA Meeting, Calgary April 1995.
381.
Turpie AGG: Overview of antithrombotic therapy in Cardiology.
of Cardiology. April 24, 1995.
382.
Turpie AGG: Adjuvant and long-term therapies:
Symposium, Hamilton, April 29, 1995.
383.
The Royal
Appropriate assessment and interventions.
Anticoagulants.
Hong Kong College
McMaster
Turpie AGG: Assessing venous thromboembolic risk and initiating appropriate
interventions. New Insights in the Prevention of Venous Thromboembolism in Joint
Replacement. Calgary, April 30, 1995.
384.
Turpie AGG: Overview of antithrombotic therapy in Cardiology.
of Cardiology, Hong Kong, April 24, 1995.
385.
Turpie AGG: Management of perioperative anticoagulant therapy. Haemostatic
problems in adult cardiac surgery. Mechanisms and Management Symposium
Proceedings. May 1995.
386.
Turpie AGG: Anticoagulation in cardiovascular disease.
McMaster University, Hamilton, May 10, 1995.
387.
Turpie AGG: Antithrombotic Therapy: Role of low molecular weight heparin. St
Francis Hospital and Medical Centre, Topeka, Kansas 66606-1609, May 11, 1995.
388.
Turpie AGG. Emerging concepts in the clinical use of low molecular weight
heparins. US Pharmacist Educational Symposia, University of Georgia College of
Pharmacy, June 4, 1995.
389.
Turpie AGG. Clinical perspective on heparin, hirudin and other antithrombin
drugs. XVth Congress of the International Society on Thrombosis and Hemostasis.
Satellite Meeting, Eilat, Israel, June 17.95.
390.
van Riel AM, Henkens CMA, Koopman MMW, Turpie AGG et al: Low molecular weight
heparin (LMWH) and compression stockings in the prevention of venous
59
Hong Kong College
Cardiology Update,
60
thromboembolism (VTE) in neurosurgery. XVth Congress of the International
Society on Thrombosis and Hemostasis, Jerusalem, June 12, 1995 #285.
391.
Cogo A, Lensing AWA, Koopman MMW Turpie AGG et al: Compression ultrasound for
the diagnostic management of clinically suspected deep vein thrombosis. XVth
Congress of the International Society on Thrombosis and Hemostasis, Jerusalem,
June 12, 1995 #758.
392.
Hirsh J, Levine M, Gent M, Turpie AGG. Out patient low molecular weight heparin
versus in-hospital standard heparin for the treatment of venous thrombosis. XVth
Congress of the International Society on Thrombosis and Haemostasis, Jerusalem,
June 12, 1995, #733.
393.
Turpie AGG: Advances in antithrombotic therapy: Novel agents. Wright Schultz
Plenary Lecture. XVth Congress of the International Society on Thrombosis and
Haemostasis, Jerusalem, June 15, 1995.
394.
Turpie AGG. Venous Thromboembolism: Appropriate assessment and interventions.
Hospital Pharmacy Practice, June 1995.
395.
Turpie AGG: LMWH in unstable angina. XVII Congress of the European Society of
Cardiology, Amsterdam, August 20, 1995.
396.
Turpie AGG: The role of aspirin in patients with heart valve prostheses. XVII
Congress of the European Society of Cardiology, Amsterdam, August 20, 1995.
Turpie AGG: HOT LINE III. FRIC Investigators. XVII Congress of the European
Society of Cardiology, Amsterdam, August 20, 1995.
397.
398.
Baird M, Toal CB, Klinke WP, Kostuk WJ, Belanger L, Turpie AG. A randomized,
double-blind multi-centre study of the effects of nifedipine (GITS) in patients
with chronic stable angina. Canadian Journal of Cardiology 11 (Supple E):132E,
August 1995.
399.
Turpie AGG, Ruddy TD, Sussex BA et al. Low molecular weight heparin (Dalteparin)
in unstable coronary artery disease (FRIC). Canadian Journal of Cardiology 11
(Suppl E):110E, August 1995.
400.
Yusuf S, Michaelis W, Hua A, Turpie AGG et al. Effects of oral anticoagulants on
mortality, reinfarction and stroke after myocardial infarction. Canadian Journal
of Cardiology 11 (Suppl E):111E, August 1995.
Davies RF, Butt R, Foris K for the Canadian Zatebradine in Angina Research Group.
Effect of zatebradine and diltiazem on ischaemia during ambulatory monitoring.
Canadian Journal of Cardiology 11 (Suppl E):132E, August 1995.
401.
402.
Turpie AGG: Rationale and use of low molecular weight heparin. "Deep venous
thrombosis and pulmonary embolism: An update on diagnosis, prophylaxis and
management" Symposium. Medical College of Pennsylvania and Hahnemann University,
Philadelphia, Pennsylvania, October 14, 1995.
403.
Turpie AGG: New therapeutic opportunities for heparin: What does low molecular
weight offer? Towards 2000: New pathways for the clinical management of acute
ischemic syndromes. CCS Satellite Symposium, October 24, 1995.
404.
Turpie AGG: Newer Clinical use of heparin and low molecular weight heparins.
Heparin and Related Drugs Session, The Sixth IBC International Symposium,
Washington, October 23, 1995.
60
61
405.
Turpie AGG: Successors to heparin; new antithrombotic agents.
Medical Center symposium at the AHA, November 14, 1995.
Duke University
406.
Turpie AGG.
407.
Turpie AGG: Antithrombotic therapy following heart valve replacement.
Surgery Fellows Symposium. March 28-31, 1996.
408.
Turpie AGG: Nhung nghien cuu ve thuoc tan soi huyet. Sixth Vietnam National
Congress of Cardiology. Ho Chi Minh City, April 27, 1996.
409.
Turpie AGG: The Prevention IV Conference.
Arizona, May 1, 1996.
410.
Turpie AGG. Carotid disease: Medical approach. International Multidisciplinary
Vascular Disease Symposium. Winnipeg, May 15, 1996.
411.
Turpie AGG: Platelets and Thrombosis: Platelet Inhibitors. International
Multidisciplinary Vascular Disease Symposium. Winnipeg, May 15, 1996.
412.
Turpie AGG: Anticoagulation for DVT: LMWH: HIT. International Multidisciplinary
Vascular Disease Symposium. Winnipeg, May 17, 1996.
413.
Turpie AGG: State of the art treatment of thrombotic disorders.
Chemistry 42 (6):S78, 1996.
414.
Turpie AGG. Advances in antithrombotic therapy and the expanding role of low
Molecular weight heparin. The University of Illinois at Chicago. July 19, 1996.
415.
Turpie AGG. Clinical aspects of thrombolytic therapy in AMI. The 2nd Great Wall
International Symposium and Exhibition on Interventional Cardiology (GWISIC '96),
October 7, 1996.
416.
Turpie AGG. Use of low molecular weight heparin and hirudin in unstable coronary
disease. The 2nd Great Wall International Symposium and Exhibition on
Interventional Cardiology (GWISIC '96), October 7, 1996.
417.
Turpie AGG. Advances in antithrombotic therapy: The expanding role for low
molecular weight heparins. Columbian Society of Internal Medicine, Bogota,
Columbia, October 11, 1996.
418.
Turpie AGG. Antithrombotic therapy in cardiac disease: New horizons.
Society of Internal Medicine, Bogota, Columbia, October 11, 1996.
419.
Wells P, Ginsberg J, Anderson D, Hirsh J, Turpie A et al. The use of a clinical
model in a prospective management study of patients with suspected pulmonary
embolism (PE). Haemostasis 26 (3) #8, 1996.
420.
Turpie AGG.
1996.
421.
Ginsberg J, Wells P, Anderson D, Hirsh J, Turpie A et al. The value of the
Simplired7 D-dimer in a prospective management study of patients with suspected
pulmonary embolism (PE). Haemostasis 26 (3) #316, 1996.
422.
Scazziota A, Altman R, Rouvier J, Gurfinkel E, Turpie GG, Glancszpigel R. Low
versus high dose aspirin plus oral anticoagulant in heart valves prostheses.
Final Report. Haemostasis 26 (3) #560, 1996.
Management of perioperative anticoagulant therapy.
Cardiac
American Heart Association, Tucson,
Management of venous thromboembolism.
61
pp 18-19, 1995.
Clinical
Columbian
Haemostasis 26 (3) #291,
62
423.
424.
Turpie AGG. Low molecular weight heparins: A major breakthrough in heparin
therapy. The 2nd International Antithrombotic Therapy Symposium. Proceedings
10-12, 1996.
Turpie AGG. Calf vein thrombosis:
(2):6-8, October 1996
To treat or not to treat.
Thrombosis Forum 2
425.
Turpie AGG (for the FRIC Study Group). Low molecular weight heparin (LMWH) in
the initial and prolonged treatment of unstable coronary artery disease: The
Fragmin in unstable Coronary heart disease study (FRIC). Canadian Cardiovascular
Society Meeting, Montreal, October 31, 1996.
426.
Klein W for the FRIC Study Group. Low molecular weight heparin in the initial
and prolonged treatment of unstable coronary artery disease - the fragmin in
unstable coronary heart disease study (FRIC). European Heart J 17:306, 1996
427.
Ray JG, Turpie AGG. Current antithrombotic therapy following heart valve
replacement in Canada and the United States. Canadian Cardiovascular Society
Meeting, Montreal, October 31, 1996.
428.
Cohen M, Demers C, Gurfinkel E, Fromell G, Langer A, Turpie AGG (ESSENCE Group).
Primary endpoint analysis from the ESSENCE Trial: Enoxaparin vs unfractionated
heparin in unstable angina and non-Q wave infarction. Circulation 94 (8) #3240,
1996.
Turpie AGG, Cruickshank MK, Latour Y, Laupacis A, Gent M, Hirsh J. Double blind
comparison of aspirin with warfarin following bioprosthetic heart valve
replacement. Circulation 94 (8) #3802, 1996.
429.
430.
Turpie AGG.
Introduction.
Presentations in Focus.
ASH Meeting, Dec 7-10, 1996.
431.
Turpie AGG.
1997.
Arterial thrombosis - new treatment approaches.
432.
Turpie AGG: Venous Thrombosis Prophylaxis in Stroke.
Conference, Amsterdam 1997.
433.
Turpie AGG: Unstable Coronary Disease:
heparin. Uppsala, 1997.
Vienna, February,
European Stroke
The rationale for low molecular weight
434.
Turpie AGG. Arterial thrombosis - New treatment approaches.
Annals of Haematology 1996; 74 (Suppl II):373.
434.
Goodman S, Langer A, Demers C, Turpie A et al. One year follow-up
of the ESSENCE trial (Enoxaparin vs heparin in unstqble angina/non Q wave myocardial
infarction): Sustained clinical benefit. Can J Cardiol 14: (Supp F) 122F, 1998.
434.
Turpie AGG, Gent M, Cruickshank M, Kovacs M. et al. Randomized
comparison of moderate (INR 3.0-3.5) with low intensity (INR 2.0-2.5) anticoagulant
therapy in ptients with prosthetic heart valves treated with aspirin (100 mg/dah). Can
J Cardiol 14: (Supp F) 123F, 1998.
434.
Turpie AGG. Cardiac Update: Low molecular weight heparin.
American College of Chest Physicians. Toronto, Nov 12, 1998.
62
63
435.
Cohen Marc, Demers Christine, Gurfinkel Enrique, Fromell Gregg, Langer Anatoly,
Turpie A.G.G. (ESSENCE Group). Management of acute ischemic coronary syndromes in the
next millenium - Review of recent clinical trials, ESSENCE and TIMI 11A-B Trials.
Annals of Haematology 1996; 74 (Suppl II):372.
436.
Cohen M, Demers C, Fromell GJ, Califf RM, Turpie AGG, Gurfinkel E, Langer A, Fox
KA. Hemorrhage incidence with low molecular weight heparin vs unfractionaed heparin in
patients with unstable angina or non-Q-wave myocardial infarction. Anaheim, March 1619, 1997.
437.
Turpie AGG.
Surgery Symposium.
Antithrombotic therapy following heart valve replacement.
Minneapolis April 4, 1997.
Cardiac
438.
Kearon C (for the LAFIT Investigators). Two years of warfarin versus placebo
following three months of anticoagulation for a first episode of idiopathic venous
thromboembolism. XVIth Congress of the International Society on Thrombosis and
Haemostasis. Florence June 6-12, 1997.
439. Ageno W, Turpie AGG. Randomized comparison of anticoagulant control by a computer
generated system with a manual system. Thrombosis and Haemostasis (Supplement) #PS2858,
June 1997.
440.
Cohen M, Turpie AGG, Demers C et al. Blind comparison of enoxaparin (a low
molecular weight heparin) with standard heparin in the treatment of unstable coronary
arery disease ESSENCE trial. Thrombosis and Haemostasis (Supplement) #SC1528, June
1997.
441.
Lowe GDO, Haverkate F, Thompson SG, Bertina RM, Turpie AGG, Mannucci PM.
Prediction of deep vein thrombosis after elective hip surgery by preoperative
haemostatic tests: The ECAT DVT Study. Thrombosis and Haemostasis (Supplement) #OC742,
June 1997.
442.
Fox KAA, Cohen M, Demers C, Gurfinkel E. Fromell G, Bigonzi F, Premmereur J,
Langer A, Goodman S, Califf R, Turpie AGG* for the ESSENCE Group. A double blind
comparison of Enoxaparin (a low molecular weight heparin) with standard heparin in the
treatment of unstable coronary artery disease "THE ESSENCE TRIAL". Heart 77 (Suppl 1)
#58, 1977.
443.
Turpie AGG. Current clinical considerations in venous thromboembolic disease:
The role of low molecular weight heparin. Lafayette, IN, July 14, 1997.
444.
Turpie AGG. Advances in antithrombotic therapy: The role of low molecular weight
heparins. St. Vincent Hospital, Grand Rounds, Indianapolis, IN, July 15, 1997.
445.
Wells PS, Ginsberg J, Anderson DR, Hirsh J, Turpie AGG et al. The value of
bilateral venous compression ultrasonography in patients with suspected pulmonary
embolism (PE). Clin Invest Med 20:#201, 1997.
446.
Buchanan MR, Brister SJ, Turpie AGG. Ticlopidine as an alternate antiplatelet
agent for aspirin nonresponders. Canadian Cardiovascular Society, Winnipeg October 5-9,
1997.
447.
Cohen M, Fox K. Turpie AGG, Demes C. Gurfinkel E, Langer A, Califf R, Fromell G,
Bigonzi F on behalf of the ESSENCE Group. Patient populations and clinical practices:
inter-region differences observed in the international ESSENCE trial. European Heart
Journal 18 (Abstract Supplement) P1046, 1997.
63
64
448.
Bozovich G, Gurfinkel E, Duronto E, Colorio C, Cohen M, Mautner B on behalf of
the ESSENCE Investigators. Relationship between acute thrombotic markers and silent
ischaemic events in patients with unstable angina or non-Q wave myocardial infarction.
European Heart Journa 18 (Abstract Supplement) #2647, 1997.
449.
Ageno W, Johnson J, Nowacki B, Siguenza M, Turpie AGG. Management of the initial
phase of warfarin treatment: Retrospective analysis of post-operative heart valve
replacement patients compared with nonsurgical patients. Blood 1997 90 (10): #3199
450. Turpie AGG. Management of acute coronary syndromes with low molecular weight
heparin: TIMI 11A & 11B. A meeting for Canadian investigators in the ESSENCE trial.
June 28, 1997.
451. Hommel M (for the FISS bis investigators Group). Fraxiparine in ischaemic Stroke
Study (Fiss bis). Cerebrovasc Dis 8 (suppl 4):19, 1998.
452. Ageno W, J Nowacki B, Turpie AGG. Accuracy and clinical utility of
anticoagulation induction using a computer generated system compared with manual dosing
in hospitalized patients. Thrombosis Research 91 (Suppl 1) #156, 1998
453. Ageno W, Johnson J, Nowacki B, Sloane D, Turpie AGG. The role of coagulation
factors II, V, VII and X in the response to oral anticoagulants in patients following
heart valve replacement. Thrombosis Research 91 (Suppl 1) #158, 1998
453. Zighetti ML, Cattaneo M, Turner RM, Thompson SG, Lowe GDO, Haverkate F, Bertina
RM, Turpie AGG, Mannucci PM on behalf of the ECAT DVT Study Group. Fasting plasma
homocysteine levels do not predict the occurrence of deep vein thrombosis after elective
hip replacement. Thrombosis Research 91 (Suppl 1) #30, 1998
454.
Turpie AGG, Gent M. Randomized comparisoN of moderate (INR 3.0 3.5) with low
intensity (INR 2.0-3.5) anticoagulant therapy in patients with prosthetic heart valves
treated with aspirin. Circulation 98 (17) #4026, 1998.
455.
Holper EM, Antman EM, McCabe CH, Turpie AGG et al. A simple,
readily available method for risk stratification of patients with unstable angina or
non-Q myocardial infarction: A TIMI 11B Substudy. Circulation 98 (17) #2594, 1998.
455.
Antman EM, McCage CH, Premmereur, Gurfinkel E, Bernink PJLM,
Turpie AGG: Enoxaparin for the acute and chronic management of unstableangina/non-Q
wave myocardial infarction: Results of TIMI 11B. Circulation 98 (17) #2649, 1998.
456.
Turpie AGG: Antiplatelet agents: Current status and future
perspectives. ISCVS, Gold Coast, Australia, October #109, 1998.
457.
Turpie AGG: The role of low molecular weight heparin in arterial
disease and following arterial interventions.
ISCVS, Gold Coast,
Australia, October
#110, 1998.
458.
Turpie AGG: Thrombophilia update: Guidelines for investigation and
treatment. ISCVS, Gold Coast, Australia, October 112, 1998.
459.
Turpie AGG: Pharmacology of the low molecular weight heparins.
Heart Journal (Supp) 135 (6):S329, 1998.
Am
460.
Turpie AGG. Reducing stroke risk – what can family physicians do?
29th Heart and Stroke Clinical Update. Toronto, Ontario, December 10, 1998.
64
65
462. Turpie AGG. Update on Antiplatelet Drugs.
Medical Grand Rounds, December 15, 1998.
Joseph Brant Memorial Hospital,
463. Bath PM for the TAIST Investigators. Tinzaparin in acute ischaemic stroke trial
(TAIST). XVII Congress of ISTH. August 1999.
464. Turpie AGG.
1999.
Looking forward in DVT treatment.
ISTH Satellite Symposium, August
465. Turpie AGG, Samama M, Cohen A, Darmon J, Desjardins L, Eldor A, Janbon C,
Leizorovicz A, N’Guyen, Olsson C-G, Weisslinger N. prophylaxis of venous
thromboembolism in acute medical patients with enoxaparin: An international, randomized
double-blind, placebo-controlled trial. Circulation 1999; 100 (18) Abst #3264.
466. Cohen M, Antman E, Gurfinkel E, Turpie A, Furst J, Bigonzi F, Radley D. The
benefit of enoxaparin in Q-wave myocardial infarction: A sub-study of the TIMI 11B and
ESSENCE meta-analysis. Circulation 1999; 100 (18) Abst #4182.
467. Antman E, Gurfinkel E, Turpie A, Bernink P, Salein D, Bayes de Luna A, Fox K,
Lablanche J-M, Radley D, Furst J, Braunwald E. Treatment benefit of enoxaparin in
unstable angina/non-Q wave myocardial infarction is maintained at one year followup in
TIMI 11B. Circulation 1999; 100 (18) Abt #2621.
468. Turpie AGG. New Role for low molecular weight heparins in unstable angina-Basis
and Clinical Experience. Donnerstag, May 18, 2000.
469. Turpie AGG, Johnson J. Temporary discontinuation of oral anticoagulants: role of
low molecular weight heparin (dalteparin). Can J Cardiol 16 (Suppl F) September 2000.
470. Turpie AGG, Johnson J. Temporary discontinuation of oral anticoagulants.
low molecular weight heparin (Dalteparin). Circulation 2000 #3983..
Role of
471. Cohen M, Antman EM, Gurfinkel EP, Turpie AGG, Furst J, Bigonzi F, Radley D. The
benefit of enoxaparin in Q-wave myocardial infarction: A Substudy of the TIMI 11B and
ESSENCE meta-analysis. Circulation 2000 #2992.
472.Treatment benefit of enoxaparin in unstable angina/non-Q wave myocardial infarction
is maintained at one year followup in TIMI 11B. Circulation 2000 #106863.
473. Batchelor WB, Radley D, Cohen M, Turpie Alexander G.G., Langer, A, Goodman S. A
comparison of the impact of practice patterns on the outcomes of patients with acute
coronary syndromes in the USA and Canada: Post Hoc analysis of ESSENCE and TIMI 11B.
JACC 37 (2) Suppl A, Feb 2001: 863-5 p 359.
474. Turpie AGG, Bauer KA, Eriksson B, Lassen MR. Pentasaccharide significantly reduces
venous thromboembolism after orthopedic surgery compared with low molecular weight
heparin. Am Coll of Chest Physicians, 2001.
475. Bauer KA, Turpie AGG, Eriksson B, Lassen M. Superiority of pentasaccharide over
low molecular weight heparin for venous thromboembolism prophylaxis is independent of
age, gender and obesity. Am Coll of Chest Physicians, 2001.
476. Peters PC, Turpie AGG, Bauer KA, Eriksson B, Lassen MR. The first synthetic factor
Xa inhibitor, Arixtra/Xantidar (pentasaccharide), shows superiority over low molecular
weight heparin in prevention of venous thromboembolism after orthopedic surgery. Am
Coll of Chest Physicians, 2001-05-15
65
66
477. Turpie AGG, Bauer KA, Eriksson B, Lassen MR, Hawkins DW on behalf of the
Pentasaccharide Orthopedic Prophylaxis Studies Investigators. Petasaccharide
superiority over low-molecular-weight heparin for prevention of venous thromboembolism
after major orthopedic surgery is independent of age. Am Soc of Consultant Pharmacists
(ASCP), 2001.
478. Inverso SM, Antman EM, Spinler SA for the ESSENCE and TIMI11B Investigators.
Safety and efficacy of unfractionated heparin versus enoxaparin in obese patients and
patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B Studies.
ACC, 2001.
479. Turpie AA, Bauer KA, Eriksson B, Lassen MR, Peters PC.
Pentasaccharide
(Fondaparinux): A novel factor Xa inhibitor that is superior to low-molecular-weight
heparin for the prevention of venous thromboembolism after orthopaedic surgery.
American Assoc of Hip and Knee Surgery. Dallas, Texas, November 9, 2001.
480. Turpie AGG.
Pentasaccharide significantly reduces venous thromboembolism after
orthopedic surgery compared with low-molecular-weight heparin. ACCP, Nov 2001.
481. Lassen MR, Eriksson BI, Bauer KA, Turpie AGG.
Pentasaccharide (Fondaparinux),
Aristra®) versus enoxaparin for the prevention of venous thromboembolism (VTE) in major
orthopedic surgery: subgroup analyses on efficacy. Blood 98 (11) Abstract #1117, 2001.
482. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, Janbon C,
Leizorovicz A, Olsson G-G, Turpie AGG.
Benefit of enoxaparin in medical patients: a
subgroup analysis. Blood 98 (11) Abstract #119, 2001.
483. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Effect on efficacy and safety of the
timing of the first pentasaccharide (Fondaparinux, Aristra®) administration in the
prevention of venous thromboembolism (CTE) after major orthopedic surgery.
Blood 908
(11) Abstract #119, 2001.
484. Eriksson B, Bauer KA, Lassen MR, Turpie AGG.
Current management of venous
thromboembolism prophylaxis after major orthopedic surgery in North America and Europe:
lessons from the pentasaccharide (Fondaparinux, Arixtra®) databse.
Blood 98 (11)
Abstract #1133, 2001.
485.
Bauer A, Eriksson BI, Lassen MR, Turpie AGG.
Relevance of systemic venographic
outcomes in venous thromboembolism (VTE) p[rophylaxis studies: lessons from the
pentasaccharide (Fondaparinux, Arixtra®) clinical program.
Blood 98 (11) abstract
#1144, 2001.
486. Kearon C, Ginsberg JS, Anderson DR, Kovacs M, Wells P, Julian J, MacKinnon B,
Demers C, Douketis J, Turpie AG, van Nguyen P, Green D, Kassis J, Kahn S, Solymoss S,
Desjardins L, Geerts W, Weitz J, Hirsh J, Gent M.
Sofast Investigators.
Four weeks
versus 12 weeks of anticoagulation for a first episode of venous thromboembolism (VTE)
provoked by a transient risk factor: A randomized double-blind trial. Blood 98 (11):
Abst#1879,2001.
487.
Turpie
AGG.
Highlights
from
Presentations
of
Thromboprophylaxis: an emerging field. Manila, The Philippines.
488. Turpie AGG.
orthopedic surgery.
Overview of the clinical results of
Haematologica 86 (Supp II) Nov. 2001.
the
Medenox
May 29, 2000.
pentasaccharide
Study.
in
major
489. Eriksson BI, Turpie AGG, Lassen MR, Bauer KA, Comparison of the first synthetic
Factor Xa inhibitor, Fondaparinux sodium, with low molecular weight heparin in the
prophylaxis of venous thromboembolism following major orthopaedic surgery. 7th Congress
of the European Association of Hospital Pharmacists, March 20-22, 2001.
66
67
490. Turpie Alexander G.T.
Setting a standard for venous thromboembolism prophylaxis.
Am J Heath – Syst Pharm 58 (Suppl 2):S-18-S23, 2001.
491. Turpie AGG.
Low molecular weight heparins, novel anticoagulants and strategies.
Am College of Cardiology, March 2002.
492.Turpie AGG.
Meet the Experts Meeting.
Am College of Cardiology, March 2002.
493. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux versus enoxaparin for
the prevention of venous thromboembolism in major orthopaedic surgery. An overview of
efficacy and safety results. International Union of Angiology, New York, April 8/02
494. Turpie AGG. Fondaparinux in the prevention of venous thromboembolism after major
orthopaedic surgery. The Official Journal of the International Society of
Cardiovascular Pharmacotherapy 16 (Supp 1) 2002 #016.
495. Leizorovicz for the PREVENT Study Group. Evaluation of the thbenefits of dalteparin
for thromboprophylaxis in acutely ill medical patients.
9
Int’l Symposium on
Thromboembolism, Seville, June7-8,2002.
496. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Efficacy and Safety of Fondaparinux
in the thromboprophylaxis of venous thromboembolism (VTE) following major orthopaedic
surgery according to the recommendations for use in the United States (USA). The
Hematology Journal, 3: (Suppl 1) June 2002, Abstract #1229.
497. Turpie AGG, Bauer KA, Eriksson B, Lassen MR.
Consistency of fondaparinux
superiority for venous thromboembolism prevention in orthopedic surgery according to
different composite efficacy endpoints. Chest 122 (4) 59S. October 2002 Supplement.
498. Muntz JE, Turpie AGG, Bauer KA, Eriksson B, Lasdsen MR. Role of the duration of
fondaparinux prophylaxis in preventing venous thromboembolism following major orthopedic
surgery. Chest 122 (4) 59S. October Supplement, 2002.
499. Cohen AT, Alikhan R, Combe S, Samama MM, Desjardins L, Eldor A, Janbon C,
Leizorovicz A, Olsson C-G, Turpie AGG. Prevention of venous thromboembolism in medical
patients with enoxaparin: A subgroup analysis of the MEDENOX Study. ICT, Bologna October
2002.
500.Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Role of the duration of fondaparinux
prophylaxis in preventing venous thromboembolism following major orthopedic surgery.
AAPM&R. Orlando, Florida, Nov. 22, 2002.
501.Bauer KA, Eriksson BI, Lassen MR, Turpie AGG.
Influence of the duration of
fondaparinux prophylaxis in preventing venous thromboembolism following hip fracture
surgery. Blood 100 (11):304, 2002.
502.The MATISSE Investigators.
Fondaparinux (Arixtra) in comparison to (low molecular
weight) heparin for the initial treatment of symptomatic deep venous thrombosis or
pulmonary embolism – The Matisse clinical outcome studies. Blood 100 (11):302, 2002.
503. Levine MN, Lee AY, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles F, Julian JA,
Haley S, Kovacs M, Gent M and the CLOT Investigators. A randomised trial of long term
dalteparin low molecular weight heparin (LMWH) versus oral anticoagulant (OA) therapy in
cancer patients with venous thromboembolism (VTE). Blood 100 (11): #298, 2002.
67
68
504. Bauer KA, Eriksson BI, Lassen MR, Turpie AGG. Effect of age on the benefit-risk
ratio of fondaparinux thromboprophylaxis in patients undergoing major orthopedic
surgery. Blood 100 (11): 1066, 2002.
505. Cohen AT, Alikhan R, Arcelus J, Haas S, Spyropoulos, Tapson V, Turpie AGG.
thromboembolism risk assessment in medical patients. Blood 100 (11): 1074, 2002.
Venous
506. Hull R, Schellong S, Tapson V, Yusen R, Monreal M, Samama MM, Turpie AGG. Extended
thromboprophylaxis in acutely ill medical patients with prolonged immobilisation: The
EXCLAIM Study. Blood 100 (11): 3988, 2002.
507. Kovacs M, Kahn S, Solymoss S, Anderson D, Desjardins L, Rodger M, Turpie A, Bates
S, Douketis J, Kearon C, Wells P.
Prospective multicentre trial of bridging therapy
with dalteparin for patients who require temporary discontinuation of OAC for prosthetic
valves or high risk atrial fibrillation. Blood 100 (11):559, 2002.
508. Kearon C, Ginsberg JS, Kovacs M, Anderson DR, Wells P, Julian J, MacKinnon B, Weitz
JI, Crowther MA, Dolan S, Turpie AGG, Geerts WH, Solymoss S, van Nguyen P, Demers C,
Kahn S, Kassis J, Rodger M, Hambleton J, Gent M for the ELATE Iinvestigators.
Low
intensity (INR 1.5-1.9) versus conventional intensity (INR 2.0-3.0) anticoagulation for
extended treatment of unprovoked VTE: a randomised double blind trial. Blood 100 (11):
562, 2002.
509. Piovella F, Turpie AG, Planes A, Gallus A, Wang CJ, Lee WC, lee K, Perdriset G,
Roullon A for the AIDA Steering Committee.
AIDA-Assessment of the incidence of deep
vein thrombosis in Asia following major orthopaedic surgery: Rationale and study design.
6th Congress of the European Federation of National Associations of Orthopaedics and
Traumatology. Helsinki Finland, July 4-10, 2003, #P6108.
510. Lassen MR, Bauer KA, Eriksson BI, Turpie AGG. Elastic stockings do not influence
superior efficacy of fondaparinux over enoxaparin for thromboprophylaxis in orthopaedic
surgery. 6th Congress of the European Federation of National Associations of Orthopaedics
and Traumatology. Helsinki Finland, July 4-10, 2003, #P1062.
511. Lassen MR, Bauer KA, Eriksson BI, Turpie AGG. Effect on efficacy and safety of the
timing of the firstth fondaparinux administration for the thromboprophylaxis in
orthopaedic surgery. 6 Congress of the European Federation of National Associations of
Orthopaedics and Traumatology. Helsinki Finland, July 4-10, 2003, #P1063.
512. Eriksson BI, Bauer KA, Lassen MR, Turpie AGG.
Management of orthopedic surgery
patients in North America, Europe and other countries: Lessons from the fondaparinux
database. 6th Congress of the European Federation of National Associations of
Orthopaedics and Traumatology. Helsinki Finland, July 4-10, 2003, #P1064.
513. Eriksson BI, Bauer KA, Lassen MR, Turpie AGG.
Fondaparinux is
enoxaparin for thromboprophylaxis in orthopedic surgery irrespective of
surgery characteristics.
6th Congress of the European Federation
Associations of Orthopaedics and Traumatology.
Helsinki Finland, July
#P1066.
superior to
patients or
of National
4-10, 2003,
514. Eriksson BI, Bauer KA, Lassen MR, Turpie AGG.
Influence of the duration of
fondaparinux prophylaxis in preventing venous thromboembolism following hip fracture
surgery. 6th Congress of the European Federation of National Associations of Orthopaedics
and Traumatology. Helsinki Finland, July 4-10, 2003, #P1067.
68
69
515. Turpie AGG, Leizorovicz A, Cohen AT, Olsson C-G, Vaitkus PT, Goldhaber SZ for the
PREVENT medical thromboprophylaxis study group.
A randomised, multicentre, placebocontrolled trial of dalteparin for the prevention of venous thromboembolism in 3706
patients hospitalised with acute medical illnesses.
10th Int’l Symposium on
Thromboembolism, London June 13-14, 2003.
516. Spyropoulos AC, Turpie AGG, Dunn A, Spandorfer J for the REGIMEN Investigators.
Clinical outcomes with the use of unfractionated heparin or low molecular weight heparin
as perioperative bridging therapy in patients on long-term oral anticoagulants:
rationale, objectives, design and interim analysis of a large, long-term multicenter
study (REGIMEN). ISTH, Birmingham, July 2003.
517. Turpie AGG, Colwell CW Jr.
Bauer KA, Eriksson BI, Lassen MR.
fondaparinux for thromboprophylaxis in high-risk patients.
Efficacy of
518.
Turpie AG, Colwell CW, Bauer K, Eriksson BI, Lassen MR.
Fondaparinux reduces
long-term risk of venous thromboembolism after surgery for hip fracture.
Chest 124 (4
Suppl): 132S, 2003.
519. Turpie AG, Colwell CW, Bauer K, Eriksson BI, Lassen MR. Efficacy of fondaparinux
for thromboprophylaxis in high-risk patients undergoing hip fracture surgery. Chest 124
(Suppl 4):240S, 2003.
520. Cohen AT,
PREVENT Medical
the prevention
(Suppl 4):132S,
Leizorovicz A, Turpie AG, Olsson C-G, Vaitkus PT, Goldhaber SZ.
The
Thromboprophylaxis Study Group. Thromboprophylaxis with dalteparin for
in acutely ill medical patients with respiratory failure.
Chest 124
2003.
521. Turpie AGG, Leizorovicz A, Cohen AT, Olsson CG, Vaitkus PT, Goldhaber SZ.
Dalteparin for the prevention of venous thromeobmeolism in acutely ill medical patients:
A randomised placebo-controlled trial in 3,706 hospitalized patients. Can J of Cardiol
19 (Suppl A) Abstract #861, 2003.
522.Turpie Alexander G, Colwell, Clifford W, Bauer K, Eriksson Bengt I, Lassen, Michael
R. Fondaparinux reduces long-term risk of venous thromboembolism after surgery for hip
fracture. Chest 124, #4, Suppl, October 2003, pp 132S.
523. Turpie Alexander G, Colwell Clifford W, Bauer Kenneth, Eriksson Bengt I, Lassen
Michael R.
Efficacy of fondaparinux for thromboprophylaxis in high-risk patients
undergoing hip fracture surgery. Chest 124, #4 Suppl, October 2003, pp. 240S.
524. Cohen AT, Davidson B L, Gallus AS, Lassen MR, Tomkowski W, Turpie AGG, Cariou RG,
Egberts JfM, Lensing AWA. Findaparinux for the prevention of VTE in acutely ill medical
patients. Blood 102 (11) #42, 2003.
525.Vaitkus PT, Leizorovicz A, Goldhaber SZ, Olsson C-G, Cohen AT, Weitz JI, Turpie AG.
Mortality is increased in patients with proximal, but not distal, deep vein thrombosis
in medically ill patients entered in the PREVENT trial. Blood 102 (11) #575, 2003.
526.Piovella F, Wang C-J, Lu H, Lee K, Lee LH, Lee WC, Turpie AG, Gallus A, Planes A et
al.
Deep vein thrombosis in Asia after major orthopedic surgery.
An epidemiological
study with mandatory bilateral venography and central indepdent adjudication.
Blood
102: (11) #733, 2003.
527.Anderson FA, Tapson VF, Decousus H, Spyropoulos AC, Turpie AGG, FitzGerald G for the
IMPROVE Investigators. IMPROVE, a multinational observational cohort study of practices
69
70
in prevention of venous thromboembolism in acutely ill medical patients: A comparison
with clinical study patient populations. Blood 102: (11) #1146, 2003.
528.Leizorovicz A, Cohen AT, Turpie AG, Olsson C-G, Vitkus PT, Weitz JI, Goldhaber SZ.
Efficacy and safety of combining dalteparin with aspirin in preventing venous
thromboembolism in medical patients. Blood 102 (11) #1153, 2003.
529.Spyropoulos AC, Turpie AGG, Dunn
Investigators.
Registry of patients on
(Low molecular weight) heparin for an
(REGIMEN): Rationale, design and interim
cohort study. Blood 102 (11) #1161, 2003.
A, Jacobson A, Douketis for the REGIMEN
chronic oral anticoagulant therapy requiring
elective surgical intervention or procedure
analysis of a large, long-term, multicenter
530. Becker F, Leizorovicz A, Olsson C-G, Cohen AT, Vaitkus PT, Turpie AG, Weitz JI,
Goldhaber SZ.
Venous ultrasound: An alternative to venography for evaluation of
dalteparin prophylaxis in 3706 medically ill hospitalised patients.
Blood 102 (11)
#1165, 2003.
531. Panju A, Kahn S, Geerts W, Pineo G, Desjardins L, Turpie A, Glezer S, Sebaldt R.
Utilization of venous thromboprophylaxis in acutely ill medical patients in Canada:
results from the Canadian Registry (CURVE). Blood 102 (11) #1813, 2003.
532. Hull R, Tapson VF, Schellong S, Yusen RD, Monreal M, Samama MM, Turpie AGGl,
Wildgoose P, Cort S. The EXCLAIM study: extended thromboprophylaxis with enoxaparin in
acutely ill medical patients with restricted mobility. Blood 102 (11) #4208, 2003.
533. Tapson VF, Decousus H, Piovella F, Zotz RB, Allegrone J, Anderson FA for the
IMPROVE Investigators.
A multinational observational cohort study in acutely ill
medical patients of practices in prevention of venous thromboembolism: findings of the
International medical prevention registry on venous thromboembolism (IMPROVE).
Blood
102 (11) #1154, 2003.
534. Kucher N, Leizorovicz A, Cohen AT, Turpie AGG, Olsson C-G, Vaitkus PT, Goldhaber
SZ for the PREVENT Medical Thromboprophylaxis Study Group. Obesity does not attenuate
the effectiveness of low-dose dalteparin in preventing venous thromboembolism. ACC New
Orleans, March 2004.
535.Turpie AGG. The diagnosis and treatment of DVT and PE. Lake Louise, April 2004.
Turpie AGG.
New Anticoagulants: Will they alter how we treat patients.
Lake Louise,
April 2004.
536.Turpie AGG.
New anticoagulants: will they alter how we treat patients.
Louise, April 2004.
Lake
537. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Tomkowski W, Turpie AGG, Cariou RG,
Egberts JFM, Lensing AWA. ARTEMIS Investigators (London, UK, Seattle WA, USA, Bedford
Park, SA Australia, Hoersholm Denmark, Warsaw Poland, Hamilton Ontario, Canada, Chilly
Mazarin, France, OSS, The Netherlands).
Thromboprophylaxis with fondaparinux acutely
ill medical patients aged 75 years or more. 21st World Congress of the Int’l Union of
angiology, May 22-26, 2004.
70
71
538. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Tomkowski W, Turpie AGG, Cariou RG,
Egberts JFM, Lensing AWA. ARTEMIS Investigators (London, UK, Seattle WA, USA, Bedford
Park, SA Australia, Hoersholm Denmark, Warsaw Poland, Hamilton Ontario, Canada, Chilly
Mazarin, France, OSS, The Netherlands). Thromboprophylaxis with fondaparinux in acutely
ill medical patients with moderate renal impairement. 21st World Congress of the Int’l
Union of angiology, May 22-26, 2004.
539. Turpie AGG.
May 22-26, 2004.
Future in ACS.
21st World Congress of the Int’l Union of Angiology,
540.
Turpie AGG.
VTE prophylaxis: clinical benefits of new antithrombotics. Int’l
Society on Thrombosis and Haemostasis. Venice, June 17-19, 2004.
541.
Turpie AGG. Preventing VTE in medical patients – clinical evidence to support a
role for LMWH. Int’l Society on Thrombosis and Haemostasis. Venice, June 17-19, 2004.
542.Fiessinger JN on behalf of the TAIPAID stdy Group. S18886, a new specific oral TP
receptor antagonist, is safe and as effective as aspirin in inhibiting platelet
aggregation in patients with peripheral arterial disease.
European Society of
Cardiology, Munich 2004.
543. Davidson B, Turpie AGG, Colwell C, Kwong LM.
Early vs delayed initiation of
fondaparinux prophylaxis to prevent postoperative pulmonary embolism:
A clinical
endpoint study. Chest 126 (4) October 2004 (783S abstr)
544. Anderson FA for the Improve Investigators.
A multinational comparison of
prophylaxis practices for venous thromboembolism during medical intensive care:
findings from IMPROVE. Chest 126 (4) October 2004 (784S abstr).
545.
Fitzgerald G. Tapson V, Spyropoulos AC, Froehlich JB, Decousus H, Bergmann J-F,
Bhong BH, Kakkar AK, Merli GJ, Monreal M, Nakamura M, Pavanello R, Pini M, Piovella F,
Turpie AG, Zotz RB, Anderson FA for the IMPROVE investigators. Does obesity influence
physician practices in provision of prophylaxis for venous thromboembolism? Lessons from
IMPROVE. Chest 126 (4) October 2004 (785 abstr).
546. Dunn AS, Spyropoulos AC, Sirko SP, Turpie AG. PROspective Perioperative Enoxaparin
Cohort Trial: a Multicenter Cohort Study of Perioperative Bridging with Enoxaparin in
Patients Requiring Interruption of Long-term Oral Anticoagulant Therapy (PROSPECT).
ASH, San Diego, December 2004.
547.Turpie AGG for the PROVE Investigators.
A prospective registry on venous
thromboembolic events: The PROVE registry. ASH, San Diego Abstr #923, December 2004.
548. Tapson VF, Decousus H, Bergmann J-F, Eriksson BI, Froehlich, Kakkar AK, Merli GJ,
Monreal M, Spyropoulos AC, Turpe AGG, Zoltz RB, Fitzgerald F, Anderson FA for the
IMPROVE investigators.
The International Medical Prevention Registry on Venous
Thromboembolism (IMPROVE): Venous thromboembolism prophylaxis practices in acutely ill
medical patients. ASH, San Diego, Abst #1762, Dec. 2004
549.
Piovella F, Wang Ching-Jen, Lu Housan, Lee Kenneth, Lee Lai Heng, Lee Lee Won
Chui, Turpie AGG, Gallus A Planes A, Passera R, Roillon A, The AIDA Investigators. High
rate of deep vein thrombosis in Asia after major orthopedic surgery: The AIDA Study
final results. ASH, San Diego, Abst 2580, Dec. 2004.
71
72
550.
Spyropoulos AC, Turpie AGG, Dunn AS, Spandorfer J, Douketis J, Jacobson A, Frost
FJ for the REGIMEN Investigators. Clinical outcomes with unfractionated heparin or lowmolecular weight heparin as bridging therapy in patients on long-term oral
anticoagulants: results from the REGIMEN Registry.
ASH, San Diego, Abst #709, Dec.
2004.
551.
Cohen AT, Alikhan R, Arcelus JI, Bergmenn J-F, Haas S, Merli GJ, Spyropoulos AC,
Tapson VF, Turpie AGG.
Identification of medical patients who should receive venous
thromboembolism prophylaxis. ASH, San Diego, Abstr #1786, Dec 2004.
552.
Dunn AS, Spyropolous AC, Spyropoulos AC, Sirko SP, Turpie AGG.
Perioperative
bridging therapy
with enoxaparin in patients requiring interruption of long-term oral
anticoagulant therapy: a multicenter cohort study.
ASH, San Diego, Abstr #1786, Dec
2004.
553.
Turpie AGG, Douketis JD.
Enoxaparin is effective and safe as bridging
anticoagulation in patients with a mechanical prosthetic heart valve who require
temporary interruption of warfarin because of surgery or an invasive procedure.
ASH,
San Diego, Abstr #703, Dec 2004.
554.
Cohen AT, Gallus AS, Davidson BL, Lassen MR, Prins MH, Tomkowski W, Turpie AGG,
Egberts JFM, Lensing AWA.
Benefit of fondaparinux in medical patients: a subgroup
analysis. ASH, San Diego, Abstr #4079, Dec 2004.
555.
Kearon C, Ginsberg jS, Julian J, Douketis J, Solymoss S, Ockelford P, Jackson S,
Turpie G, McCarty D, MacKinnon B, Hirsh J, Gent M, FIDO Investigators.
Fixed dose,
weight-adjusted, unfractionated heparin (UFH) given subcutaneously (sc) without
laboratory monitoring for acute treatment of venous thromboembolism (VTE):
Randomized
comparison with low molecular weight heparin (LMWH).
ASH, San Diego, Abstr #707, Dec
2004.
556. Spyropoulos AC, Dunn AS, Gurpie AGG, Kaatz S, Spandorfer J, Douketis J, Jacobson A,
Frost FJ for the REGIMEN Investigators, Lovelace Medical Centre, Albuquerque, NM.
Perioperative bridging therapy with unfractionated heparin or low molecular weight
heparin in patients with mechanical heart valves on long-term oral anticoagulants:
Results from the REGIMEN Registry. JACC 45 #3 (Suppl A): 1016-47, 2005.
557.Eriksson BI, Borris LC, Dahl OE, Haas SK, Huisman MV, kakkar AK, Kalebo P,
Misselwitz F, Muhlhofer EM for the ODIXa-HIP Study Investigators. Prevention of venous
thromboembolilsm with an oral, direct factor Xa inhibitor – Bay 59-7939 –in Elective Hip
Replacement: a dose-ranging study.
Oral presentation at the XXth ISTH, Sydney,
Australia, 6-12 August, 2005.
558. Turpie AGG, Fisher WD, Bauer K, Kwiong L, Gent M, Misselwitz F for the ODIXa-Knee
Investigators.
An oral, Direct Factor Xa Inhibitor – Bay 59-7939 – for prophylaxis
against venous Thromboembolism after total knee replacement: a dose-ranging study. Oral
presentation at the XXth ISTH, Sydney, Australia, 6-12 August, 2005.
559.Zotz RB, Decousus H, Monreal M, Chong BH, Pavanello R, Pini M, Turpie AGG, Huang W,
Anderson Jr. FA for the IMPROVE Investigators. J Thromb Haemost 3 (Suppl 1), 2005.
560. Turpie AGG for the PROVE Investigators.
The PROVE Registry:
A Prospective
Registry on venous Thromboembolic Events. J Thromb Haemost 3 (Suppl 1), 2005.
72
73
561. Turpie AGG for the PROVE Investigators. A comparison of patients with DVT in Asia
and Europe/Australia: Findings from the PROVE Registry. J Thromb Haemost 3 (Suppl 1),
2005.
562. Julian J, Kearon C, Solymoss S, Douketis J, Ockelford P, Jackson S, Turpie AGG,
McCarty D, MacKinnon B, Hirsh J, Gent M, Ginsberg JS for the FIDO Investigators.
Heparin levels with subcutaneously (sc) low molecular weight heparin (LMWH) and
Unfractionated heparin (UFH): results from a randomised trial.
J Thromb Haemost 3
(Suppl 1), 2005.
563. Kearon C, Ginsberg JS, Julian J, Douketis J, Solymoss S, Ockelford P, Jackson S,
Turpie AGG, McCarty D, MacKinnon B, Hirsh J, Gent M (for the FIDO Investigators). J
Thromb Haemost 3 (Suppl 1), 2005.
564. Spyropoulos AC, Turpie AGG, Dunn AS, Spandorfer J, Douketis J, Jacobson A, Frost FJ
for the REGIMEN Investigators. low molecular weight heparin or unfractionated heparin
as bridging therapy in patients on long-term oral anticoagulants: results from the
REGIMEN Registry. J Thromb Haemost 3 (Suppl 1), 2005.
565. Kwong LM, Colwell CW, Turpie AGG, Davidson BL.
Self-injection of fondaparinux
(Arixtra) in the prophylaxis against venous Thromboembolism after major orthopedic
surgery is well accepted, effective and save: data from the FLEXTRA Trial.
J Thromb
Haemost 3 (Suppl 1), 2005.
566. Turpie AG,
investigators.
versus IPC along
APOLLO study. J
Bauer K, Caprini J, Comp P, Gent M, Muntz J on behalf of the APOLLO
Fondaparinux combined with intermittent pneumatic compression (IPC)
in the prevention of VTE after major abdominal surgery: Results of the
Thromb Haemost 3 (Suppl 1), 2005.
567. O’Donnell MJ, Kearon C, Johnson J, Turpie ID, Zondag M, Robinson M, Turpie AGG.
Predictors of mid-interval low molecular weight heparin anti-Xa levels.
J Thromb
Haemost 3 (Suppl 1), 2005.
568. O’Donnell MJ, Kearon C, Johnson J, Turpie ID, Zondag M, Robinson M, Turpie AGG.
Residual anticoagulant activity following bridging low molecular weight heparin:
prevalence and risk factors. J Thromb Haemost 3 (Suppl 1), 2005.
569. Turpie AGG, Douketis J. Bridging anticoagulation with enoxaparin is effective and
safe in patients with a mechanical heart valve (MHV) who require temporary interruption
of vitamin K antagonist (VKA) therapy. J Thromb Haemost 3 (Suppl 1), 2005.
570. Tapson VF, Spyropoulos AC, Froehlich JB, Kakkar AK, Merli GJ, Monreal M, Pavanello
R, Turpie AGG, Fitzgerald G, Anderson Jr. FA for the IMPROVE investigators. Does body
weight influence physician practices for providing venous Thromboembolism prophylaxis to
acutely ill medical patients:
Findings from IMPROVE. J Thromb Haemost 3 (Suppl 1),
2005.
571.Piovella F, Wang CJ, Lee LH, Lee WC, Turpie AG, Gallus A, Planes A, Passera R for
the AIDA Investigators.
Long-term outcomes after deep vein thrombosis in Asia.
The
AIDA-extension study. J Thromb Haemost 3 (Suppl 1), 2005.
572. Piovella F, Wang CJ, Lu H, Lee K, Lee LH, Lee WC, Turpie AG, Gallus A, Planes A,
Passera R, Rouillon A for the AIDA Investigators. High rate of deep vein thrombosis in
Asia after major orthopedic surgery: an epidemiological study with mandatory bilateral
venography and central independent adjudication. J Thromb Haemost 3 (Suppl 1), 2005.
73
74
573. Kwong LM, Bauer KA, Eriksson BI, Lassen MR, Turpie AGG. The benefit-to-risk ratio
of fondaparinux thromboprophylaxis in patients undergoing major orthopedic surgery is
independent of age. J Thromb Haemost 3 (Suppl 1), 2005.
574. Turpie AGG for the PROVE Investigators. Clinical history, risk factors and use of
VTE prophylaxis in patients with symptomatic DVT in China.
J Thromb Haemost 3 (Suppl
1), 2005.
575. Turpie AGG for the PROVE Investigators.
A characterization of patients with
symptomatic DVT in India. J Thromb Haemost 3 (Suppl 1), 2005.
576. Turpie AGG, Fisher WD, Bauer K, Kwong L, Gent M, Misselwitz F for the ODIXa-KNEE
Investigators.
An oral, direct factor Xa inhibitor – BAY 59-7939 – for prophylaxis
against venous Thromboembolism after total knee replacement: a dose ranging study.
J
Thromb Haemost 3 (Suppl 1), 2005.
577.
Cohen AT, Davidson BL, Gallus
Egberts JFM, Lensing AWA for the
fondaparinux in acutely III medical
renal impairment. J Thromb Haemost 3
AS, Lassen MR, Prins MH, Tomkowski W, Turie AGG,
ARTEMIS Investigators.
Thromboprophylaxis with
patients aged 75 years or more, or with moderate
(Suppl 1), 2005.
578. Cohen AT, Gallus AG, Davidson BL, Lassen MR, Prins MH, Tomkowski W, Turpie AGG,
Egberts JFM, Lensing AWA for the ARTEMIS Investigators.
Benefit of fondaparinux in
medical patients: A subgroup analysis. J Thromb Haemost 3 (Suppl 1), 2005.
579. Anderson FA Jr., Decousus H, Fitzgerald G, Bergmann JR, Froehlich JB, Nakamura M,
Spyropoulos AC, Zotz RB, Spender F, Turpie AGG for the IMPROVE Investigators. Observed
rates of clinically apparent venous Thromboembolism and death due to pulmonary embolism
among unselected hospitalised acutely ill medical patients compared to rates predicted
from clinical trials. J Thromb Haemost 3 (Suppl 1), 2005.
580. Davidson BL, Turpie AGG, kwong LM, Colwell CW Jr. for the FLEXTRA Investigators.
Thromb Haemost 3 (Suppl 1), 2005.
581. Douketis Jd, Johnson JA, Turpie AG.
anticoagulation during interruption of
periprocedural anticoagulation regimen.
17(2):176, 2005.
J
Low molecular weight heparin qs bridtging
warfarin: assessment of a standardized
Perspect Vasc Surg Endovasc Ther June
582.
Eriksson
BI,
Turpie
AGG.
An
oral,
direct
factor
Xa
inhibitor
thromboprophylaxis after orthopaedic surgery; pooled results. AAOS, March 2005.
for
581.Bauer K, Caprini J, Comp P, Gent M, Muntz J, Turpie AGG. Combined pharmacologic and
mechanical prophylaxis for the prevention of VTE after major abdominal surgery: Results
of the APOLLO Study. ASCRS, Dec 1, 2005.
582. Turpie AGG, Bauer KA, Borris L, Dahl OE, Fraser WD, Gent M, Haas S, Menno, Huisman
MV, Kakker AK, Kalebo P, Kwong LM, Homering M, Misselwitz F, Eriksson B.
Thromboprophylaxis after orthopaedic surgery with an oral, direct factor Xa inhibitor:
Pooled results of two phase IIb lclinical trials. Blood 106 (11), 2005, #277.
583. Schellong SM, Beyer J, Halbritter K, Schmidt B, Turpie AGG, Eriksson BI, Misselwitz
F, Kalebo P.
VENUS – a study to validate centrally adjudicated venous ultrasound
against venography after major orthopaedic surgery. Blood 106 (11), 2005, #281.
74
75
584. Monreal M, Zotz RB, Decousus H, Chong BH, Merli G, Pavanello R, Pini M, Turpie AGG,
Huand W, Anderson FA.
Influence of perceived risk factors for bleeding on venos
thromboembolism prophylaxis practices in acutely ill medical patients: findings from
IMPROVE. Blood 106 (11), 2005. #917
585. Eriksson BI, Turpie AGG, Lassen MR, Prins MH, Agnelli G, Gaillard ML, Meems B (Intr
by Jawed Fareed). YM150, an oral direct factor Xa inhibitor, as prophylaxis for venous
thromboembolism in patients with elective primary hip replacement surgery.
A dose
escalation study. Blood 106 (11), 2005. #1865
586. Piovella F, Anderson FA, Decousus H, Fitzgerald G, Bergmann J-F, kakkar AK,
Spyropoulos AC, Zotz RB, Spencer FA, Turpie AGG for the IMPROVE investigators. Rates of
clinically apparent venous thromboembolism and death resulting from pulmonary embolism
among unselected hospitalised acutely ill medical patients versus rats predicted from
clinical studies. Blood 106 (11), 2005 #1620.
587. Turpie AGG, Bauer KA, Caprini JA, Comp PP, Gent M, Muntz JE. Fondaparinux combined
with intermittent pneumatic compression (IPC) versus IPC alone in the prevention of
venous thromboembolism after major abdominal surgery: The randomised APOLLO study.
Blood 106 (11), 2005 #279.
588. Caprini j, Bauer K, Comp P, Gent M, Muntz J, Turpie AGG for the APOLLO
investigators. Combined pharmacologic and mechanical prophylaxis for the prevention of
VTE after major abdominal surgery: results of the APOLLO study. ASCRS, 2005.
589. Turpie AGG. Is it time to rethink the management of venous thromboembolic disease
– evidence-based approached. ASH, Atlanta, 2005.
590. Piovella F, Wang C-J, Lee LH, Lee WC, Turpie AG, Gallus A, Planes A, Passera R.
Long-term outcomes of post-surgical deep vein thrombosis in Asia:
The AIDA-Extension
Study. ASH, December, 2005.
591. Colwell CW, Kwong LM, Turpie AGG.
Timing of the first dose of fondaparinux for
thromboprophylaxis after major orthopaedic surgery: The FLEXTRA Trial. AAOS, 2006.
592.
Turpie AGG.
Haematologica reports.
New anticoagulant drugs in venous and
La Thuile Italy, March 26-April 1, 2006.
arterial
thrombosis.
593. Caprini J, Bauer K, Comp P, Gent M, Muntz J, Turpie AGG on behalf of the Apollo
Investigators.
Fondaparinux combined with intermittent pneumatic compression (IPC)
versus IPC along in the prevention of VTE after major abdominal surgery: An analysis of
higher risk patients. ASCRS June 2006.
594. Colwell CW, Kwong LM, Turpie AGG.
Timing of the first dose of fondaparinux for
thromboprophylaxis after major orthopaedic surgery: The FLEXTRA Trial.
75
76
BOOK CHAPTERS
1.
Clinical Pharmacology (Dilling) Formulary, 21st Edition.
2.
Clinical Pharmacology (Dilling) Revision, 22nd Edition.
Macarthur, 1964.
Ed. S. Alstead, 1963.
Ed. S. Alstead and J.G.
3.
Clinical Pharmacology and Therapeutics.
Practice, Medical Progress", 1964.
"The British Encyclopedia of Medical
4.
Clinical Pharmacology and Therapeutics.
Practice, Medical Progress", 1967.
"The British Encyclopedia of Medical
5.
Clinical Pharmacology and therapeutics.
Practice, Medical Progress", 1968.
"The British Encyclopedia of Medical
6.
Platelets: Haemostasis and Thrombosis.
A. Goldberg and M.C. Brain, 1971.
"Recent Advances in Haematology", Eds.
7.
Ancrod - A new anticoagulant.
Biggs and R.G. McFarlane, 1972.
8.
The Oesophagus.
Thomson, 1972.
"Human Blood Coagulation," 4th Edition, Eds. R.
"Integrated Gastroenterology", Eds. I.A. Gillespie and T.J.
9.
Ancrod - a new anticoagulant. "Human Blood Coagulation", 4th Edition (Revised),
Eds. R. Biggs and R.G. McFarlane, 1973.
10.
Nonpharmacologic prophylaxis against venous thrombosis: Prevention of venous
thrombosis in neurosurgical patients with intermittent calf compression. "Venous
Thromboembolism: Prevention and Management", Chapter 10, Eds. J.L. Madden and M. Hume,
1976.
11.
The role of platelets in thrombosis. "The Detection and Treatment of
Thromboembolism", Eds. C.D. Forbes and N. MacKay, 1977.
12.
The use of antiplatelet agents in the prevention of arterial thrombosis. "The
Detection and Treatment of Thromboembolism", Eds. C.D. Forbes and N. MacKay, 1977.
13.
Platelet Suppressant Therapy.
and L.A. Sherman, 1979.
"Venous and Arterial Thrombosis", Eds. J. Joist
14.
Thromboembolic Cerebral Vascular Diseases "Clinical Textbook on Thrombosis", W.B.
Saunders Company, 1980.
15.
Genton E, Turpie AGG: Venous thromboembolism associated with gynaecological
surgery. Symposium on Operative Gynaecology. W. Droegemueller (Eds), Clinical
Obstetrics and Gynaecology 23:209-242, 1980.
16.
Antithrombotic effects of drugs which suppress platelet function: Their
potential in preventing growth of tumor cells. "Interaction of Platelets and Tumor
Cells" Alan R. Liss Inc. New York, pp 31-62, 1982.
17.
Blood tests for the diagnosis of thromboembolism "Cardiology" Eds. E.I. Chazov,
V.N. Smirnov, R.G. Oganov, Plenu,m Publishing, pp 417-422, 1984.
76
77
18.
Doyle DJ, Turpie AGG, Cairns JA, Holder DA, McEwan MP: Systemic lytic effects
and coagulation changes with intravenous thrombolytic therapy in evolving myocardial
infarction. "Progress in Fibrinolysis VII" Davidson JF, Donati MB, Coccheri (Eds)
Churchill Livingstone, 1985.
19.
Venous Thromboembolism "Current Therapy in Hematology-Oncology" Bayliss TM, Brain
MC, Cherniack RM (Eds) B.C. Decker, 1987.
20.
Thrombosis prevention and treatment in spinal cord injured patients, "Spinal Cord
Rehabilitation", Bloch RF, Basbaum M (Eds), Williams and Wilkins, 212-240, 1986.
21.
Antiplatelet drugs in ischemic heart disease, coronary artery bypass or
peripheral artery surgery. "Internal Medicine Today and Tomorrow", Oda T, Hamaguchi A,
Homma M, Kawai C (Eds), 403-407, 1986.
22.
Thrombolytic therapy in venous thromboembolism "Tissue Plasminogen Activator in
Thrombolytic therapy" Sobel BE, Collen D, Grossbard EB (Eds), Marcel Dekker, Inc. New
York and Basel, 1987.
23.
Thrombolytic therapy in venous thromboembolism "Thrombose - diagnostiek,
preventie en behandeling anno" J.W. ten Cate (Ed), 1986.
24.
Thrombolysis in deep vein thrombosis "Thrombolysis in Cardiovascular Disease"
Julian D, Kubler W, Norris RM, Swan HJC, Collen D, Verstraete M (Eds), 397-408, 1989.
25.
Oczkowski WJ, Turpie AGG: Antithrombotic treatment of cerebrovascular disease
"Antithrombotic Therapy" Bailliere's Clinical Haematology (International Practice and
Research) J. Hirsh (ed): 3 (3) 781-813, 1990.
26.
Turpie AGG, LeClerc JR: Prophylaxis of venous thromboembolism. in "Venous
Thromboembolic Disorders" Lea & Febiger Publishers, LeClerc J (Ed), 303-345, 1990.
27.
Hirsh J, Levine M, Turpie AGG: Prevention de la maladie thromo-embolique.
"Embolie pulmonaire et thrombose veineuse profonde" Simonneau G, Huet Y (Ed), 167-178,
1991.
28.
Turpie AGG: Principals of thromboprophylaxis in Pregnancy and after
Gynaecological Surgery. "Haemostasis and Thrombosis in Obstetrics and Gynaecology".
Greer IA, Turpie AGG, Forbes CD (eds). Chapman and Hall 1991 pp 305-315.
29.
Turpie AGG:
Vascular Surgery".
Thrombolytic therapy in acute venous thrombosis. "Technologies in
Yao JST, Pearce WH (eds). W.B. Saunders Company 1992 pp 504-511.
30.
Turpie AGG: La terapia trombolitica nella trombosi venosa "Trombolisi Yearbook"
G. Agnelli (ed). Excerpta Medica 1992 pp 143-153.
31.
Turpie AGG: Antithrombotic therapy following heart valve replacement.
"Thrombosis and its Management" Poller L, Thomson JM (eds). Churchill Livingstone 1992
pp 182-187.
32.
New concepts in stroke pathophysiology and prevention. Sanofi Winthrop Symposium
to the Second International Stroke Conference N.M. Bornstein, A.G.G. Turpie (ed),
Geneva, May 15, 1993.
33.
Turpie AGG: La terapia trombolitica nella trombosi venosa "Trombolisi Yearbook
1994" G. Agnelli (ed). Excerpta Medica 1994 pp 141-155.
77
78
34.
Prins MH, Turpie AGG: Diagnosis and treatment of venous thromboembolism.
"Haemostasis and Thrombosis" Bloom AL, Forbes CD, Thomas DP, Tuddenham EG (ed).
Churchill Livingstone 1994 pp 1381-1414.
35.
Ginsberg JS, Murmohamed MT, Gent M, MacKinnon B, Sicurella J, Brill-Edwards P,
Levine MN, Panju AA, Powers P, Stevens P, Turpie AGG et al. Use of Hirulog in the
prevention of venous thrombosis after major hip or knee surgery. "Prevention of Venous
Thrombosis" M.T. Nurmohamed (ed). Haveka BV, Amsterdam, The Netherlands, 1994.
36.
Turpie AGG. Orgaran (ORG 10172): A low molecular weight heparin. "Prevention of
Venous Thromboembolism" Bergqvist D, Comerota AJ, Nicolaides AN, Scurr JH (ed). MedOrion Publishing 1994 pp 173-180.
37.
Turpie AGG. Oral anticoagulants and antiplatelet drugs. "Prevention of Venous
Thromboembolism" Bergqvist D, Comerota AJ, Nicolaides AN, Scurr JH (ed). Med-Orion
Publishing 1994 pp 173-180.
38.
Turpie AGG.
1994 pp 151-166.
Thrombolytic therapy in venous thrombosis.
Thrombolysis Yearbook,
39.
Prins MH, Turpie AGG. Management of venous thromboembolism. "A Textbook of
Vascular Medicine". Tooke E, Lowe G (ed). Arnold Publishing, 1995, pp 515-537.
40.
Turpie AGG. Neurosurgery and stroke patients. "Venous Thromboembolism: An
Evidence-Based Atlas". Hull R, Raskob G, Pineo G (eds). Futura Publishing Co., 1996,
pp 63-66.
41.
Turpie AGG. Danaparoid. "Cardiovascular Drug Therapy" Messerli FH (editor)
Saunders Publishing, 1996, pp 1505-1510.
42.
Turpie AGG. Enoxaparin (Lovenox). "Cardiovascular Drug Therapy" Messerli FH
(editor) Saunders Publishing, 1996, pp 1511-1517.
43.
Turpie AGG. La Terapia trombolitica nella trombosi venosa.
Yearbook, 1997", G. Agnelli (ed), 1996 pp 165-183.
"Trombolisi
44.
Turpie AGG. Valvular heart disease and heart valve prostheses.
Anticoagulants", L. Poller, J. Hirsh (eds), 1997 pp 143-148.
45.
Turpie AGG. La terapia trombolitica nella trombosi venosa.
Yearbook", G. Agnelli (ed), 1998 pp 181-201.
"Oral
"Trombolisi
46.
Ageno W, Turpie AGG. Heparinoids. "Cardiovascular Thrombosis", M. Verstraete,
V. Fuster, E. Topol (ed), 1998 pp 221-234.
47.
Turpie AGG. Secondary prevention of deep vein thrombosis and pulmonary embolism.
"Cardiovascular Thrombosis", M. Verstraete, V. Fuster, E. Topol (ed), 1998 pp 683-689.
48.
Turpie AGG. Antithrombotic therapy after heart valve replacement. "Evidence
Based Cardiology" S. Yusuf, J.A. Cairns, A.J. Gamm, E.L. Fallen, B.J. Gersh (ed), 1998
pp 905-911.
49.Turpie AGG.
1998.
Venous Thromboembolism.
"Therapeutic Choices".
50. Turpie AGG et al. Acute Coronary Syndromes.
Monograph Series, 2000.
78
Chapter 31; pp 249-255,
International Cardiology Forum.
79
51,
2000.
Turpie AGG.
Venous thromboembolism.
Therapeutic Choices.
Chapter 31;273-280,
52.
Turpie AGG, Ageno W. Antithrombotic therapy after heart valve replacement.
“Evidence Based Cardiology” S. Yusuf, J.A. Cairns, A.J. Gamm, E.L. Fallen, B.J. Gersh
(ed), 2002 pp 832-836.
53. Turpie AGG.
2003.
Venous thromboembolism.
Therapeutic Choices.
Chapter 31:358-369,
54. Turpie AG, Ageno W. Venous thromboembolism: Pathophysiology and diagnosis.
Therapeutic Strategies in Thrombosis. Chapter 17, 2006.
79
In